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 Among U.S. states, Kansas children’s HPV vaccination rates remain low. 
Parent/guardian HPV vaccine-beliefs likely influence vaccination rates. Additionally, 
Facebook’s popularity suggests that this forum’s representation may influence 
parent/guardian decisions to vaccinate children. This dissertation explores how 
Kansan parents/guardians of HPV vaccine-eligible children perceive the vaccine in 
the contexts of the health belief model (Rosenstock, 1974; Rosenstock, Strecher, & 
Becker, 1988) and the social amplification of risk framework (R. Kasperson et al., 
1988), parent/guardian engagement with HPV vaccine-related information, and 
Facebook representations by general users and the Centers for Disease Control and 
Prevention during the vaccine’s first decade on the market. Results indicate HPV 
vaccine risk perceptions among some Kansan parents/guardians, social media as an 
active and passive source of information, and the HPV vaccine’s representation on 
Facebook as increasingly negative. HPV vaccine promotion strategies should 
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Chapter 1: Introduction 
On a rainy weekday morning in Kansas, a doctoral student was running late to 
an appointment on the University campus. She had missed the bus, and proceeded to 
request an Uber. Fortunately, the Uber driver quickly arrived, and she was hopeful 
that she would make it to campus on time.  
The driver was friendly.  
“In school?” he asked.  
“Yeah,” she responded.  
“What for?”   
That was all the prompting she needed to start talking about how she hoped to earn a 
Ph.D. in Journalism and Mass Communications by writing her dissertation about low 
human papillomavirus (HPV) vaccination rates among Kansan children. She knew 
her facts. She knew that a vaccine had been available since 2006  (U.S. Food and 
Drug Administration, 2006), but that in 2013 Kansas held the title of being tied for 
last among U.S. states for HPV vaccination rates  (Hart, 2015). She knew that more 
than 70 million U.S. Americans are infected with the HPV, and there are more than 
10 million new cases each year. Also, she was aware that HPV is associated with 
cancer (Centers for Disease Control and Prevention, 2016n). 
He knew about the cancer.  
At a red light, the Uber driver faced the front passenger window, and pulled 
down the collar of his shirt. His neck outstretched, he asked “see that scar right there? 
Cancer in my neck. HPV-associated. I can’t believe there’s a vaccine out there for it, 
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and people aren’t getting it; because I sure wish it was around when I was a kid.”
 Facts and figures were now illustrated in reality, right in front of the face of a 
doctoral student who now wished she could remain in the sedan a little while longer 
and ask him a few questions. But, she had arrived at her destination, on time. So, she 
thanked the driver, and walked into the drizzle. Time would pass, and she would ever 
so often reflect on that encounter and continue to wonder why are HPV vaccination 
rates so low among Kansan children? 
The story of low HPV vaccination rates in Kansas is not new. The U.S. Food 
and Drug Administration (FDA), the U.S. agency responsible for assuring that 
vaccines for humans are safe and effective (U.S. Food & Drug Administration, 2017)  
approved the first HPV vaccine, brand name Gardasil®, on June 8, 2006 (U.S. Food 
and Drug Administration, 2006). The vaccine is recommended to children 11 or 12 
years old, but is not required  (Petrosky et al., 2015). In addition to tying for the 
lowest state HPV vaccination rates in 2013 (Hart, 2015), in 2014, it was estimated 
that HPV vaccination completion rates (3-dose series) ranged from 3% to 48% by 
Kansan county (Immunize Kansas Coalition, 2017c). Even getting children started on 
the vaccine was a challenge. In 2015, Kansan females and males ages, 13-17 years, 
ranked 48
th
 among the 50 U.S. states for receiving at least one dose of the HPV 
vaccine (Centers for Disease Control and Prevention, 2016a). 
The study of non-compliance to preventive health behavior is also not a new 
endeavor. The health belief model (HBM) was developed to study this type of 
phenomena (Rosenstock, 1974; Rosenstock et al., 1988). HBM posits that though 
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people generally want to avoid disease, people are more likely to perform or engage 
in disease preventive behaviors if they hold a certain set of beliefs. In the context of 
HPV and HPV vaccination, people will more likely get vaccinated if they think they 
will likely get HPV, that HPV infection could be severe, that benefits of HPV 
vaccination are high, that barriers to HPV vaccination are low, and that they actually 
believe they have access to the HPV vaccine. Also, someone telling them to get the 
HPV vaccine, a cue to action, would encourage them to actually get vaccinated. 
Newer is the amount of research examining health beliefs and how they 
influence parents to get their children the HPV vaccine. A body of research is 
developing that applies HBM to look at parents’ decision making about HPV 
vaccination. Studies have looked at reasons for HPV vaccine acceptance or refusal 
(e.g., Grandahl et al., 2017; A. Krawczyk et al., 2015) and parental health beliefs in 
certain geographic regions (e.g., Brewer et al., 2011; Fazekas, Brewer, & Smith, 
2008), but studies are often focused on perceptions of parents regarding either their 
daughters (e.g., Brewer & Fazekas, 2007; Brewer et al., 2011; Fazekas et al., 2008; 
Grandahl et al., 2017; A. Krawczyk et al., 2015; Reiter, Brewer, Gottlieb, McRee, & 
Smith, 2009) or their sons (e.g., Radisic, Chapman, Flight, & Wilson, 2017), and not 
both. A search and review of literature found a gap concerning the study of the low 
HPV vaccination rates among Kansan children and the role of parent and guardian 
health beliefs. An effort to fill this gap, such as this dissertation, could be the first step 
to addressing barriers to HPV vaccination uptake, understanding non-compliance to a 
preventive health behavior, and improve vaccination rates. 
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The story behind the phenomenological and theoretical underpinnings of this 
dissertation does not end with the Uber ride. The same doctoral student would work 
on a project with several colleagues examining news coverage about the 2016 Zika 
outbreak. That project analyzed messages in the context of the social amplification of 
risk framework (SARF) (J. Kasperson, Kasperson, Pidgeon, & Slovic, 2003; R. 
Kasperson et al., 1988). SARF describes the amplification or attenuation of risk 
perceptions and associated effects being the result of interactions between several 
social and individual factors. These factors include, but are not limited to, risks 
communicated in the media (Chung & Yun, 2013; e.g., Eldridge & Reilly, 2003; J. 
Kasperson et al., 2003; R. Kasperson et al., 1988; Lewis & Tyshenko, 2009; Raupp, 
2014; Susarla, 2003).  
Before going any further, this is not going to be a story about mediated risk 
messages related to HPV infection or its associated diseases. HPV infection is 
pervasive; it is the most common sexually transmitted infection in the United States, 
and nearly all sexually active people will be infected in their lifetime  (Centers for 
Disease Control and Prevention, 2016n). Instead, this is a story about risk messages 
of another kind: those about the HPV vaccine. 
Sometime during the Zika project, the doctoral student would receive a text 
message from her sister that would wake up her up from a much needed night’s sleep. 
The details are hazy, but the text message contained a link to a YouTube video. 
Memory has it that there was a young woman being interviewed about the HPV 
vaccine on what looked like a news program. The guest argued that the vaccine was 
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dangerous and that there are safer and more natural alternatives to preventing HPV 
infection.  
“Anti-vaxxer,” the doctoral student thought, “one of those people often 
believes vaccines are harmful and ineffective” (Addis, 2015). Yes, the HPV vaccine 
has potential side effects (U.S. Food and Drug Administration, 2009b, 2011, 2014b), 
but who would choose to take the chance of letting their vaccine-eligible children 
(ages 9-17) be exposed to a cancer-associated virus, when there is something that 
could prevent it? So what if the shot could cause some pain at the injection site? 
However, that was her perception, and perceptions are diverse and complicated.    
 That text message led the doctoral student to consider two (or three) things. 
First, what if people are assuming that the HPV vaccine is always perceived as a 
preventive health behavior? What if instead it is perceived by some as a risk event? 
Second, how many social media messages have negative, risk amplifying content 
about the HPV vaccine, like were in that video (and third, maybe she should silence 
her phone before bed)? From a search and review of literature, a gap was found in the 
research: risk messages about vaccines have not been greatly analyzed in-depth, and 
especially not in the context of SARF. It was decided at that point that this 
dissertation would also address parent and guardian HPV vaccine perceptions in the 
context of SARF, with the vaccine (and not the virus) being the risk event subject. 
The aforementioned YouTube video would also inspire an interest in HPV 
vaccine representations on social media. Research demonstrates that social media 
platforms allow users to connect and communicate about many topics, including 
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health-related topics (Moorhead et al., 2013). A number of studies have analyzed 
communicated messages about the HPV vaccine on the internet or social media, or 
have experimented with the effects of exposure to HPV vaccine-related social media 
messages (e.g., Ache & Wallace, 2008; Briones, Nan, Madden, & Waks, 2012; 
Keelan, Pavri, Balakrishnan, & Wilson, 2010; Lai et al., 2015; McRee, Reiter, & 
Brewer, 2012; Nan & Madden, 2012). Some studies have even analyzed content in 
the context of HBM variables, though none were found in the context of SARF. Thus, 
this dissertation also investigates how Kansan parents and guardians perceive HPV 
vaccine-related social media content. Furthermore, this study analyzes actual HPV 
vaccine-related social media content (spoiler alert: Facebook was the most used social 
media platform identified by Kansan parents and guardians in a survey, and was the 
source of posts for the content analysis). 
Though research has analyzed HPV vaccine-related messages on several 
social media platforms, what was most peculiar was that research has not analyzed 
public posts across Facebook. Facebook is the most used social media platform 
among U.S. adults over 18 years of age (Greenwood, Perrin, & Duggan, 2016), so it 
is likely the most used social media platform among parents and guardians of 9-17 
year olds in Kansas. Research found that the archival of public posts across the 
platform was likely impossible for a researcher to do prior to 2013, because 
Facebook’s search feature was not available until that year (Facebook, 2013). With 
over two trillion posts in its index, there was hope that HPV vaccine-related posts 
would be plentiful and available for analysis. With the availability of the search 
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feature and that vaccine had been on the market for a little more than a decade at the 
time of this study, the doctoral student decided to conduct an analysis on how HBM 
and SARF messages in HPV vaccine-related Facebook posts had changed over time. 
This longitudinal research pursuit on a highly used platform among adults is a 
contribution this dissertation makes to the understanding of messages communicated 
about the HPV vaccine. 
Upon the doctoral student becoming a doctoral candidate, she would also 
consider one other source of HPV vaccine-related Facebook posts – the Centers for 
Disease Control and Prevention (CDC). The CDC is the United States’ health 
protection agency (Centers for Disease Control and Prevention, 2014a), and 
advocates that eligible persons receive the HPV vaccine (e.g., Centers for Disease 
Control and Prevention, 2013, 2015b, 2016c, 2016m; Centers for Disease Control and 
Prevention, 2016n, 2016o). A search on Facebook would find that the CDC officially 
operates two pages where the vaccine has been mentioned: “CDC” and “CDC STD.” 
Comparing HBM and SARF messages in HPV vaccine-related posts with posts 
published by the CDC would show how messages on Facebook at-large have 
compared with messages communicated by the United States’ health protection 
agency. These messages, by extension, inform how the vaccine is perceived and 
represented. The longitudinal analysis would also show how those messages have 
compared over the vaccine’s ten year history. Findings demonstrate how aligned the 
communication of Facebook public is, or is not, with the communication of the U.S. 
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government’s initiatives. This is the final contribution that this dissertation makes to 
the research. 
In summary, a doctoral candidate’s intellectual curiosity about a regional 
phenomenon, a conversation with an Uber driver, a sleep-interrupting text message, 
and a theoretical approach used in a Zika-related project inspired this dissertation.
 This dissertation investigates the HPV vaccine-related perceptions held by 
Kansan parents and guardians of children ages 9-17 years, their perceptions of social 
media representations about the HPV vaccine, what the most used social media 
platform by these parents actually communicates about the HPV vaccine, and how the 
messages compare with U.S. government messages. Following this Chapter, Chapter 
two discusses HPV and HPV-associated disease, the HPV vaccine, Kansas HPV 
vaccination information, the health belief model, and the social amplification of risk 
framework more in-depth. The research questions guiding the study are presented at 
the end of the chapter. Chapter three presents the methods employed to conduct the 
dissertation research. Survey development, pre-survey interviews, respondent 
recruitment strategies, content analysis procedure, and the data analysis process are 
included. Data analyses pertaining to the research questions are in Chapter four. The 
fifth and final chapter is a discussion of the research findings in the contexts of HBM 
and SARF. This chapter also discusses the limitations of the dissertation, implications 
for the health belief model, health communication, and healthcare providers, as well 




Chapter 2: Literature Review 
The Human Papillomavirus 
Discovery and research. The discovery of HPV is connected with the history 
of cancer research. In the early 1900’s, U.S. American researcher Peyton Rous 
conducted an experiment. Rous extracted material from a cancerous tumor in a 
chicken, then injected that material into a healthy chicken (Nobelprize.org, 
2014b).The healthy chicken later developed cancer, and Rous concluded that the 
original tumor contained a virus that transmitted cancer. This observation led to 
decades of research dedicated to demonstrating that in humans, cancer could also be 
the result of viral infections (Bakalar, 2011).  
It was German scientist Harald zur Hausen, who would become renowned for 
leading the study in linking papillomavirus to cancer in humans (Nobelprize.org, 
2014a). Zur Hausen recalled studying reports that mentioned genital warts converting 
into malignant carcinomas. He states, “[s]ince genital warts had been shown to 
contain typical papillomavirus particles, this triggered the suspicion that the genital 
wart virus might represent the causative agent for cervical cancer” (Nobelprize.org, 
2014a, para. 10). Zur Hausen and other scientists also suspected that there were a 
variety of papillomavirus types. Throughout the 1970s and 1980s, scientists would 
isolate, clone, and link a variety of human papillomavirus types to cancer. 
What is HPV?  The human papillomavirus is a group of viruses named for 
the papillomas (genital warts) caused by some of the strains, like the one seen below 
(see Figure 1)  (Centers for Disease Control and Prevention, 2015c). Each virus in the 
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group has a designated number, called a HPV type. There are at least “174 completely 
characterized types, with new HPV types being continuously found” (Bzhalava, 
Guan, Franceschi, Dillner, & Clifford, 2013, p. 224).  
 
Figure 1: An electron micrograph of the human papillomavirus, a virus associated with warts and cancer 
(Laboratory of Tumor Virus Biology, 1986) 
HPV transmission commonly occurs through contact during vaginal and anal 
sexual activity, but can also be transmitted during oral sex (Centers for Disease 
Control and Prevention, 2016n). HPV can also be spread in the absence of penetrative 
sex through skin-to-skin genital contact with someone who has HPV (World Health 
Organization, 2016). Regardless of whether an HPV infected person shows signs or 
symptoms of infection (e.g. genital warts) it is still possible for that person to spread 
the infection.  
HPV prevalence, incidence, and associated disease. The Centers for 
Disease Control and Prevention (CDC) estimate that approximately 79 million U.S. 
Americans have HPV, with an incidence of 14 million new cases annually (Centers 
for Disease Control and Prevention, 2016n). The CDC states that HPV infection “is 
so common that most sexually-active men and women will get at least one type of 
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HPV at some point in their lives” (Centers for Disease Control and Prevention, 
2016n, para. 1). While HPV infection does not cause complications in all cases, it has 
been linked to genital warts and several types of cancer.  
HPV-associated cancers include cervical, vulvar, vaginal, penile, anal, and 
oropharyngeal cancers (Centers for Disease Control and Prevention, 2015d). These 
cancers are responsible for nearly 16,000 deaths each year (see Table 1) (American 
Cancer Society, 2016; Centers for Disease Control and Prevention, 2016d, 2016e; 
National Institutes of Health & National Cancer Institute, 2016), and more than 
38,000 new cancer cases in the United States (Centers for Disease Control and 
Prevention, 2016g). 
Table 1:  HPV 2016: Associated Cancer, Probability Links, U.S. Incidence & Deaths 
Cancer Type Probability of 
Cancer Type Being 




















Vaginal 75% 802 437 
 4
 
Penile 63% 1,168 340 
5 
Anal 91% 5,010 1,080 
6
 








1. (Centers for Disease Control and Prevention, 2015f) 
2. (Centers for Disease Control and Prevention, 2016g) 
3. (Centers for Disease Control and Prevention, 2016d) 
4. (Centers for Disease Control and Prevention, 2016e) 
5. (American Cancer Society, 2016) 
6. (National Institutes of Health & National Cancer Institute, 2016) 
7. (Centers for Disease Control and Prevention, 2016h) 
 
As of 2017, nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) and their 
associated diseases are preventable by vaccination and subsequent immunization 
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(Petrosky et al., 2015). HPV types 16 and 18 are linked to nearly 64% of HPV-
associated cancers (63% for males and 65% for females), and to 90% of genital warts 
cases. HPV types 31, 33, 45, 52, and 58 account for 10% of HPV-associated cancer 
cases (4% for males and 14% for females).  
HPV-associated cancer: Race and gender. Cancer is arguably one of the 
most severe diseases associated with human papillomavirus infection. Research finds 
that HPV-associated cancer disproportionally affects several demographics. 
 Cervical cancer. From the years 2008-2012, blacks reported the highest 
incidence (cases per 100,000 women) of HPV-associated cervical cancer (9.2), 
followed by whites (7.1), American Indians/Alaska Natives (6.3), then Asians/Pacific 
Islanders. Furthermore, Hispanics have a higher reported incidence of cervical cancer 
(9.7) than non-Hispanics (7.1). It is estimated that more than 11,000 new cases of 
HPV-associated cervical cancer are diagnosed in the United States annually (Centers 
for Disease Control and Prevention, 2016c), and that HPV is responsible for 91% of 
HPV-associated cervical cancer cases (Centers for Disease Control and Prevention, 




Figure 2: The female reproductive system. For the National Cancer Institute © 2009 Terese Winslow, U.S. Govt. 
has certain rights. 
 
Vulvar cancer. (see From 2008-2012, whites reported the highest incidence 
(cases per 100,000 women) of HPV-associated cervical cancer (2.1), followed by 
blacks (1.5), American Indians/Alaska Natives (1.1), then Asians/Pacific Islanders 
(0.4) (Centers for Disease Control and Prevention, 2016l). Furthermore, Hispanics 
had a higher reported incidence of vulvar cancer (2.1) than non-Hispanics (1.3). It is 
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estimated that more than 3,500 new cases of HPV-associated vulvar cancer are 
diagnosed in the United States annually (Centers for Disease Control and Prevention, 
2016c). HPV infection is likely responsible for 69% of HPV-associated vulvar 
cancers (Centers for Disease Control and Prevention, 2015f). 
Vaginal cancer. From 2008-2012, blacks reported the highest incidence 
(cases per 100,000 women) of HPV-associated vaginal cancer (0.6), followed by 
whites (0.4), American Indians/Alaska Natives (0.3), then Asians/Pacific Islanders 
(0.2) (Centers for Disease Control and Prevention, 2016k). Furthermore, Hispanics 
had a slightly higher reported incidence of vaginal cancer (0.5) than non-Hispanics 
(0.4). Estimates report that about 800 new cases of HPV-associated vulvar cancer are 
diagnosed in the United States annually (Centers for Disease Control and Prevention, 
2016c), and that HPV is responsible for 75% of HPV-associated vaginal cancers 
(Centers for Disease Control and Prevention, 2015f) (see  Figure 2 to see the location 
of the vagina). 
 Penile cancer. From 2008-2012, blacks reported the highest incidence (cases 
per 100,000 men) of HPV-associated penile cancer (0.9), followed by whites (0.8), 
American Indians/Alaska Natives (0.7), then Asians/Pacific Islanders (0.4) (Centers 
for Disease Control and Prevention, 2016j). Furthermore, Hispanics had nearly twice 
the reported incidence of penile cancer (1.3) than non-Hispanics (0.7). Estimates 
report that more than 1,100 new cases of HPV-associated penile cancer are diagnosed 
in the United States annually (Centers for Disease Control and Prevention, 2016c), 
15 
 
and that HPV is responsible for 63% of HPV-associated penile cancers (Centers for 
Disease Control and Prevention, 2015f) (see Figure 3).  
 
Figure 3: Image of an HPV-infected cell in the human foreskin of a penis that has experienced structural changes 
(E. Krawczyk, 2008). 
  
Anal cancer. From 2008-2012, for all races and ethnicities except for blacks, 
women reported more cases (incidence per 100,000 people) of HPV-associated anal 
cancer than men (white, 1.9/1.1; black 1.4/1.5; American Indian/Alaska Native, 
0.9/0.5, Asian/Pacific Islander, 0.4/0.2; non-Hispanic, 1.9/1.2; and Hispanics 1.4/1.2) 
(Centers for Disease Control and Prevention, 2016b). White women and non-
Hispanic women reported the highest incidences (1.9) of anal cancer among women, 
and black men had the highest reported incidence (1.5) of all men. It is estimated that 
more than 5,000 new cases of HPV-associated anal cancer are diagnosed in the 
United States annually (Centers for Disease Control and Prevention, 2016c). It is 
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estimated that HPV is responsible for 91% of HPV-associated anal cancers (Centers 
for Disease Control and Prevention, 2015f) (see Figure 4 for the location of the anus).  
 
Figure 4: Representation of the colon, rectum, and surrounding organs (Hoofring, 2006).  
 
Oropharyngeal cancer. From 2008-2012, for all races and ethnicities, women 
reported far fewer cases (incidence per 100,000 people) of HPV-associated 
oropharyngeal cancer than men (white, 1.8/8.0; black 1.5/6.9; American 
Indian/Alaska Native, 0.9/4.4, Asian/Pacific Islander, 0.6/2.0; non-Hispanic, 1.8/8.0; 
and Hispanics 0.9/4.2) (Centers for Disease Control and Prevention, 2016i). White 
men and non-Hispanic men reported the highest incidences (8.0) of oropharyngeal 
cancer among men, and white and non-Hispanic women had the highest reported 
incidence (1.8) of all women. Reports estimate that more than 15,700 new cases of 
HPV-associated oropharyngeal cancer are diagnosed in the United States annually 
(Centers for Disease Control and Prevention, 2016c), and that HPV is responsible for 
72% of HPV-associated oropharyngeal cancers cases (Centers for Disease Control 
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and Prevention, 2015f). The average age for diagnosis of these cancers ranges 
between 49 and 68 years of age (Centers for Disease Control and Prevention, 2016f). 
Even though the diagnosis of these cancers happen often in the later years of the life 
of someone infected with HPV, it is possible to prevent nine types (6, 11, 16, 18, 31, 
33, 45, 52, and 58) and their associated diseases through vaccination and subsequent 
immunization (Petrosky et al., 2015) (see Figure 5 for parts of the oropharynx). 
 




HPV-associated cancer in Kansas. The rates for HPV-related cancer cases in 
Kansas are close to the reported  U.S. national rates (see Table 2) (Viens et al., 2016). 
The (per 100,000) rate of cervical, female anal cancer, and female oropharyngeal 
cancer for Kansas was lower than U.S. national rates and the rate for vulvar cancer 
was higher for Kansas than the nation. Vaginal and penile cancer rates in both Kansas 
and the United States were the same. Rates of anal cancer in men were reported to be 
more than triple U.S. national rates, but rates of oropharyngeal cancer in men were 
lower.
 
Table 2: HPV-Associated Cancer Rates U.S and Kansas (per 100,000)1 
Cancer Type Kansas 
(Female) 
U.S. (Female) Kansas 
(Male) 
U.S (Male) 
Cervical 6.90  7.40 - - 
Vulvar 2.20 2.00 - - 
Vaginal 0.40 0.40 - - 
Penile - - 0.80 0.80 
Anal 1.70 1.80 0.70 0.20 
Oropharyngeal 1.40 1.70 7.50 7.60 
(Viens et al., 2016) 
 Despite the rates of cancer hovering close to U.S. national averages, there is a 
danger that low HPV vaccination rates among children could make them more 
susceptible to infection and the development of HPV-associated cancer in adulthood.  
The Human Papillomavirus Vaccine 
 What is the HPV vaccine? The human papillomavirus vaccine is a formula 
developed with virus-like particles (VLPs)  which are “multiprotein structures that 
mimic the organization and conformation of authentic native viruses but lack the viral 
genome, potentially yielding safer and cheaper vaccine candidates” (Roldao, Mellado, 
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Castilho, Carrondo, & Alves, 2010, p. 1149). Vaccines generally causes one’s 
immune system to recognize the agent (in this case, the VLPs) as foreign, and destroy 
it (World Health Organization, 2017). This process, called immunity development, 
improves the immune system’s ability to recognize the virus and destroy it with 
antibodies (Centers for Disease Control and Prevention, 2014b). 
 Gardasil®. The first HPV vaccine was approved by the U.S. Food and Drug 
Administration (FDA) on June 8, 2006  (U.S. Food and Drug Administration, 2006). 
The vaccine, “Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine” 
(U.S. Food and Drug Administration, 2006), is manufactured by Merck & Co., Inc., 
under the brand name Gardasil®. This vaccine is also known as “quadrivalent HPV 
vaccine” and “4vHPV” (Centers for Disease Control and Prevention, 2016p). 
Gardasil® is “a non-infectious recombinant quadrivalent vaccine prepared 
from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV 
Types 6, 11, 16, and 18.” (U.S. Food and Drug Administration, 2011, p. 12). In other 
words, the vaccine contains proteins that resemble the HPV types, but cannot cause 
HPV infection because it does not contain the actual virus. The proteins are treated in 
a process that involves the use of “vitamins, amino acids, mineral salts and 
carbohydrates” (p. 11). The final vaccine also contains aluminum, sodium chloride, 
L-histidine, polysorbate, sodium borate, yeast protein, and water, but no preservatives 
or antibiotics. According to the Gardasil® insert “[a]nimal studies with analogous 
papillomaviruses suggest that the efficacy of L1 VLP vaccines may involve the 
development of humoral immune response. Human beings develop a humoral 
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immune response to the vaccine, although the exact mechanism of protection is 
unknown” (p. 12). 
The U.S. Food and Drug Administration approved the vaccine for females 9-
26 years of age to prevent types 6, 11, 16, and 18 of HPV, and HPV-associated 
genital warts and cancers (cervical, anal, vulvar, and vaginal) (U.S. Food and Drug 
Administration, 2011). On October 16, 2009, a little more than three years after its 
initial approval, the FDA approved Gardasil® for the prevention of HPV-associated 
genital warts in males 9-26 years of age  (U.S. Food and Drug Administration, 
2009a). 
At the time of approval, administration of the vaccine was recommended via 
three intramuscular injections at zero, two, and six months. (U.S. Food and Drug 
Administration, 2011). The vaccine is not recommended for anyone who has an 
allergy or hypersensitivity to any of the ingredients, including yeast or a previous 
injection of the vaccine. Concerning adverse reactions:  
“Headache, fever, nausea, and dizziness; and local injection site reactions 
(pain, swelling, erythema, pruritus, and bruising) occurred after administration with 
GARDASIL. Syncope, sometimes associated with tonic-clonic movements and other 
seizure-like activity, has been reported following vaccination with GARDASIL and 
may result in falling with injury; observation for 15 minutes after administration is 
recommended.” (U.S. Food and Drug Administration, 2011, p. 3)  
According to the package insert, Gardasil® had not been clinically evaluated 
to see if it can cause cancer, cell mutations, or infertility in males, but was found to 
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not cause effects on fertility on male rats (U.S. Food and Drug Administration, 2011). 
Double-blind, randomized clinical studies evaluated 24,596 people (20,541 women 
ages 16-26 years old, and 4,055 men 16-26 years old at the time of enrollment), who 
received all three vaccinations within a year of their enrollment, and were unaware of 
HPV types (6, 11, 16, and 18) before their first dose  (MerckVaccines.com, 2015). 
Compared to those receiving a placebo, the following efficacy rates were reported: 
cervical cancer 98% (95% CI [93.5, 99.8]), vulvar/vaginal cancer 100% (95% CI 
[55.5, 100]), anal cancer 75% (95% CI [8.8, 95.4]), genital warts (males) 89% (95% 
CI [65.3, 97.9]), and genital warts (females) 99% (95% CI [96.2, 99.9]). In summary 
the study found that the HPV vaccine was effective in preventing most cases of HPV-
associated cancer and genital warts. 
Cervarix®. On October 16, 2009, another human papillomavirus vaccine was 
approved by the FDA (2012). This vaccine, “Human Papillomavirus Bivalent (Types 
16 and 18) Vaccine, Recombinant” (Centers for Disease Control and Prevention, 
2016l), brand name Cervarix® is also known as “bivalent HPV vaccine” and 
“2vHPV” (Centers for Disease Control and Prevention, 2016p). This vaccine is 
manufactured by GlaxoSmithKline Biologicals  (U.S. Food and Drug Administration, 
2012). The FDA approved the vaccine for females 10-25 years of age, to prevent 
cervical cancer. Later, Cervarix® would be also be approved for females as young as 
age nine years (U.S. Food and Drug Administration, 2009b). 
Cervarix® “is a non-infectious recombinant, AS04-adjuvanted vaccine that 
contains recombinant L1 protein, the major antigenic protein of capsid, of oncogenic 
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HPV types 16 and 18” (U.S. Food and Drug Administration, 2009b, p. 12). This 
vaccine is developed in a process that uses aluminum, sodium chloride, sodium 
dihydrogen phosphate dehydrate, and water. The final formula contains sodium 
chloride, sodium dihydrogen phosphate dehydrate and “may also contain residual 
amounts of insect cell and viral protein,” and “bacterial cell protein” (p. 13), but does 
not contain preservatives. The Cervarix® insert states that “[a]nimal studies suggest 
that the efficacy of L1 VLP vaccines may be mediated by the development of IgG 
neutralizing antibodies directed against the HPV-L1 capsid proteins generated as a 
result of vaccination” (p. 13). 
At the time of its approval, Cervarix® was recommended to be administered 
by three separate intermuscular injections, at zero, one, and six months (U.S. Food 
and Drug Administration, 2009b). The vaccine insert warns that people who are 
allergic to latex may have allergic reactions to the product, and that syncope has been 
reported with Cervarix® use. The most common adverse reactions include “pain 
redness, and swelling at the injection site,” and “fatigue, headache, myalgia, 
gastrointestinal symptoms, and arthralgia” (p. 3). Studies found no evidence that 
Cervarix® harmed the fetus or impaired fertility of female rats. The insert also 
indicates that studies had been conducted to evaluate the vaccine for its potential to 
cause cancer or mutations. Controlled clinical trials that were double-blind and 
randomized consisting of 19,778 women ages 15-25 years, and efficacy rates for 
preventing cervical cancer were reported at 91.7% [95% CI: 66.6, 99.1]. 
Gardasil® 9. The latest HPV vaccine was approved by the FDA on 
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December 10, 2014 (U.S. Food and Drug Administration, 2014a). The vaccine, 
“Human Papillomavirus 9-valent Vaccine, Recombinant” (Centers for Disease 
Control and Prevention, 2016j), brand name Gardasil® 9, and also known as “9-
valent HPV” and “9vHPV” (Centers for Disease Control and Prevention, 2016p), is 
manufactured by Merck & Sharp & Dohme Corp. This vaccine was approved for the 
prevention of HPV-associated cancer (cervical, vulvar, anal) caused by HPV types 
16, 18, 31, 33, 45, 52, and 58, and genital warts that are caused by HPV types 6 and 
11 in females 9-26 years of age. It was also approved for the prevention of HPV-
associated cancer (anal) caused by HPV types 16, 18, 31, 33, 45, 52, and 58, and 
genital warts caused by infection from HPV types 6 and 11 in males 9-26 years of 
age. 
Gardasil® 9 is “a non-infectious recombinant 9-valent vaccine prepared from 
the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV 
Types 6, 11, 16, 18, 31, 33, 45, 52, and 58” (U.S. Food and Drug Administration, 
2014b, p. 11). The proteins are treated in a process that uses “vitamins, amino acids, 
mineral salts and carbohydrates” (p. 11). In addition to the VLPs, the final vaccine 
also contains aluminum, sodium chloride, L-histidine, polysorbate, sodium borate, 
yeast protein, and water. According to the Gardasil® 9, like with Gardasil®, the exact 
mechanism of vaccine protection is unknown, but thought to be through a humoral 
response. 
At the time of approval, the vaccine was recommended to be administered via 
intramuscular injections in three doses at zero, between three and six months, and a 
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year (U.S. Food and Drug Administration, 2014b). The most common adverse 
reactions include pain, injection site swelling and redness, and headache. Gardasil® 
9, according to the package information, has not been clinically evaluated to see if it 
can cause cancer, cell mutations, or infertility in males, but was found to not cause 
effects on fertility of female rats  (U.S. Food and Drug Administration, 2014b). Like 
Gardasil® 9, the following efficacy rates were reported: cervical cancer 98% (95% CI 
[93.5, 99.8]), vulvar/vaginal cancer 100% (95% CI [55.5, 100]), anal cancer 75% 
(95% CI [8.8, 95.4]), genital warts (males) 89% (95% CI [65.3, 97.9]), and genital 
warts (females) 99% (95% CI [96.2, 99.9]). In another efficacy study comparing 
Gardasil® 9 to its predecessor, Gardasil®, Gardasil® 9 was found to be 97% 
effective (95% CI [80.9, 99.8]) in preventing cervical, vulvar, and vaginal cancers 
associated to HPV (types 31, 33, 45, 52, and 58). 
Summary of recommendations. The Advisory Committee on Immunization 
Practice (ACIP), “a group of medical and public health experts that develop 
recommendations on the use of vaccines in the civilian population of the United 
States” (Centers for Disease Control and Prevention, 2016b, para. 1), released its 
recommendations for HPV vaccination on March 27, 2015 in the Morbidity and 
Mortality Weekly Report (MMWR) (Petrosky et al., 2015). The ACIP recommends 
HPV vaccination for females ages 11 or 12 years, with catch-up vaccines for females 
aged 13-26 years. For males, the ACIP recommends vaccination at ages 11 or 12 
years, with catch-up vaccines at ages 13-21 years, or if immunocompromised, 
through age 26 years. It is also recommended that men who engage in sexual 
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relationships with other men (MSM) also receive catch-up vaccinations through age 
26 years. Both males and females can begin receiving the HPV vaccine as early as 
age nine years. Recommendation of the vaccine prior to adolescence has been done 
with the goal of getting children vaccinated and immunized against HPV prior to 
potential exposure to infection (Schuchat, 2015).  
Researchers have studied whether a two-dose series was sufficient to develop 
immunity against HPV. While the exact level of antibodies needed for protection 
against HPV is unknown, a Costa Rican study of the bivalent HPV vaccine found that 
those who received one, two, or three doses of the vaccine produced antibodies 
against HPV, at stable levels, four years after vaccination (Safaeian et al., 2013). 
Recipients of two doses had higher antibody levels than one-dose recipients, but 
similar levels of protection to those who received three doses. Such findings led the 
CDC to issue a press release on October 19, 2016 that stated that vaccine recipients 
11-12 years of age need only receive just two doses of the HPV vaccine at least six 
months apart (Centers for Disease Control and Prevention, 2016c). The CDC also 
recommends that those who begin their vaccination series between ages 15-26 years 
receive the traditional three-series vaccination sequence. In this series, after receiving 
the first dose, the recipient should wait one to two months prior to receiving the 
second dose (Petrosky et al., 2015). The third dose should be administered at least six 
months after the first dose. If the vaccination schedule is interrupted, it does not need 
to be restarted.  
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As of 2016, the HPV vaccine has been available in the United States for a 
decade. Despite this vaccine being on the market and the CDC and ACIP advocating 
that people get vaccinated, vaccination rates in several parts of the nation, including 
Kansas, are low. 
HPV vaccination in Kansas. In 2013, Kansas was tied for last among U.S. 
states with the lowest rate of three-series vaccination completion (Hart, 
2015).Vaccination rates have varied widely across the state. Reports from 2014 
estimate that by  county, HPV vaccination 3-dose series completion rates among 11-
18 year olds ranged from 3% (Clark County [Southwest Region]) to 48% (Graham 
County [Northwest Region]) (Immunize Kansas Coalition, 2017c; Kansas Adjutant 
General's Department, 2017). For females, the HPV vaccination rates by county range 
from 4% (Clark County) to 58% (Lane County [Southwest]) (Immunize Kansas 
Coalition, 2017a; Kansas Adjutant General's Department, 2017), and for males, 1% 
(Clark, Hamilton [Southwest], Harper [South Central], and Stanton County 
[Southwest]) to 42% (Graham County [Northwest]) (Immunize Kansas Coalition, 
2017b; Kansas Adjutant General's Department, 2017). 
According to the CDC’s 2015 National Immunization Survey-Teen (NIS-
Teen), Kansas females 13-17 years of age ranked 48th among the 50 U.S. states for 
receiving at least one dose, 38
th
 for two doses of the series, and 44
th
 for receiving 
three or more doses. Of those females that received at least one dose, Kansas ranked 
34
th
 in the nation for series completion (Centers for Disease Control and Prevention, 




Table 3: HPV Vaccination Coverage, U.S. and Kansan Females (13-17 Years of Age)1 
Doses (at least) U.S. Kansas Kansas Rank (50 
U.S. states) 
One dose 62.0% 50.9% 48
th
 
Two doses 52.1% 43.6% 38
th
 













1. (Centers for Disease Control and Prevention, 2016a) 
Kansas males (see Table 4 and Figure 6) 13-17 years of age ranked 48
th
 
among the U.S. 50 states for receiving one dose of the HPV vaccine as well as for 
two doses, and 47
th
 for three or more doses. Of males that received at least one dose, 
Kansas ranked 40
th
 in the nation for series completion.  
Table 4: HPV Vaccination Rates, U.S. and Kansan Males (13-17 Years of Age)1 
Doses (at least) U.S. Kansas Kansas Rank (50 
U.S. states) 
One dose 50.0% 36.0% 48
th
 
Two doses 39.1% 26.3% 48
th
  


















Figure 6: HPV vaccination rates of those who have received one or more doses of the HPV vaccine, by gender. 
For both females and males, Kansas ranks in the lowest groups (National Cancer Institute, 2016) 
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Concerning race and HPV vaccination rate, complete data for Kansas is not 
available, but national and state statistics can provide some context. Most Kansans 
identified as White (non-Hispanic or Latino) (76.4%), greatly outnumbering the 
percentage of Hispanic or Latino (11.6%), Black (6.3%), Asian (2.9%), multiracial 
(2.9%), American Indian and Alaska Native (1.2%), and Native Hawaiian and other 
Pacific Islander (0.1%) people; also, females (50.1%) slightly outnumber males 
(49.9%) (United States Census Bureau, 2017). The NIS-Teen survey reported that in 
2015 among females 13-17 white adolescents received the HPV vaccine at a lower 
rate than other groups for one, two and three doses (see Table 5) (Reagan-Steiner et 
al., 2016). 
 
Table 5: U.S. HPV Vaccination Rates, Race (Females 13-17 Years of Age)1 
Doses 
(at least) 
White* Black* American 
Indian/Alaska 
Native* 
Hispanic Asian* Multiracial 
≥1 dose 59.2% 66.9% 68.4% 70.5% 63.8% 62% 
≥2 doses 49.4% 51.9% 57.8% 55.4% 58.1% 51.0% 
≥3 doses 39.6% 40.8% 46.2% 38.7% 53.5% 42.5% 
*Non-Hispanic         \ 
1.  (Reagan-Steiner et al., 2016) 
 
Among males 13-17 years of age, like females, white adolescents received the 






Table 6: U.S. HPV Vaccination Rates, Race (Males 13-17 Years of Age)1 
Doses 
(at least) 
White* Black* American 
Indian/Alaska 
Native* 
Hispanic Asian* Multiracial 
≥1 dose 43.8% 54.0% 58.9% 58.5% 49.6% 58.8% 
≥2 doses 34.9% 37.1% 47.8% 48.6% 39.8% 46.8% 
≥3 doses 25.2% 26.0% 35.0% 34.6% 30.7% 30.6% 
*Non-Hispanic          
  
1. (Reagan-Steiner et al., 2016) 
 
Between sexes, females receive the HPV vaccination at a higher rate than males. 
White males and females are the least HPV-vaccinated group compared with other 
races of the same sex.  
Concerning socioeconomic status, 13.6% of Kansans live below poverty level 
(Kansas Health Matters, 2017). For all races and genders, and doses, people who are 
below the poverty level in the United States have higher reported HPV vaccination 
rates than those who are at or below the poverty level (see Table 7) (Reagan-Steiner 
et al., 2016). 
 
Table 7: U.S. HPV Vaccination Rates, Poverty Level (13-17 Years of Age) 1 
Doses (at least) Below poverty level At or above poverty level 
Females   
≥1 dose 70.0% 60.4% 
≥2 doses 56.6% 50.5% 




≥1 dose 61.1% 46.0% 
≥2 doses 46.7% 36.3% 
≥3doses 31.0% 27.4% 




In summary, it is likely that because most Kansans identify as a white and live 
above the poverty level, vaccination rates are going to be lower for a larger segment 
of the population. Because parents and guardians are most likely charged with the 
responsibility of getting their children vaccinated, and the health belief model (HBM) 
(Rosenstock, 1974; Rosenstock et al., 1988) suggests that their health beliefs may 
influence whether or not they get their children vaccinated against HPV, insight into 
their HPV vaccine perceptions may provide insight regarding low vaccination rates. 
The Health Belief Model in Context 
The health belief model (HBM) (Rosenstock, 1974; Rosenstock et al., 1988) is 
useful to examine the low HPV vaccine rates among Kansas children because the 
model was designed to examine engagement in preventive health behaviors. These 
are behaviors that individuals perform to avoid disease. While theories are very useful 
in explaining phenomena, theory-based approaches sometimes exclude social 
environmental factors that may influence people on an individual level (Corcoran, 
2007). Models, however, “usually seek to include key elements of behavior and 
decision-making processes” (p. 11), and take individual differences more into 
account. Given the regional focus of this study, and the emphasis on parents and 
guardians, a model-based approach was found to be a good fit for this research. 
Rosenstock (1974) credits the origin of the model to be the result of the 
research environment and the experiences and training of the researchers who 
contributed to the model’s development. Considering the setting, Rosenstock states 
that during the 1950s (the defined starting point of HBM development), the Public 
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Health Service in the United States was focused mainly on preventing disease, not 
disease treatment. Furthermore, there was “widespread failure of people” (p. 328) to 
engage in disease-preventing behavior despite the various preventive measures (e.g., 
screening test) being free or inexpensive. Concerning the researchers, Rosenstock 
(1974) shares that he and colleagues were phenomenologically oriented, meaning 
they believed individual perceptions determines whether one will engage in a 
behavior. The development of HBM was not solely motivated by solving problems 
one by one, but with “a strong commitment toward theory building” and a 
commitment “toward the gradual accretion of scientific information by building on 
the work of others” (p. 329). 
According to Rosenstock (1974) the driving assumption of the health belief 
model is that diseases have a negative value in a person’s “life space” (p. 330), thus, 
people will try to move away from that “region” (p. 330), or the state of acquiring 
disease. In this study, the disease is HPV infection. In the context of HBM, in order 
for a person to engage in a preventive health behavior, Kansan parents and guardians 
getting their children the HPV vaccination in this study, a parent would need to 
believe that 1) their child is susceptible to getting HPV regardless of whether or not it 
is symptomatic, 2) that HPV would be, at minimum, of moderate severity, and 3) that 
getting their children the vaccine, would serve as a benefit by reducing the 
susceptibility or severity of HPV infection in their children. Furthermore, getting their 
children vaccinated would need to avoid having to overcome psychological barriers 





Figure 7: Representation of the health belief model (Clipartsgram.com, 2017) 
 
Perceived susceptibility. Perceived susceptibility is the level of subjective 
risk that one feels that he or she has to acquiring a disease (Rosenstock, 1974). 
Rosenstock (1974) notes that while a person may acknowledge a statistical possibility 
of acquiring a disease, the same person may also feel their odds of acquiring the 
disease are low. For this reason, HBM focuses on personal perception of risk, and not 
scientific assessment of disease susceptibility.  
Despite HPV being the most common sexually transmitted infection (Centers 
for Disease Control and Prevention, 2016n), some people perceive low personal 
susceptibility to infection. Cohen and Head (2013) conducted 83 in-depth interviews 
with women 18 to 26 years of age and found that participants who did not get the 
HPV vaccine “demonstrated a particular lack of understanding about their probability 
of susceptibility to HPV infection” (p. 1126). When women were asked about why 
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they did not get the vaccine, some participants responded that they did not feel it was 
necessary because they did not have sex a lot, or did not engage in promiscuous 
sexual behavior. Some participants indicated that their religious and moral beliefs, 
picking the right partners, and using birth control made them less at risk for infection. 
Regarding parents getting their children vaccinated, a study found that the two most 
common reasons that parents (with no intention to vaccinate during the next 12 
months) gave for not getting their daughters vaccinated against HPV were that the 
HPV vaccine was not necessary and that their daughter was not sexually active 
(Centers for Disease Control and Prevention, 2013).  
According to Rosenstock (1974), perceived susceptibility of a disease 
influences one’s perception of threat from that disease, which in turn, influences the 
likelihood of engaging in a preventive health behavior. As this model extended to this 
research, it is likely that Kansas parents who perceive that their children are not 
susceptible to HPV infection are less likely to get their children vaccinated against 
HPV. 
 Perceived severity. Perceived severity focuses on the subjective feeling that 
acquiring a disease will have further negative consequences and implications on one’s 
life. Rosenstock (1974) adds that the perception of severity could be the result of the 
health events caused by having a disease, or more distant events, such as social or 
economic consequences. 
According to HBM, it is likely that the more severe a disease is perceived, the 
greater the likelihood of engagement in preventive health behavior (Rosenstock, 
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1974). Rosenstock (1974) states that “[p]erceived susceptibility and severity having a 
strong cognitive component are at least partly dependent on knowledge” (p. 331). An 
assessment of Kansan parents and guardian knowledge and awareness of HPV would 
provide insights into their perception of their children’s level of susceptibility to HPV 
and how severe the consequences of HPV infection might be for those children. This 
could provide key insights about HPV vaccination rates among children in Kanas.  
Perceived benefits and barriers. Rosenstock (1974) notes that while a 
person may feel susceptible to acquiring a disease, and that the disease is also severe, 
that the preventive health behavior may present varying levels of benefits and 
barriers. Benefits, perceived as efficacious steps to prevent and/or control acquisition 
of a disease, are factors that would encourage one to engage in a preventive health 
behavior. HPV vaccination’s ability to protect Kansan children from infection and 
associated diseases would be a benefit. Research supports that the HPV vaccine can 
reduce the incidence of HPV-associated genital warts (Canvin, Sinka, Hughes, & 
Mesher, 2016). In England, researchers noted a decades-long trend of increasing 
incidence of genital warts. Then, following the introduction of bivalent (Types 16 and 
18) HPV vaccine in 2008, there was a reduction in genital wart diagnoses of “30.6% 
among young women aged 15–19 years and 25.4% among same age heterosexual 
young men” (p. 125), demonstrating a positive outcome of HPV vaccination. 
In HBM, barriers, perceived as negative factors associated with the preventive 
health behavior (e.g., expensive, painful), would discourage preventive health 
behavior engagement. An individual’s demographic characteristics (e.g., age, sex, 
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gender, race), sociopsychological variables (e.g., socioeconomic class, social groups), 
and structural variables (e.g. knowledge about the disease) influence the perceptions 
of benefits and barriers of the preventive health behavior. Concerning the HPV 
vaccine, the benefits of preventing HPV infection and associated diseases may 
compete with barriers of cost, lack of effective initiatives, along with negative 
attitudes and beliefs about the vaccine.   
Cost and legislation. Cost can be a barrier to engaging in preventive health 
behavior (Rosenstock, 1974). Without insurance, the HPV vaccine costs $130 per 
injection, $390 for three doses (The Henry J. Kaiser Family Foundation, 2015). 
However, because the HPV vaccine is recommended by the ACIP, it is covered by 
insurance in most cases (Centers for Disease Control and Prevention, 2016m). For 
parents who need assistance to pay for the HPV vaccine, the Vaccines for Children 
Program (VFC) provides vaccines for children 18 years of age and younger, those 
who are uninsured or underinsured, Medicaid eligible, or are American Indian/Alaska 
Native. Additionally, the Affordable Care Act (ACA) requires that new private 
insurance plans cover the HPV vaccine for adolescents (The Henry J. Kaiser Family 
Foundation, 2015). However, lack of insurance coverage or limited in-network 
providers in rural areas, along with grandfathered insurance plans that do not have to 
adhere to ACA guidelines may result in the HPV vaccine being costly (Schuchat, 
2015). Recommendations have been provided to address barriers to HPV vaccination. 
Public financing resources such as Vaccines for Children (VFC) Program, the 
Immunization Grant Program, Medicaid, and the Children’s Health Insurance 
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Program (CHIP), may help alleviate the financial burden of the HPV vaccine 
(Petrosky et al., 2015).  
Across the United States, mandates, education, and funding programs have 
been implemented to increase access to the HPV vaccine, but these efforts vary. As of 
2016, 29 states have no laws requiring HPV vaccination for school entry, funding to 
cover the cost of the vaccine, or requiring public education about the vaccine (The 
Henry J. Kaiser Family Foundation, 2015). Five states mandate funding for the 
vaccine, twelve states mandate education, two states mandate funding and education, 
one state and the District of Columbia mandate the vaccine for school entry, and one 
state mandates funding and requires the vaccine for school entry. Kansas has no laws 
requiring HPV vaccinations for school entry, for providing funding for the vaccine, 
nor for requiring public education about the vaccine (The Henry J. Kaiser Family 
Foundation, 2015).   
Government initiatives. The Kansas Department of Health and Environment 
(KDHE), which “is committed to finding areas for continual improvement and 
working together to achieve success in preventing disease and injury, helping people 
manage existing health conditions and promoting healthy behaviors” (Kansas 
Department of Health and Environment, 2016a, p. 37), has a dedicated mission to 
stop the spread of sexually transmitted infections and HIV (Kansas Department of 
Health and Environment, 2016b). While HPV is a sexually transmitted infection, the 
Disease Intervention Program “focuses on gonorrhea, syphilis, and HIV, but also 
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provides some follow-up with chlamydia” (Kansas Department of Health and 
Environment, 2016b, para. 3) and does not mention HPV.  
Information about Kansas’ goals for addressing HPV however can be found in 
the Kansas Cancer Prevention and Control Plan 2012-2016 (Kansas Department of 
Health and Environment, 2012). In their 2012 Plan, the KDHE outlines that one of its 
objectives is to increase the rates of HPV immunizations among adolescents. The 
agency’s strategies are, first, to “[a]ssess the knowledge, attitudes, and practices of 
Kansas health care providers as it relates to HPV,” and second, to “[d]evelop, 
coordinate, and disseminate tools to promote HPV vaccination based on assessment 
of Kansas health care providers and in partnership with key partners” (p. 21). In the 
Plan, KDHE states that 25.1% of females aged 13-17 years old reported being 
vaccinated with three or more doses of the HPV vaccine. The KDHE’s five-year 
target goal was to increase that 25.1% to 40%. However, as the number of Kansas 
females who receive three or more doses of the HPV vaccine is reported to most 
recently be at 31.7% (Centers for Disease Control and Prevention, 2016a), the KDHE 
has fallen short of its objective. Concerning Kansas males 13-17 years of age, the 
Kansas Cancer Prevention and Control Plan 2012-2016 reported no baseline data for 
Kansas males 13-17 years of age receiving three or more doses of the HPV vaccine, 
and had no five-year target objective.  
While the Kansas Cancer Prevention and Control Plan 2012-2016 strategies 
for increasing HPV vaccination rates stated that KDHE took into consideration the 
perspective and knowledge of Kansas healthcare providers, the agency did not report 
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the perspective and knowledge of Kansan parents and guardians of adolescents. 
Assessment of Kansas parents’ attitudes, beliefs, and perception of risk surrounding 
HPV and the HPV vaccine may prove useful to explaining low HPV vaccination rates 
among adolescents in the state.  
Attitudes & beliefs. Support for vaccines in the U.S. varies. In a U.S. national 
telephone survey, Gellin, Maibach, and Marcuse (2000) found that while the majority 
of parents support vaccination, about one-fourth believe that their child’s immune 
system would be weakened if the child received too many immunizations. Slightly 
less than a quarter of surveyed parents (23%) felt that their children receive an 
excessive amount of immunizations. A more recent study found that 83% of U.S. 
adults think that vaccines are healthy for children (Doherty, Motel, & Weisel, 2015). 
The same study also found that nearly one-tenth of U.S. adults felt that vaccines were 
unsafe. This study gave participants the opportunity to express their opinions about 
vaccines in answer to open-ended questions. One participant stated that vaccinations 
are unsafe “[b]ecause they’re injecting you with a disease to prevent a disease” (p. 3). 
Another participant stated that “[s]ome children cannot take the vaccines. They cause 
autism and other problems, muscular problems, occasionally, but not often” (p. 3) In 
another recent study, most Americans (82%) support requiring all school-age children 
being vaccinated against measles, mumps, and rubella (MMR), but 10% believe that 
vaccination risks outweigh the benefits (Funk, Kennedy, & Hefferon, 2017). 
The opposition to vaccines can be often attributed to the anti-vaccination, or 
the “anti-vax,” movement (Addis, 2015). Despite the immunity to disease that 
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vaccinations offer, and their potential to prevent illness, disability, and death, 
followers of the movement, (i.e., “anti-vaxxers”), often believe vaccines are harmful 
and ineffective. Anti-vaxxers range in their views from being completely against 
vaccines, to only supporting a select few vaccines, to supporting alternative 
vaccination schedules. Anti-vaxxers often root their stance in distrust of the 
government. In 2007, pediatrician Robert Sears published the book The Vaccine 
Book: Making the Right Decision for your Child. In his book, Sears suggests that the 
Centers for Disease Control and Prevention and pharmaceutical companies work 
together to create vaccines with the goal of achieving profit, even if it is at the 
expense of public safety (Offit & Moser, 2009; Sears, 2007). Sears also speaks at 
length about vaccine safety. Concerned that children receive too many vaccinations in 
their tender youth, Sears offers an alternative vaccination schedule, suggesting that 
parents can space out, delay, or even forgo various vaccinations. Sears also claims 
that anti-vaxxers can rely on other people getting vaccinated to protect them (herd 
immunity), and that some diseases, for which there are vaccines, are not harmful 
(Sears, 2007). Although this book has been widely criticized and has been said to 
contain misleading and false information, it has managed to sell an excess of 40,000 
copies (Offit & Moser, 2009). 
Sears is not the only successful person to influence people that vaccines can 
be unsafe. In 1998, former medical research and gastroenterologist Andrew 
Wakefield, along with his colleagues published an article in The Lancet that held that 
the measles, mumps, and rubella (MMR) vaccine was responsible for cases of autism 
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and bowel disease in children (Wakefield et al., 1998). More than a decade later in 
2010, the article was retracted after a British medical panel found that Wakefield and 
colleagues had produced unethical and dishonest research (Harris, 2010). The 
influence of the article has and still continues to be felt, as people still fear that 
vaccines cause autism (Doherty et al., 2015), and even medical professionals have 
been found spreading anti-vaccine messages (Belluz, 2017). 
In addition to parents expressing attitudes that the HPV vaccine is 
unnecessary for their children because they are not sexually active, some were 
concerned that the HPV vaccine would lead to children engaging in sexual activity 
(Brewer & Fazekas, 2007). In response to these concerns, Smith, Kaufman, Strumpf, 
and Lévesque (2014) conducted a study to investigate if there was evidence to 
support the fear of many parents that if girls were to receive the HPV vaccine, that it 
would invite them to engage more often in risky sexual behaviors. In the study, 
researchers collected data about 260,493 grade 8 girls in Ontario, Canada, two years 
before and two years after the implementation of the Ontario HPV vaccination 
program to see if those who received the vaccine (post program implementation) 
engaged in riskier sexual behavior compared to the control (before the program). To 
measure this, researchers looked at indicators for risky sexual behavior (incidence of 
pregnancy and non-HPV STIs) in grades 10-12. There was no evidence that 
vaccination increased risk of sexually risky behavior (RD: -0.61, RR: 0.96). Thus, 
research supports that this vaccine is not a license for increased sexual activity.  
Cues to action and self-efficacy. Internal (e.g. psychological) or external 
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(e.g. a conversation with a clinician) cues to actions can prompt engagement in a 
preventive health behavior (Rosenstock, 1974). Recommendations for addressing 
attitude barriers that can prevent HPV vaccination include stronger HPV vaccine 
recommendations from healthcare providers, giving the vaccine to patients at the 
same time as T-DAP boosters and meningococcal vaccinations, giving frequent 
reminders, and allowing for quick vaccination visits (Centers for Disease Control and 
Prevention, 2015e, 2015g; Petrosky et al., 2015). It is also recommended that greater 
emphasis is placed on the vaccine as a cancer-preventing measure as research 
suggests that vaccination does not lead to increased sexually promiscuous behavior 
(Centers for Disease Control and Prevention, 2013; Smith et al., 2014).  
The CDC has also published guides for how clinicians should talk to parents 
about the HPV vaccine. Some of the tips include “[r]ecommend HPV vaccination in 
the same way and on the same day as all adolescent vaccines,” (p. 1) and guides 
clinicians to tell parents who are “worried my child will think that getting this vaccine 
makes it Ok to have sex” that “[s]tudies tell us that getting HPV vaccine doesn’t 
make kids more likely to start having sex. I recommend we give your child her first 
shot today” (Centers for Disease Control and Prevention, 2016o, p. 1). 
In 1988, the health belief model was updated to include the component of self-
efficacy (Rosenstock et al., 1988). While a person can believe that she is susceptible 
to a disease, that it would be severe, and that engaging in a preventive health behavior 
presents more benefits than barriers, she would still have to believe that she “can 
successfully execute the behavior required to produce the outcomes” (p. 178). 
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Although this has been previously included under perceived barriers, its specific and 
separate categorization allow for “[g]reater advances in explanation, prediction, and 
control” in “reducing, not increasing, the range of dimensions included in this concept 
[perceived barriers]” (p. 179). Self-efficacy information can be based in performance 
accomplishments (e.g., going to get a child another vaccination), vicarious 
experiences (e.g., seeing a friend get his child vaccinated), verbal persuasion (e.g., a 
commercial telling a parent how to get their child vaccinated), and physiological 
states (e.g., anxiety about cancer causes a parent to get their child vaccinated). In the 
field of psychology, self-efficacy theory posits that “expectations of personal efficacy 
determine whether coping behavior with be initiated, how much effort will be 
expended, and how long it will be sustained in the face of obstacles in personal and 
aversive experiences” (Bandura, 1977, p. 191). Applied to HBM, Rosenstock et al. 
(1988) argue that the addition of self-efficacy is especially important when 
considering chronic illness and health issues requiring long-term changes and lifelong 
habits.  
 Self-efficacy was one of the variables analyzed by Briones et al. (2012) in 
their study of the representation of the HPV vaccine on YouTube. In their study, the 
variable was “defined as steps one could take to obtain the vaccine” (p. 481), and was 
present in 34.30% of videos analyzed. According to research, representations of self-
efficacy could strengthen one’s resolve to get the HPV vaccine, however more 
research is needed in this area to understand the variable’s role in engaging in 
preventive health behavior. 
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The health belief model is a useful lens to approach the study of Kansan 
parent and guardian engagement in the preventive health behavior of getting their 
children vaccinated. The overview of literature highlights that previous HPV vaccine-
related research focuses heavily on perceived barriers. However, it is suspected the 
HPV vaccine may be perceived by some Kansan parents and guardians as more than 
just a barrier, and possibly also a risk event. 
 Social Amplification of Risk Framework  
In addition to health beliefs, this research also considers Kansan parent and 
guardian HPV vaccine-related risk perceptions. The popularity of the work done by 
Sears (2007) and Wakefield et al. (1998), along with studies that indicate that some 
people believe that vaccines are dangerous (Doherty et al., 2015; Funk et al., 2017) 
suggests that participants may perceive the HPV vaccine as a risk event. Thus, 
incorporating an additional lens of the social amplification of risk framework (SARF) 
is useful to analyzing perceptions of the HPV vaccine.  
The social amplification of risk framework (SARF) (R. Kasperson et al., 
1988) was introduced in the late 1980s, based in organizational risk communication 
as an: 
“[a]ttempt to overcome the fragmented nature of risk perception and risk 
communication research by developing an integrative theoretical framework 
capable for accounting for findings from a wide range of studies…to describe 
the various dynamic social processes underlying risk perceptions and 
response.” (J. Kasperson et al., 2003, p. 13) 
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In the framework, a risk event occurs, defined by several characteristics (e.g. 
someone gets sick after receiving the HPV vaccine) (R. Kasperson et al., 1988). 
Information about that event is portrayed (e.g., in a social media post about someone 
becoming sick after receiving HPV vaccine), which in turn gives a signal about the 
risk event. The interpretation of the portrayal of the event could either amplify (e.g., 
thinking the HPV vaccine is dangerous) or attenuate the perception of risk (e.g. 
thinking the HPV vaccine is not dangerous). The interpretation and response to the 
risk event could have ripples (e.g., Kansan parents avoid getting their children the 
HPV vaccine), and even secondary impacts (e.g., incidences of HPV-associated 
genital warts increase among Kansan adolescents). While this research will look for 
evidence of related ripples and impacts, this dissertation is primarily concerned with 
the orientation of the HPV vaccination as a risk event and whether the perception of 
risk is amplified or attenuated through social media channels (see Figure 8).   
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Risk amplification and media. According to SARF, risk is not only a 
physical experience, but also “the result of processes by which groups and individuals 
learn to acquire or create interpretations of risk” (J. Kasperson et al., 2003, p. 15). 
Interpretations, according to the model, are influenced by interactions between 
sources of information, information channels, social stations, individual stations, and 
institutional and social behavior. The interpretation in turn can amplify one’s 
perception of risk, or attenuate it.  
Originating in organizational risk communication, SARF has also been 
applied to  the analysis of health-related events ranging from Bovine Spongiform 
Encephalopathy (BSE) and the British media (Eldridge & Reilly, 2003), to the 
influence of mass media and blame related to the Plague and arsenic levels in India 
(Susarla, 2003). In their study of BSE and the British media, Eldridge and Reilly 
(2003) found that the number of news stories focused on BSE did not represent the 
number of reported BSE cases. In fact, the number of BSE-related news articles 
peaked when the number of reported cases was lower, and when there was peak in 
reported cases in 1996, the number of news articles was on the decline, demonstrating 
that panic does not always mirror reality. Furthermore, media can have a role in 
blame. In his study of arsenic and Plague cases in India, Susarla (2003) found that 
there were incidences of mass media stories assigning blame for the Plague to the 
victims, and inferred from this that the characteristics of mass media blaming 
messages may matter as much as the quantity of their presence. 
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The HPV vaccine has potential side effects (e.g., headache, injection site 
reactions, nausea) (U.S. Food and Drug Administration, 2011). The CDC states that 
despite the potential side effects that the HPV vaccine is safe. To test their safety, the 
different types of HPV vaccine were tested in 74,000 volunteers, and monitoring 
systems are in place to oversee adverse events. Adverse events are classified as 
serious if they threaten one’s life, result in death, lead to disability, birth defects, or 
prolonged hospitalization. The CDC states that from June 2006 to March 2016, nearly 
79 million doses of Gardasil® have been distributed and that 33,945 adverse events 
have been reported in the United States. There were also 232 reported adverse cases 
related to Cervarix® (of 720,000 doses), and 1,447 adverse event cases related to 
Gardasil® 9 (of 10 million doses), nationwide. Of the reported adverse events, 7% 
were reported to be serious. Also, although 117 deaths were reported in people who 
received Gardasil® between June 2006 and September 2015, the CDC concluded that 
there was no evidence that Gardasil® was the cause of death.  
The review of literature demonstrates that if one perceives the HPV vaccine as 
dangerous, that it could be a barrier to vaccination. It is then useful to examine if the 
portrayal of the HPV vaccine could possibly amplify Kansan parents’ and guardians’ 
risk perceptions. Going a step further, it may be useful to analyze the role of media in 
shaping HPV vaccine-related risk perceptions, as the studies conducted by Susarla 
(2003) and Eldridge and Reilly (2003) emphasize the role of media in risk messaging. 
Specifically, given the increase in the function and popularity of the internet, 
particularly social media, this study focuses on the HPV vaccination-related messages 
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from that channel. 
Internet Use and Health Information 
When the Pew Research Center began keeping record in 1995, a survey 
reported that 14% of U.S. American used the internet (Pew Research Center, 2017a). 
As of January 2016, a reported 88% of U.S. American adults use the internet (Pew 
Research Center, 2017b). The internet has become a source of information and 
influence for health. A survey found that 35% of U.S. adults have used the internet to 
diagnose a medical condition for themselves or someone else (Fox & Duggan, 2013). 
These searches would have mixed results. Nearly half (46%) of the respondents 
reported that their research made them think that they needed the attention of a 
medical professional, while 38% thought it could be handled at home, and the 11% 
thought it was either both or somewhere in the middle of spectrum. Less than half 
(41%) of people who researched and diagnosed from online information have a 
medical professional confirm a diagnosis(Fox & Duggan, 2013). Often times, many 
of those (35%) that diagnosed from online research did not get a professional opinion, 
and a number of those who did (18%) reported that a medical professional either 
offered a differing opinion or did not agree with the online-based diagnosis.  
This same survey found that women are more likely than men to diagnose 
conditions from information found on the internet (Fox & Duggan, 2013). 
Additionally, younger, white, wealthier (i.e., house incomes of $75,000+, and more 
educated [i.e., those with college degrees or greater]), are more likely to go online to 
try to diagnose a condition. 
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The internet has facilitated the ability of health information to become more 
social. Twenty-six percent of U.S. adults report reading or watching someone else’s 
health or medical issue experience within the past year and 16% report going online 
to find others who share in like health concerns (Fox & Duggan, 2013). Seventy-two 
percent of U.S. adult internet users reported looking online for health-related 
information in the past year (Fox & Duggan, 2013). Of those searches, 77% began on 
search engines (e.g. Google), 13% on a website which specializes in providing health 
information (e.g., Centers for Disease Control), 2% began on general websites (e.g., 
Wikipedia), and 1% began on a social media website (e.g., Facebook).  
Although only 1% of health-related information searches begin on social 
media, this is certainly not where the influence of social media on health information 
ends. Social media influences how people now gather, communicate, and perceive 
health-related information, like the HPV vaccine. 
  Social media. Developments in technology have allowed for expression, 
communication, and information-seeking on digital platforms in the form of social 
networking sites (Ellison & boyd, 2013) (also known as SNS; hereafter social media). 
Ellison and boyd (2013) define social media as networked communication platforms 
possessing these three characteristics: 
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1. The ability for users, or entities, to create unique profiles (which can be done 
at the individual, group, or organizational level). 
2. The ability for entities to publicly articulate their connections with other 
entities. 
3. The ability for entities to consume, produce, and interact with user-generated 
content through their connection with other entities. 
To illustrate what distinguishes a social media platform, one can look at the 
difference between Facebook and Netflix as an example. On Facebook, an individual 
can subscribe and create a profile (Facebook, 2017b) as well as add connections 
(friends) (Facebook, 2017a) which can be publicly displayed. Users create their own 
posts, view the posts of other users, and interact with those posts through reactions, 
comments, and shares (Facebook, 2017d, 2017e). In contrast, on Netflix, while a 
subscriber can create a profile (Netflix, 2017), users do not have the ability to connect 
with other members using different accounts, thus they are unable to publically 
articulate those connections. Additionally, there are no possibilities to produce 
content or interact, save the ability to rate available media. Therefore, Ellison and 
Boyd’s (2013) definition would qualify Facebook as a social media platform, but not 
Netflix. 
Ellison and boyd (2013) note that a challenge to defining social media is that 
both the characteristics and expectations for social media platforms continue to 
evolve. For example, the establishment of connections between entities varies from 
one social media platform to another. On Twitter, users can engage in following 
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(Twitter, 2017). When one user follows another, he or she subscribes to the other 
user’s tweets, seeing the other user’s updates, and can receive direct messages from 
the followed user. However, “[f]ollowing on Twitter isn’t mutual. Someone who 
thinks you’re interesting can follow you, and you don’t have to approve it or follow 
them back” (sec. 10) However on another social media platform, Facebook, when you 
request to add another user as a friend, if the invitation is accepted “you automatically 
follow that person, and they automatically follow you” (Facebook, 2017a, para. 1). 
Thus, while connections on Facebook are mutual, connections on Twitter can be 
either mutual or one-way paths. 
 Internet, social media and health information. Anticipating the influence of 
social media, researchers have studied its relationship with health. Since near its 
beginnings, researchers have found that Facebook, in particular, provides an 
accessible channel for patients and healthcare professionals to share with one another 
their experiences related to disease (Farmer, Bruckner Holt, Cook, & Hearing, 2009). 
Looking at social media in more general terms, Moorhead et al. (2013) conducted an 
analysis of literature to “identify the uses, benefits, and limitations of social media for 
health communication among the general public, patients, and health professionals” 
(p. 1). From their analysis of 98 original research publications (published 2007-2012), 
the researchers identified the following seven uses of social media for health 
communication: (1) providing health information for a range of health conditions 
(general public, patients, health professionals); (2) providing answers to medical 
questions (general public, patients, health professionals); (3) facilitating patient-to-
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patient and patient-health professional conversation (patients, health professionals); 
(4) collection of data on patients about their opinions and experiences (patients, 
health professionals); (5) conducting health interventions, promotions, and education 
(general public, patients, health professionals); (6) reducing stigma (patients, health 
professionals); and (7) providing consultations online (patients, health professionals).  
Despite the health communication uses and benefits that social media affords, 
there are also limitations to its use. According to Moorhead et al. (2013), limitations 
included the following: diminished reliability (general public, patients, health 
professionals); concerns about quality (general public, patients, health professionals); 
diminished confidentiality and privacy (general public, patients, health professionals); 
lack of awareness of risk associated with disclosure of personal information on the 
internet (general public, patients); risk associated with using social media and 
communicating incorrect or harmful advice (general public, patients); information 
overloading (general public, patients); uncertainty in correctly applying online 
information to personal health issue (general public, patients); inequity in 
effectiveness of social media to bring about behavior change (general public); adverse 
health outcomes (general public); negative health behavior (general public); deterring 
patients from visiting healthcare providers (patients, health professionals); non-use of 
social media to communicate to patients (health professionals). Research has also 
found that online access to information can be helpful, but if not coupled with 
training about where and how to search for information could have negative 
consequences (e.g., waiting too long for appropriate healthcare) (Geana & Greiner, 
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2011). Concerning a particular forum, the analysis conducted by Moorhead et al. 
(2013) also found that Facebook was the most frequently reported social media site 
used, with sexual health topics being the most frequently discussed. It is likely that 
how these topics (e.g., the HPV vaccine) are discussed in social media could 
influence the perceptions of these topics. 
 Representations of the HPV vaccine on internet and social media. HPV 
vaccination is one of the many sexual health topics that have been discussed on the 
internet and in social media. McRee et al. (2012) examined associations between 
parents’ information-seeking habits with their knowledge, attitudes, and beliefs about 
the HPV vaccine. The researchers found that information had a positive influence on 
parents’ knowledge and attitudes. However, the study did not analyze where on the 
internet parents sourced their information. In another study, Battles (2010) analyzed 
discussions about the HPV vaccine on public internet message boards and found that 
members mostly had positive attitudes toward the vaccine and shared information 
such as opinions about when best to get the vaccine, whether or not they planned to 
be sexually active, and their reasons and barriers to getting the vaccine. These studies 
demonstrate the use of the internet as a forum for generating discussion about the 
HPV vaccine. 
On social media, Keelan, Pavri-Garcia, Tomlinson, and Wilson (2007) 
conducted a content analysis of YouTube videos as a source of information about 
immunizations, and analyzed claims about various vaccines. Of the sample of 153 
videos, the researchers found that the HPV vaccine was the most commonly 
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discussed vaccine (36 videos, 24% of the sample), supporting that it is popular topic 
of discussion. Ache and Wallace (2008) also analyzed YouTube videos, specifically 
about the HPV vaccine. The researchers found that most of the content was user 
generated, and that three-quarters of the videos in their sample portrayed the vaccine 
positively. In another study analyzing YouTube videos, Briones et al. (2012) found in 
their sample of 172 videos that most videos were negative and disapproving of the 
HPV vaccine. Another finding was that negative videos were found to have 
information about the HPV vaccine that was not factual, and had more allusions to 
conspiracy theories and threats to civil liberties than positive videos possessed.  
On the social media website Myspace, Keelan et al. (2010) found that most 
posts about the HPV vaccine were positive (52%), but many were negative (43%). In 
this study, the researchers also studied the location of the users involved in the 
conversation, finding that opinions (positive/negative expression) were related to 
geography. Negative blogs focused more on questions of safety, cost, objected 
mandatory vaccination policies, collusion by companies and the government, and 
argued the position of abstinence and monogamy as an alternative to the HPV 
vaccine.   
There is evidence that the presence of negative HPV vaccine-related social 
media post can lead to negative perceptions and responses. Dunn, Leask, Zhou, 
Mandl, and Coiera (2015) examined whether or not exposure to negative opinions 
about the HPV vaccination via Twitter communities is associated with “the 
subsequent expression of negative opinions” (p. 1). The researchers found that those 
55 
 
who were more often exposed to negative opinions were more likely to post negative 
opinions themselves. In another study Nan and Madden (2012) performed an 
experiment where they exposed college students to either a negative or positive blog 
post about the HPV vaccine. When compared the control group, those who were 
exposed to the negative blog post held more negative views toward the vaccine, 
perceived it being less safe, and expressed reduced intentions to get the vaccine. 
Exposure to the positive blog post, meanwhile, changed neither the participants’ 
perceptions nor attitudes toward the vaccine, nor their intentions to get vaccinated. In 
summary negative posts about the HPV vaccine may have more an effect than 
positive posts in influencing perceptions. 
This research recognizes the incredible value that previous studies have in 
providing a foundation for this dissertation research. At the time of this particular 
study, however, there is a gap in research related to examining the representation of 
the HPV vaccine on the social media site Facebook – the most used social media site 
among U.S. adults (Greenwood et al., 2016), a popular forum for discussions about 
sexual health Moorhead et al. (2013). Also absent is research about HPV vaccine-
related risk messages. 
Facebook. Not all social media platforms are used equally. Since the 
beginning of measuring social media use, the Pew Research Center has found that 
Facebook is consistently the most popular social media platform among U.S. adults 
18 years of age and older (Greenwood et al., 2016). In 2012, a little over 60% of 
online U.S. adults used Facebook; this number has increased to 79% as of 2016. The 
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use of other social media platforms such as Instagram (32%), Pinterest (31%), 
LinkedIn (29%), and Twitter (24%), have much lower usage rates among U.S. adults, 
by comparison. 
Facebook was launched in 2004 (Facebook, 2017f). Initially developed to 
network university and college students, Facebook launched the “Facebook Wall” 
which allowed people to post messages to their social connections, or “friends.” 
Facebook reached one million active users on December 1, 2004, and the number of 
users would only continue to grow. In 2005, Facebook would increase their 
accessibility by allowing people to subscribe through high school networks, and even 
adding international school networks later that same year. That year also saw the 
addition of Facebook Photos, and the number of users growing to six million.  
In 2006, Facebook for Mobile was launched, further increasing user access 
(Facebook, 2017f). The number of users who would be able to subscribe would 
increase yet again with the addition of work networks, finally expanding availability 
to people regardless of their network connections. At the end of 2006, Facebook 
reported having 12 million active users. Also Facebook introduced the News Feed, 
which “updates a personalized list of news stories throughout the day” (Facebook, 
2006, para. 2), increasing users’ ability to stay current on the activity of other users 
and events. 
 A variety of additions, such as Facebook Video (2007), and the ability to 
access Facebook in different languages (e.g. Spanish, 2008) would further entice 
more users to subscribe (Facebook, 2017f). Facebook would introduce the ability for 
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users to go beyond messaging and react via comments to a user’s wall in 2008 
(Facebook, 2008) and the “Like” button in 2009 (Facebook, 2017f). The number of 
users continued to grow, reaching 500 million active users by 2010. The company 
would unveil the latest iteration of Facebook, “Timeline,” in 2011, allowing for users 
“an easy way to rediscover the things you shared and collect your most important 
moments” and “tell your story” (Facebook, 2011, para. 2-4). Additionally, users were 
now able to subscribe (or not) to the profiles and pages of others, allowing control of 
how often content from various users appears on one’s News Feed (Rait, 2011). By 
2012, Facebook had more than one billion active users (Facebook, 2017f). The 
company would introduce the “Share” button feature to mobile devices, allowing 
users the option to  quickly share stories from other pages and profiles with their 
social network (Koolwal, 2012).   
In 2013, Facebook introduced Like and Share buttons that allowed not only 
allow for exchanges of and reactions to posts inside of Facebook, but also across the 
internet (He, 2013). Furthermore, the company introduced Embedded Posts (Capra & 
He, 2013). According to Capra and He (2013) in Facebook’s Newsroom,  “[w]hen 
embedded, posts can include pictures, videos, hashtags, and other content” (para. 3). 
For example, if someone includes a hashtag in his or her post (a “#” followed by a 
single word/topic/phrase without spaces, punctuation, or special characters 
(Facebook, 2017c)), that hashtag is now able to be clicked, revealing similar content 
posted on Facebook (Capra & He, 2013).  
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Also in 2013, Facebook introduced “Graph Search” (for users using U.S. 
English) which would allow people to search for more than just other users, but also 
for “something specific across people photos, places, interests, and more” (Facebook, 
2013). Facebook would enhance would enhance the now just known as “Search” 
feature (now available across the world) in 2015 (Stocky, 2015). Facebook reported 
that this is intended to be a long-term task, as there are more than one and a half 
billion daily searches, and more than two trillion posts in their index. Through this 
feature, users have the ability to search public posts and conversations along with 
posts from friends from any point in time. Users also have the ability to control the 
audience of posts, both past and present. This feature makes it possible to search 
HPV-vaccine related posts across Facebook. 
In 2016, Facebook increased the way that users can interact with content 
through launching the “Reactions” feature globally (Facebook, 2017f; Krug, 2016). 
Reactions, which Facebook describes as “an extension of the Like button” (Krug, 
2016) allows users to react to a post in a greater variety of ways. In addition to Like, 
added reactions include “Love, Haha, Wow, Sad, or Angry.” That same year, 
Facebook reported an average of 1.18 billion active users and 1.09 billion active 
mobile users each day. Facebook’s reach to such large populations also suggests that 
the messages on the platform, including HPV vaccine-related messages, have an 
audience who can engage with the content in a variety of ways. 
 Facebook use in the U.S. and Kansas. No reliable data about Facebook use 
on the state-level was found in the review of literature, and was inferred by other 
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statistics. It is estimated that Kansas population was 2,907,289 as of July 1, 2016 
(United States Census Bureau, 2017). Slightly more than three-quarters of Kansas 
(75.3%) are 18 years of age or older. 
Based on available data, if 75.3% of the Kansas population is 18 years of age 
or older (United States Census Bureau, 2017) there would be approximately 2.1 
million adults in Kansas. Based on data reported that 88% of U.S. adults use the 
internet (Pew Research Center, 2017c), it is estimated that 1.9 million Kansas adults 
use the internet. Applying the U.S. national data that 79% of adult internet users use 
Facebook, it is estimated that 1.5 million adult Kansans would be Facebook users. 
This is a large audience, which if influenced by HPV vaccine-related messages, could 
possibly be reflected in statewide vaccination rates. 
Research Questions  
The review of literature suggests that the health beliefs and risk perceptions 
held by Kansan parents and guardians may have a role in determining HPV vaccine 
acceptance. Their acceptance or refusal of the HPV vaccine could in turn affect HPV 
vaccination rates among Kansan children. The HPV vaccine-related HBM 
perceptions of specifically Kansan parents and guardians are an uncharted area of 
research. In the context of the social amplification of risk framework, research about 
HPV vaccine-related perception is also uncharted. In addition to awareness of their 
perceptions, awareness of how Kansan parents and guardians engage with the media 
provides insight into who are the key stakeholders in influencing their knowledge. 
Information about the influence of social media provides insights of the influence of a 
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pervasive and ever-developing source of messages. This dissertation was designed to 
address these gaps in research to further knowledge about a phenomenon and 
theoretical application and asks these research questions: 
RQ1. What are the perceptions that Kansan parents and guardians have about 
the human papillomavirus (HPV) vaccine as they relate to the health belief model and 
the social amplification of risk framework?    
RQ2. Regarding information about the HPV vaccine, how do Kansan parents 
and guardians engage with HPV vaccine-related information on social media? 
For these research questions, a survey was conducted to ascertain how the 
population of interest, Kansan parents and guardians of vaccine-eligible children 
(ages 9-17 years), perceive the HPV vaccine and engage with health information 
about the vaccine on social media. The review of literature demonstrates that there is 
a wealth of information about the reasons for low HPV vaccination rates at the 
national level in the United States, but that regional level, specifically in Kansas, 
information is absent. A survey provides a means for analyzing the factors related to 
this phenomenon, as a survey is “a social scientific method for gathering quantifiable 
information about a specific group of people by asking the group members questions 
about their individual attitudes, values, beliefs, behaviors, knowledge, and 
perceptions” (p. 214). Kansan parents and guardians are the focus population in this 
dissertation because they are charged with the responsibility of getting their children 
vaccinated, and thus affect vaccination rates, which are currently low across several 
demographic groups in the state. Furthermore, Kansan parents and guardians of 
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children ages 9-17 years are of specific interest because children in this age group are 
eligible to receive the vaccine, and have not reached the age of majority.  
Developing the survey in the context of the health belief model is appropriate 
because of the model’s focus on the influence of beliefs on preventive health 
behaviors, in this case, the respondents’ children receiving the HPV vaccine. The 
additional focus through the perspective of the social amplification of risk framework 
assists the analysis by allowing research to examine held perceptions in a more 
dynamic way, beyond the assumption of the HPV vaccine being perceived as a 
preventive health behavior. 
 Due to the lack of previous regional-level research regarding low-HPV 
vaccination rates and the role of parents and their beliefs, a series of semi-structured 
interviews with members of the target population were conducted prior to survey 
distribution. Hesse-Biber and Leavy (2011) explain: “[i]nterviewees often have 
information or knowledge that may not have been thought of in advance by the 
researcher” (p. 102). Information from the interviews could reinforce or expand on 
concepts observed in the literature review, but also help survey development to be 
designed specifically for the target audience.  
The research inquiry that this dissertation pursues does not end with the 
perception of Kansan parents and guardians. In addition to perceptions of the HPV 
vaccine, this dissertation also investigates messages communicated by social media in 
the context of the health belief model and social amplification of risk framework, and 
how these messages compare to messages from the nation’s health agency, the CDC. 
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To analyze these messages, a quantitative content analysis was found to be the most 
appropriate methodological approach. A quantitative content analysis is a replicable 
method that allows one to systemically assign numeric values to communication 
symbols, so that statistical methods can be applied which allow the researcher to infer 
conclusions about communication phenomenon, all done in the context of theoretical 
approaches (Riffe, Lacy, & Fico, 2014). The findings from this analysis assist in 
answering the third and fourth research questions: 
RQ3. What are the prevalent HPV vaccine-related messages in posts on the 
social media site Kansan parents and guardians use most often, in the context of the 
health belief model and social amplification of risk framework? 
RQ4. How do prevalent HPV vaccine-related messages in posts on the social 
media site media site Kansan parents and guardian use most often, in the context of 
the health belief model and social amplification of risk framework, compare to HPV 
vaccine-related messages in posts published by Centers for Disease Control and 
Prevention in the decade since the HPV vaccine was approved by the U.S. Food and 
Drug Administration (FDA) (2006-2016)?  
The review of literature found that since the HPV has been available, there 
have been a wealth of studies conducted focusing on its representation on the internet, 
and on social media in particular (Ache & Wallace, 2008; Briones et al., 2012; 
Keelan et al., 2010). These studies, over time, have found a variety of results, some of 
which may appear to contradict one another. It is suspected that the representation, 
and by extension the perception, of the HPV vaccine may have changed over time. As 
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the vaccine has been now available in the United States for ten years, this is an 
optimal time to conduct a longitudinal analysis on the representation of the vaccine 
on social media. Even more, how messages on social media in general compare to the 
messages from the Centers for Disease Control and Prevention – a U.S. government 
organization charged with the role of “[p]romoting healthy and safe behaviors, 
communities and environment” (Centers for Disease Control and Prevention, 2014a), 
is also of interest, and may provide insight into how aligned the public is, or is not, 
with government health interests. 
 While several studies have focused on blogs, Twitter, Myspace, and YouTube, 
the most used social media site among adults over 18 years of age in the United 
States, Facebook, was often not the social media of focus. Other social media sites 
had search capabilities (as indicated in the previous studies), but Facebook did not 
have search capabilities until 2013. Given this development, the use of Facebook 
among adults (which would the survey would support), and the high presence of 
discussion of sexual health topics on this platform, the findings from the survey, and 
that the CDC maintains pages on the platform, Facebook was the most relevant 








Chapter 3: Methods 
Addressing the research questions required the implementation of several 
research methods, resulting in this dissertation being a mixed methods project. 
Because the first two research questions focus on perceptions and behaviors of 
Kansan parents of children ages 9-17 years, the researcher chose to conduct 
qualitative interview that informed an eventual a survey, collecting data from the 
target population. As the latter research questions focus on the prevalence of HBM 
and SARF-related characteristics in social media messages, a quantitative content 
analysis was conducted for data collection.  
Pre-survey Interviews  
Materials and methods used in the process of developing the interview and 
survey instruments and the process of data collection were approved by Human 
Research Protection Program, the research institutional review board of the 
University of Kansas (IRB ID: STUDY00140067), on October 4, 2016.  
Kansan parents and guardians of children ages 9-17 (n = 4) were recruited via 
snowball sampling of personal contacts, reached through face-to-face conversation 
and electronic messaging. The interviewees were interviewed in December 2016 and 
January 2017. Three of the interviews were conducted in-person on the campus of a 
public university and one was conducted over the telephone. Participants were 
furnished with an information statement either electronically or in person. Consent to 
audio record the interview was required to participate. 
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The interviews lasted between approximately eight (8:02) and twelve (12:02) 
minutes. Interviews were transcribed and analyzed. The original audio recordings 
were destroyed upon completion of this dissertation project. 
 Protocol. The interview schedule (see Appendix 1) included questions about 
the participants’ children (ex. “how many children do you have?), challenges about 
finding information related to their children’s health issues, sources of that 
information, social media use, familiarity with HPV and the HPV vaccine, whether 
they had seen information about either on the internet or social media, perceptions 
towards vaccinations in general, the HPV vaccination status of their children, intent to 
get their children vaccinated against HPV, and demographic questions. 
Analysis. The transcriptions (discussed in the findings chapter) were analyzed 
via a close reading. Themes were repeated across the four interviews and often 
reinforced findings from the literature. The results of the analysis were used to tailor 
the final survey instrument to the target population of Kansan parents of children ages 
9-17 years. Findings led to the inclusion of questions about HPV and HPV vaccine 
awareness and their main source of information about the virus and vaccine. The 
interviews also prompted the researcher to ask participant about their social media 
and who they recall posting information about the HPV vaccine. Furthermore, 
interview findings influenced the inclusion of survey questions asking the HPV 




  Recruitment. The survey was generated and administered online using 
Qualtrics software (Qualtrics, 2017), and survey data were collected January 31, 2017 
- March 21, 2017. To recruit participants, the survey hyperlink was sent to each 
county health department administrator of all 105 counties in Kansas, and several 
directors of the Kansas Department of Health and environment. Each email was also 
followed up by phone call. A total of 38 county health departments (Barber, Barton, 
Butler, Chautauqua, Cherokee, Clark, Clay, Crawford, Douglas, Ellis, Finney, 
Graham, Grant, Harvey, Hodgeman, Jewell, Johnson, Logan, Marshall, Meade, 
Osage, Ottawa, Pawnee, Pottawatomie, Reno, Rice, Riley, Shawnee, Sheridan, 
Sherman, Stafford, Stanton, Stevens, Thomas, Wichita, Wilson, Washington, and 
Wyandotte), the Bureau of Family Health Director, and the Director of the Bureau of 
Disease Control agreed to assist in distributing the survey by posting a link to 
webpages and social media pages that they manage. The researcher also posted the 
survey hyperlink to personal social media accounts and sent it via email to personal 
contacts. 
 Instrument. The survey instrument (see Appendix 2) consisted of the 
following 13 sections: informed consent, eligibility, parent/guardian information, 
HPV awareness, HPV perceptions, HPV vaccine awareness, HPV vaccine 
perceptions, media use, social media and HPV representation perceptions, social 
media and HPV vaccine representation perceptions, HPV vaccination status of 
children, demographics and additional questions. 
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The informed consent section provided participants with the informed consent 
letter approved for the study. Respondents who did not agree to the terms of the study 
as defined in the informed consent letter were directed to the end of the survey. The 
eligibility section asked participants if they lived in Kansans, and if they were the 
parent or guardian of a child age 9-17 years old. If participants indicated “no” to 
either of these questions they were directed to the end of the survey. If they 
participants indicated “yes” to both of these questions, they were allowed to proceed 
in the survey. 
The HPV awareness section asked respondents if they had ever heard about 
HPV (human papillomavirus). If yes, respondents were then directed to answer 
questions about HPV perceptions. Respondents were asked about the perceptions of 
HPV on a six-point Likert scale (i.e. “strongly agree,” “agree,” “somewhat agree,” 
“somewhat disagree,” “disagree,” “strongly disagree,” and “I don’t know” [treated as 
missing responses]). Perceptions were gauged in a series of statements about HPV in 
the context of the health belief model (perceptions of children’s susceptibility to HPV 
infection, and the perception of severity of HPV infection in their children) and the 
social amplification of risk framework (is HPV perceived as a risk to their children). 
In the following HPV vaccine awareness section, respondents were asked if 
they had heard of the HPV vaccine (either by that term or other terms, e.g. Cervarix®, 
Gardasil®, or human papillomavirus vaccine). If so, they were then directed to 
questions about HPV vaccine perceptions. In this section, respondents were asked 
about their perceptions of the HPV vaccine in the context of HBM (perceived benefits 
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and barriers related to getting the HPV vaccine for their children) in addition to SARF 
(is the HPV vaccine perceived as a risk to their children). 
Respondents were then directed to questions related to their media use. They 
were asked about their main source for learning about health information for their 
children, questions about social media use, and if/where they had heard about HPV 
and the HPV vaccine on social media. Respondents who indicated that they had seen 
information about HPV were then presented with questions about social media and 
their perception of HPV representations. Respondents were asked to evaluate their 
level agreement with statements about how social media represents HPV in the 
context of HBM (perceived susceptibility of their children, and perceived severity of 
HPV infection in their children) and SARF (is HPV infection in their children a risk). 
Once again, participants were asked to evaluate statements on a six-point Likert scale. 
Respondents were then asked questions about if and how social media influences 
their perception of HPV. 
Respondents who indicated that they had seen information HPV vaccine on 
social media were then presented with a section of questions about their perception of 
HPV vaccine representations on social media. Respondents were asked to indicate 
their level agreement with statements about how social media represents the HPV 
vaccine in the context of HBM (perceived risk and barriers to getting the HPV 
vaccine for their children) and SARF (is HPV vaccination for their children a risk) on 
a six-point Likert scale. Respondents were also asked about if and how social media 
influences their perception about the HPV vaccine. 
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In the next section, parents were asked about the vaccination status of their 
children. Respondents who indicated that their children had not received the HPV 
vaccine were then asked about whether they had any intent on getting their children 
vaccinate before they were 18 years old. In the penultimate section of the survey, 
parents were asked about their demographic characteristics (e.g. sex, race, ethnicity, 
year of birth, county of residence, highest level of education, and household income). 
In the event that respondents indicated that they did not know what HPV 
and/or HPV vaccine were, they were not prompted to answer questions about related 
personal perceptions, perceptions of social media representations, and vaccination 
status of their children. Instead, respondents were furnished with a short description 
of HPV and the HPV vaccine, and then asked if they would engage in follow-up 
actions after receiving the information.  
Analysis. To answer the first research question regarding Kansan parents and 
guardians HPV vaccine-related perceptions, eligible, completed surveys were 
analyzed, using descriptive statistics to calculate the percentage of respondents who 
were and were not aware of HPV and the HPV vaccine. Descriptive statistical 
analyses were conducted to study and report how respondents perceived the HPV 
vaccine in the context of HBM: their children’s susceptibility to HPV infection, 
perception of HPV infection severity, vaccine benefits and barriers, self-efficacy to 
get their children vaccinated, and receptions of cues to get their children vaccinated. 
These analyses were also used to measure respondents’ HPV vaccine related risk 
perceptions in the context of social amplification of risk: amplification or attenuation. 
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Among those who indicated that they were not aware of HPV or the HPV vaccine, 
descriptive statistics were applied to analyze intended behaviors after receiving 
information about the virus and vaccine. Furthermore, the descriptive statistics were 
applied to measure the HPV vaccination status of the respondents’ children, and their 
intent to get them the HPV vaccine prior to their eighteen birthdays. 
For the second research question examining how Kansan parents engage with 
HPV vaccine-related from social media, descriptive statistics were calculated to 
report media usage among respondents who completed the survey. The same 
statistical procedures were applied to analyze respondents’ recall of HPV vaccine-
related posts on social media in the contest of HBM (susceptibility, severity, benefits, 
barriers, self-efficacy, and cue to action) and SARF (amplification). Also analyzed 
were their perceptions of how much social media has influenced their own 
perceptions about the HPV vaccine. Data analyses were performed using Qualtrics 
(Qualtrics, 2017) and SPSS version 23.   
Content Analysis. 
Protocol. The unit of analysis was an individual public Facebook post. This 
study defines a public post as the content of an individual post that can be viewed by 
the public and not just personal connections, as it appears in a search result feed. 
Searches on Facebook indicate if a post is public. The posts will be analyzed as they 
appear in the search results, how it appears on one’s actual personal feed, and 
excludes text beyond the readily displayed information as shown by the Facebook 





Figure 9: An example of a public post. This is the first post under the header “Public Posts.” This post was found 
using the search term "Gardasil." 
 
Non-public posts were not included in the sample as they are not available to all 
audiences beyond the researcher, reducing the replicability of this study. Furthermore, 
the researcher assumed that if the post was not public that the author of the post has 
some expectation of the message remaining private. 
The Facebook search feature was used to collect posts. Searches were 
conducted February 10-16, 2017. The search terms Cervarix, Gardasil, HPV vaccine, 
and human papillomavirus vaccine, were used to focus the search on the type and 
brand names of the vaccine of interest. When searching the terms, the researcher used 
Facebook’s filters to search at the most specific available date level (year, month). 
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The search was limited to Facebook posts that were published between June 2006 and 
June 2016, a decade-long span. The returned results could not be organized by date, 
but are, according to Facebook’s algorithm, organized by relevance (personal context, 
social context, the query, and global popularity) (Wable, 2010). To gather posts from 
the CDC, two additional sets of searches were performed which added a filter that 
allowed the researcher to collect Facebook posts using the defined search terms on 
two Facebook pages run by the Centers for Disease Control and Prevention (“CDC”, 
and “CDC STD”). The researcher printed the results from each search using a 
portable document format (PDF). 
  Due to limitations imposed by how Facebook displays archived public posts 
and the limited technological capabilities of the computers used to compile the 
retrieved data, the researcher was only able to save the first 40 pages of each search (a 
page is defined as all the unique posts displayed in the internet browser at one time). 
A total of 21,130 posts were collected in from the searches (see Table 8).   
 
Table 8: Results by Search Term 





3,615 7,987 7,755 1,733 
CDC - - 35 - 
CDC STD - - 5 - 
 3,615 7,987 7,795 1,733 




Various posts were excluded from the final sample. Because this study was 
concerned with analyzing posts published in the decade since the HPV vaccine’s 
debut, posts published before June 8, 2006 and after June 8, 2016, or had no posting 
date available were excluded from the sample. Posts that were not public were also 
excluded from the sample. This sample also excluded posts that were not written in 
English (including those translated by Facebook), or that were deemed irrelevant 
(e.g., did not discuss the HPV vaccine, or only had the search term in the author or 
audience name, or the search term was not found in the post before clicking “continue 
reading”). 
After the preliminary exclusions, due to time constraints in conducting this 
study, the researcher determined that for years where a search of terms yielded more 
than 300 posts, only 300 randomly selected (via random sequence generator) posts 
from that year/search term would be included in the final sample for analysis. After 
exclusion, the remaining 6,537 posts (n = 6,537) constituted the final sample for the 










Table 9: Posts, Term and Year 







2006 1 9 29 0 0 0 
2007 7 197 175 1 0 0 
2008 8 245 118 1 0 0 
2009 84 300 300 10 0 0 
2010 213 300 300 32 2 0 
2011 300 300 300 99 2 0 
2012 300 300 300 135 1 0 
2013 139 96 300 213 8 0 
2014 57 30 41 194 5 2 
2015 8 300 75 194 5 0 
2016 5 300 64 126 6 0 
Totals 1,122 2,377 2,002 1,005 29 2 
Note. *CDC and CDC STD only used the term “HPV Vaccine” 
The researcher developed the codebook (see Appendix 3) to conduct the 
content analysis. The codebook consisted of four sections: content characteristics, 
tone, HPV-associated disease, health belief model content, and social amplification of 
risk framework content.  
The content characteristics section of the codebook focused on the 
characteristics of the Facebook post that were not related to the theoretical 
components of the study. The analysis included the year the post was published, and 
then the date (day/month) was also coded. Other variables coded included the author 
of the post (Facebook profile, Facebook Page, CDC/CDC STD), gender of the author 
(a page, or if a person, the name and profile picture image cues were used to attempt 
to determine if it should be coded as male, female, or unsure), audience (general, to 
Facebook page, to a Facebook profile), whether that post had a hyperlink 
(absent/present), and whether the post had an embedded video or picture 
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(absent/present). Also, the analysis would involve coding of the number of reactions, 
comments, and shares the post had, and the tone of the post (neutral, positive, 
negative) the tone of the post towards the HPV vaccine (neutral, positive, or 
negative).  
The HPV-associated disease section asked whether or not the posts had any 
mention of cancer (absent/present) or any mention genital warts (absent/present).  
In the health belief model content section, coding items included a record if 
the post had messages about HPV infection susceptibility (absent/present), severity of 
HPV infection (absent/present),  the benefits of the HPV vaccination (absent/present), 
barriers to HPV vaccination (absent/present), HPV vaccine-related self-efficacy 
messages (absent/present), and cues to get the HPV vaccine (absent/present), cues to 
avoid the HPV vaccine (absent/present). 
In the social amplification of risk framework section of the codebook, coding 
items asked if the post amplified or attenuated the perception of HPV vaccine being 
as risk (amplifies, attenuates, neither), whether or not the post indicated any ripples 
(an entity changing behavior because of the perceived risk of the HPV vaccine; 
absent/present), and if there were any secondary impacts as a result of ripples 
indicated in the post; absent/present). The codebook also contained coding 
instructions, examples and notes. In developing the coding sheet, the researcher 
ensured that each question and item in the codebook had a corresponding coding 
sheet item name, and coders were instructed to code accordingly. 
Reliability. Two coders were trained on the codebook, definitions of sections, 
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coding sheet items, and relevant theoretical concepts. Before coding the entire 
sample, 12.3% (n = 808) of the posts were randomly selected, and coded 
independently by both coders to calculate intercoder reliability for the variables. After 
coding the reliability sample, the coders discussed all questions requiring clarification 
and to resolve disagreements, and went back to review their coding sheets. Prior to 
calculating reliability, it was decided that a Krippendorf’s alpha (α) of 0.667 or 
greater would be an acceptable level of agreement for each variable, based on 
previous research that argues that α  ≥ 0.667 should be the lowest limit, a limit that 
allows for tentative conclusions (Krippendorf, 2004a, 2004b). The alpha for each 
variable was calculated, and considered acceptable for reliability (0.67-1.00; see 
Appendix 4 for variable alphas).  
Data analysis. To address the third research question, asking what messages 
about the HPV vaccine were on Facebook in the context of the health belief model 
and social amplification of risk framework, descriptive statistics were calculated to 
report the presence of coding items as related to the theoretical concepts. To address 
the fourth research question, examining how messages about the HPV vaccine on 
Facebook (in the context of the health belief model and social amplification of risk 
framework) have changed over a decade and how they compare to Centers for 
Disease Control and Prevention messages about the HPV vaccine, the researcher 
performed statistical analyses to examine trends of the annual average appearance of 
HBM and SARF variables in Facebook posts. These findings were compared to the 
findings from the content analysis of Facebook posts from CDC-operated Facebook 
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Chapter 4: Results 
This study investigated Kansan parent and guardian perceptions about the 
HPV vaccine, their engagement with HPV vaccine-related information on social 
media, how the HPV vaccine is represented on social media, and how representations 
compare to the CDC’s representation in the decade since its first FDA approval. This 
chapter presents results from the analysis of semi-structured interviews and their 
application to the survey development, along with the results from the statistical 
analyses of data collected from the survey and content analysis.   
Semi-Structured Interviews and Application 
Along with HBM and SARF, findings from a series of interviews contributed 
to the design of the survey instrument used in this study. Recruiting interview 
participants was a notable challenge. Because a portion of the study was dedicated to 
examining perceptions of Kansan parents of children ages 9-17 years, the same group 
was the population of interest for the interviews. Finding such parents was a 
challenge, given the specific population and the sensitive nature of the topic. The 
same challenge would present itself again during the surveying portion of the study, 
and may account for part of the reason that some of the parents and guardians who 
began the survey chose not to complete it.   
Four semi-structured interviews were conducted with Kansan parents of 
children ages 9-17 years (see 
Table 10). Participants were from Douglas, Rice and Shawnee counties. They 
were white (non-Latino) and ranged 31-49 years of age. Three of the participants 
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were female, and all identified as mothers. Their annual household income ranged 
between less than $10,000 and $60,000, and each had at least some college education, 
with the highest degree obtained being a master’s. Participants had either one or two 
children between ages 9-17 years, and none of the children had received the HPV 
vaccine at the time of the interview.  
 
Table 10: Demographics, Semi-Structured Interview Participants 
Sex Female Male Female Female 
Parent/Guardian 
Identity 










Age (Years) 44 49 32 31 
Children 9-17 (sex, 
age [years], HPV 
vaccination status) 
- male, 9, 
unvaccinated 
- female, 9, 
unvaccinate
d 
- female 16, 
unvaccinate
d 
- male, 9, 
unvaccin
ated 
- ?, 9, 
unvaccinated 























When asked where they looking for information about their children’s health, 
all participants mentioned healthcare providers, and two mentioned the internet, 
WebMD in particular. Speaking on vaccines in general, one participant, despite 
recalling that a vaccination led to the development of a high fever, subsequent brain 
damages and seizures, indicated that vaccines are important to prevent “any kind of 
epidemic.” However, she added that she believes there is such thing as too much 
80 
 
vaccination, and does not want to expose her son to a virus as “his immunize system 
is not at all compromised.” Two others supported vaccines, saying they are a “very 
important thing” and “I’m all for it.” However another participant mentioned that she 
was “iffy” about vaccines. 
Participants were also asked if they knew what HPV and the HPV vaccine 
were and all but one were aware; though the aware parents did not know much about 
either. This finding suggested that while likely a greater number of participants were 
aware about the virus and vaccine, that a population of unware parents and guardians 
exists. This led the inclusion of questions asking about HPV and HPV vaccine 
awareness (e.g., “Have you heard of HPV [also known as the human 
papillomavirus]”), so that only aware parents and guardians would be asked their 
perceptions.  
Parents and guardians were asked about their plans to get their children the 
HPV vaccine, as none of the children were vaccinated at the time of the interview. 
One participant felt that her child did not need the vaccine yet, while one was 
concerned, stating: “it’s a little scary; um my son is old enough to receive it. He has 
not received it yet, mostly because of side effects that I’ve heard from people.” The 
mother recalled hearing about her friends’ children experiencing symptoms such as 
dizziness and fainting. Her opinion was that age 17 or 18 years would be an 
appropriate time for vaccination. The vaccine being “new” was also a concern. These 
findings highlighted the value of not only asking about children’s HPV vaccination 
status, but also asking if parents and guardians of unvaccinated children intended on 
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getting their children vaccinated before their eighteenth birthday; thus, this was 
factored into the survey instrument (“…Do you intent on getting this child the HPV 
vaccine before the child is 18 years of age?”). 
The one parent who had not heard of the HPV vaccine mentioned that he 
intended on finding out more information about HPV and the HPV vaccine after the 
interview. This led to an interest in behavioral intentions following exposure to 
information to parents and guardians who had no previous awareness of the vaccine. 
Because the survey design would separate those who were and were not aware, it was 
decided that the survey instrument should also include prompts about HPV and the 
HPV vaccine for those with no awareness. These prompts would also be followed by 
behavioral intention questions related to HPV vaccination of their children (“Based 
on the information that you have just read about HPV and the HPV vaccine, would 
you consider…”). 
None of the participants recalled seeing anything about the HPV vaccine on 
social media. Still, three of the participants identified as social media users. This 
finding led to the inclusion of questions that asked parents and guardians if they had 
seen information about the HPV vaccine on social media before asking them their 
perceptions about the representation of the HPV vaccine on social media (“Have you 
ever seen information about the HPV vaccine on social media? This also includes if 
you’ve only see the information that you have posted, if any.”). Additionally, one 
participant claimed that social media “tend to lie about a lot of things.” Another 
however thought that social media is an important tool to inform about disease and 
82 
 
children’s health issues. Thus, survey questions about their perception about how 
much the information from social media influences their perceptions of the HPV 
vaccine were included in the survey instrument (e.g., “I believe that what I read on 
social media ____ my fear about getting the HPV vaccine for my child” [increases, 
decreases, neither increases nor decreases]). 
Participants were not asked about their social media use during the interview. 
The researcher decided that in order to perform a relevant content analysis, that is, an 
analysis on a social media platform relevant to the target population, that survey 
questions would need to be included to ask parents which social media the use, and 
use primarily (e.g. “Please rank your three most used social media accounts…”).   
Kansan Parents and Guardians, Perceptions of the HPV Vaccine 
Data from the survey were analyzed and used to address the first research 
question (“How do Kansan parents and guardians perceive the human papillomavirus 
(HPV) vaccination [in the context of the health belief model and the social 
amplification of risk framework]?). Before the HPV vaccine perception questions, 
parents and guardians were asked if they had heard of HPV and the HPV vaccine. 
Aware parents and guardians were then presented with statements, and agreement 
was measured on a six-point Likert scale (recoded for data analysis: 1 = “strongly 
disagree,” 2 = “disagree,” 3 = “somewhat disagree,” 4 = “somewhat agree,” 5 = 
“agree,” and 6 = “strongly agree,”), with a higher number indicated greater agreement 
with the statement. The scale also included an “I do not know” response (treated as a 
missing response item) (see  
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Table 11). These parents were also asked about their children’s HPV 
vaccination status and intent to vaccinate if their children were unvaccinated.  
Parents and guardians who had not heard of HPV or the HPV vaccine were 
not asked about perceptions, nor were they asked about their children’s HPV 
vaccination status, as they would likely not know. Instead, these respondents were 
provided with information and then asked about their intent to engage in follow-up 
behaviors.  
 Demographics. The survey was started by 233 individuals. Of those, one 
disagreed to take part in the study after being presented with the information 
statement and three more exited the survey. Of the remaining 229 respondents, 16 did 
not live in Kansas, and three more discontinued the survey. The 160 individuals who 
indicated they were parents of children ages 9-17 years were eligible to continue the 
survey.  
Of the 160 eligible parents and guardians, 63 ended their participation at 
various points, resulting in 97 completed surveys by eligible respondents. Most of the 
data analysis presented in this section is based on the responses from those 97 
respondents; however, some additional information is provided that includes 
responses of all the participants that completed the survey up to that question.  
Respondent demographic questions were placed at the end of the survey, and 
results were only available for 97 parents and guardians. Most of the respondents 
were female (n = 83, 87.4%; males n = 12, 12.6%), and all female respondents 
identified as mothers (see Figure 10). Eleven of the male respondents indicated that 
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they were fathers; the other two reported different guardian identities (“grandfather” 
and “step dad”). Respondents were from 30 of the 105 Kansas counties, and mostly 
from counties in the Kansas City Metro (Johnson and Wyandotte), followed by South 
Central (Barton, Butler, Kingman, Reno, Rice, and Sedgewick), Northeast (Douglas, 
Jackson, Jefferson, Miami, Shawnee, Wabaunsee, and Washington), Southeast 
(Allen, Cherokee, and Crawford) and Southwest (Finney, Seward, and Stevens), 
Northwest (Ellis, Graham, Harvey, Riley, Rush, and Thomas), and North Central 
(Clay, Republic, and Saline) (see Figure 11). The majority of the respondents 
identified as white (n = 86; 90.5%) and non-Latino (n = 91, 95.8%) (see Figure 12). 
Reported birth years ranged from 1957 to 1986 (M = 1975, SD = 6.2) (see Figure 13), 
making respondents approximately between 30 and 60 years of age at the time of this 
study. Most of the respondents had earned a four-year or bachelor’s degree (n = 29; 
29.9%) (see Figure 14), and reported that their annual household income was greater 




Figure 10: The parent identity of survey respondents. Demographic information was only available from eligible 
participants who completed the survey (n = 97). 
 
Figure 11: Respondent region of residence. Demographic information was only available from eligible participants 























Prefer not to answer 
1% 




Figure 12: Racial identity of survey respondents. Demographic information was only available from eligible 
participants who completed the survey (n = 97). 
 
 
Figure 13: Birth years of survey respondents. Demographic information was only available from eligible 


























































































































































































Reported Birth Years 
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Figure 14: Survey respondent education. Demographic information was only available from eligible participants 
who completed the survey (n = 97). 
 
 
Figure 15:  Survey respondent annual household income. Demographic information was only available from 
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Children. There were 155 participants who answered questions about how 
many children 9-17 years of age they had. Among them, they had 270 children (M = 
1.74, SD = 1.13), with a range of one to ten children. The 97 respondents who were 
eligible and completed the survey were parents or guardians of 163 children. Of 
those, there were 160 children between the 95 parents who were aware of HPV and 
the HPV vaccine. These 95 respondents had a range of one to four children (M = 1.7, 
SD = 0.7) who were 9-17 years of age. Demographic information questions about the 
respondent’s children were placed at the end of the survey, and age and sex 
information was only available for the children of 97 parents (eligible, completed 
surveys). The average age of the 160 children of aware parents was 12.8 years (M = 
12.8, SD = 2.5) (see Figure 16), and most were female (n = 102, 63.8%; males n = 56, 
35.0%). 
Figure 16: Age of Respondents' Children. Age information was only available for the children of 97 respondents. 






























Age of Repsondents' Children (Years) 
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Most of the 160 children had not received the HPV vaccine at the time of the 
study (n = 93, 58.1%) (see Figure 17). Unvaccinated children ranged from 10-17 
years of age (M =13.85, SD = 1.99) and vaccinated children ranged from 9-17 years 
of age (M = 12.11, SD = 2.60) (see Figure 18). Vaccinations rates were the same 
among female (n = 40, 39.2%) and male (n = 22, 39.2%) children (see Figure 19). 
The HPV vaccination rates were 41.2% among children of white respondents, 25.0% 
among children of black respondents, 66.7% among children of American Indian or 
Alaska Natives, 25.0% among children of Asians, 50.0% among children whose 
parent selected multiple races, and 0% for children of parents who indicated they 
belonged to other racial groups, or who preferred not to answer the racial 
demographic question (see Figure 20 and Figure 21). The cluster of children with 
parents and guardians earning an annual household income of more than $100,000 
was the only income cluster that had more vaccinated than unvaccinated children (see 
Figure 22). Concerning education, those with a two-year degree or associate’s degree 
was the only income cluster that had more vaccinated than unvaccinated children (see 




Figure 17: HPV vaccination status of children. The survey only asked parents who were aware of the HPV about 




Figure 18: HPV vaccination status of children by age. Vaccination and age information was provided for 160 





























Figure 19: HPV vaccination status of 160 children of parents (n = 95), by children's gender 
 
 



























































Figure 21: HPV vaccination status of 160 children of parents, by parent’s race, non-white (n = 12). 
 
Figure 22: This figure shows the breakdown of the 160 children's HPV vaccination status by their parent or 
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Figure 23: The breakdown of the 160 children's HPV vaccination status by their parent or guardian's highest level 
of education (n = 95) 
 
Of the 62 children who had received the HPV vaccine it was reported that four 
children had received all of their HPV vaccine shots or have completed the 
vaccination series. Most children who had received the vaccine received three 
injections (see Figure 24). Parents leaned slightly towards having the intent to get 
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Figure 24: Number of HPV vaccination shots that children have received. Among HPV vaccinated children, this is 
the number of injections parents recalled their children receiving (n = 62). 
 
Figure 25: Parent and guardian intent to get children the HPV vaccine before children are age 18 years (n = 93). 
 
Awareness. To assess their HPV vaccination perceptions, respondents were 
first asked if they had ever heard of the human papillomavirus and the vaccine. There 
were 154 responses regarding the virus, and 98% (n = 151) had heard of it. 
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Intent to Get Child HPV Vaccine Before Age 18 Years 
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awareness. These findings were reflected in the completed sample of eligible, 
completed surveys (n = 97), as 95 parents and guardians (97.9%) reported that they 
had heard of both, and two (2.1%) had not heard of either. This section will discuss 
the results from the eligible 95 surveys, but a complete outline of findings from all 
eligible surveys can be found in Table 11. 
 Perceived susceptibility. Kansan parents’ and guardians’ perception of their 
children’ susceptibility to HPV infection was assessed by their agreement with 
statements about the risk of their child getting HPV and the likelihood that their child 
will be infected. Overall, respondents somewhat agreed that their children were at risk 
to get HPV (M = 4.30, SD = 1.48), and somewhat disagreed with the statement that it 
was unlikely that their child would ever been infected with HPV (M = 2.84, SD = 
1.51).  
Perceived severity. Perceived severity of HPV infection was assessed by 
asking respondents to evaluate statements about HPV causing genital warts, cancer, 
and death. Most of the respondents agreed that HPV could cause genital warts (M = 
4.86, SD = 1.21), and agreement with the statement HPV could cause cancer was 
stronger (M = 5.21, SD = 0.95). There was less agreement with the statement that 
HPV could kill their child (M = 4.17, SD = 1.42), than there was with HPV causing 
genital warts or cancer. 
 Perceived benefits and barriers. Answers to statements about the HPV 
vaccine’s effectiveness, affordability, convenience, and consequences were analyzed 
to assess perceived benefits and risks. There was an overall agreement that the HPV 
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vaccine could prevent HPV (M = 4.42, SD = 1.37), genital warts (M = 4.36, SD = 
1.49), and cancer (M = 4.40, SD = 1.39). Most somewhat disagreed that getting the 
HPV vaccine was inconvenient (M = 2.70, SD = 1.51), and leaned towards somewhat 
agreeing that the HPV vaccine was financially affordable (M = 3.78, SD = 1.55). 
Overall, respondents disagreed with the statement that the HPV vaccine would 
encourage their child to be more sexually active (M = 1.82, SD = 1.07). The parents 
and guardians also indicated that they generally had not been discouraged to get their 
children the HPV vaccine (M = 2.70, SD = 1.56), and somewhat agreed that the 
people closest to them would respect them if they got their child the HPV vaccine (M 
= 4.07, SD = 1.47). There was disagreement with the statement that the HPV vaccine 
has more consequences than benefits for their children (M = 2.93, SD = 1.79).  
 Cues to action and self-efficacy. Cues to actions were assessed by asking 
respondents if they had been encouraged to get their child vaccinated for HPV. There 
was a leaning towards agreement that they had been encouraged (M = 4.33, SD = 
1.34). Self-efficacy was assessed by asking parents and guardians if they felt able to 
protect their children from HPV infection, and most parents indicated that they felt 
that they could (M = 4.86, SD = 1.23).  
 Perceived risk. This research was also interested in the risk perceptions that 
Kansan parents and guardians have toward the HPV vaccine. Respondents were asked 
to indicate their agreement with additional statements about side effects and the 
comparative risk of the HPV vaccine to HPV infection. Parents and guardians 
indicated they mostly somewhat disagree that their child will experience harmful side 
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effects if she or he receives the HPV vaccine (M = 2.98, SD = 1.46), and disagree 
even more so with the statement that the HPV vaccine could kill their child (M = 
2.51, SD = 1.50). Overall, there was a slight level of disagreement with the statement 
that the HPV vaccine was risky for their child to receive (M = 3.08, SD = 1.66), and 
even greater disagreement with the HPV vaccine being more risky than the infection 
(M = 2.56, SD = 1.65). 
 












   
 My child is at risk to 
get HPV. 
94 [138] 4.30 [4.24] 1.48 [1.52] 
  
It is unlikely that my 
child will ever be 
infected with HPV. 






 HPV can cause genital 
warts. 
79 [118] 4.86 [5.09] 1.21 [1.17] 
     
 HPV can cause cancer. 91 [138] 5.21 [5.46]  0.95 [0.66] 
  












   
 The HPV vaccine can 
prevent HPV. 
91 [119] 4.42 [4.57] 1.37 [1.33] 
  
The HPV vaccine can 
prevent genital warts. 




The HPV vaccine can 
prevent cancer. 
88 [115] 4.40 [4.63] 1.39 [1.35] 
  
The HPV vaccine is 
not convenient to get 
for my child. 
87 [114] 2.70 [2.39] 1.51 [1.44] 
  
The HPV vaccine is 
financially affordable. 
60 [79] 3.78 [4.16] 1.55 [1.59] 
  
The HPV vaccine will 
encourage my child to 
be more sexually 
active. 
94 [121] 1.82 [1.44] 1.07 [0.72] 
  
I have been 
discouraged from 
getting my child 
vaccinated against 
HPV. 
92 [121] 2.70 [2.41] 1.56 [1.50] 
  
The people closest to 
me would respect me if 












The HPV vaccine has 
more consequences 
than benefits for my 
child. 
85 [111] 2.93 [2.71] 1.79 [1.76] 
Cues to action*     
 I have been encouraged 
to get my child 
vaccinated against 
HPV. 
92 [120] 4.33 [4.54] 1.34 [1.30] 
Self-efficacy  
I can protect my child 
from HPV. 




   
 My child will 
experience harmful 
side effects if they 
81 [108] 2.98 [2.70] 1.46 [1.50] 
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receive the HPV 
vaccine. 
  
The HPV vaccine 








It is risky for my child 
to receive the HPV 
vaccine. 
89 [115] 3.08 [2.88] 1.66 [1.67] 
  
There are more risks 
for my child getting the 
HPV vaccine than 
having HPV. 
85 [112] 2.56 [2.47] 1.65 [1.62] 
*Health belief model variables 
**Social amplification of risks variables 
 
Note. The information presented in the table first shows the results from the responses of the 95 HPV 
and HPV vaccine aware adults, followed by brackets ( [ ] ) where results from all survey responses are 
recorded. For perceived susceptibility, severity, and self-efficacy there were 95[142] respondents. 
Other variables had 95 [124] respondents. Missing cases resulted from respondents answering “I do 
not know” to the statements.   
 
 Perception following awareness. Two of the survey respondents indicated 
that they had never heard of neither HPV nor the HPV vaccine prior to taking this 
survey. One of these participants (male, Asian, born in 1980, Douglas County 
resident, Master’s degree completed, income between $20,000 and $40,000) was a 
father of two children (a 12-year old female and an 11-year old male). After being 
shown prompts discussing HPV and the HPV vaccine (see Appendices 2, questions 
42-44) he indicated that he would consider talking to a doctor or a health care 
provider about HPV. The other respondent (female, white, born in 1986, Thomas 
County resident, 2-year degree completed, income of $100,000 or more), a mother of 
one child (a 15-year old female), indicated that she would consider getting her child 
vaccinated against HPV. 
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Engagement with Health Information on Social Media 
The second research question of this study asked how Kansan parents and 
guardians engaged with health information from social media regarding the HPV 
vaccine. Respondents were asked their main source for information about the HPV 
vaccine, social media use, if they had seen information about the HPV vaccine on 
social media, and their perceptions on how the HPV vaccine was portrayed on social 
media in the context of the health belief model and social amplification of risk 
framework. 
 Sources. There were 138 respondents who reported their main source for 
learning about the HPV vaccine. A healthcare provider was the modal source (n =79, 
57.2%), and social media was only identified by 6 respondents (4.3%) as their 
primary information source. Similarly, healthcare providers were identified most 
often as their main source of information about HPV vaccine (n = 51, 53.7%) for the 
95 eligible and aware respondents; and 4.2% percent of the sample (n = 4) indicated 
that social media was their main source (n = 4, 4.2%) (see Figure 26). Of all 123 
survey responses, 117 (95.1%) parents and guardians indicated that use social media. 
Of the aware and eligible parents and guardians 91 (91, 95.8%) indicated they use 




Figure 26: Main source for information about the HPV vaccine among HPV and HPV vaccine aware parents that 
completed the survey (n = 95). 
 
The vast majority of all remaining respondents who indicated that they use 
social media (n = 113) indicated that they use Facebook (n = 109, 96.5%), similar to 
the sample of 95 aware and eligible respondents who completed the survey. Of the 
entire sample of respondents, 101 (n = 90.2%) indicated that Facebook their most 
used social media platform, which was also the most used social media platform 
among the 95 complete surveys of aware parents and guardians (n = 79, 87.8%).   
A total of 98 survey respondents answered if they had ever seen information 
about the HPV vaccine on social media, most indicated that they had (n = 65, 66.3%). 













Main Source for HPV Vaccine Information 
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and 59 (93.6%) of those respondents recalled Facebook being their most used social 
media platform. Of the 95 completed surveys by aware parents and guardians, 56 
(62.9%) reported that they had seen information about the HPV vaccine on social 
media. From the 56, 50 (89.2%) indicated that Facebook was their most used social 
media account.  
 Because almost all of the survey respondents had a Facebook account, and for 
many it was their most used, the researcher decided to conduct the analysis of 
perceptions about how the HPV vaccine is represented on social media from the 
perspective of those who had 1) seen information about the HPV vaccine on social 
media and 2) had indicated that Facebook was their most used social media platform.  
Of the 50 parents and guardians, about a quarter (n = 14, 28.0%) reported that 
they had searched for information about the HPV vaccine on social media, and 
reported posting or sharing something about the HPV vaccine on social media (n = 
14, 28.0%). The most frequently reported sources for HPV vaccine-related content 




Figure 27: The sources of HPV vaccine-related social media posts. For those who had seen information about the 
HPV vaccine posted to social media, these are the sources they see posting the information.  
 
Like their personal perceptions, parent and guardian perceptions of HPV vaccine representation on social media 
vaccine representation on social media were analyzed in the context of the health belief model and the social 
belief model and the social amplification of risk framework. Respondents were asked to indicated their level of 
to indicated their level of agreement with a series of statements on a six-point Likert scale (recoded for data 
scale (recoded for data analysis:1 = “strongly disagree,” 2 = “disagree,” 3 = “somewhat disagree,” 4 = “somewhat 
“somewhat disagree,” 4 = “somewhat agree,” 5 = “agree,” and 6 = “strongly agree,”) with a response of “I do not 















Source of HPV Vaccine-Related Social Media Posts 
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Table 12). Results from all eligible responses are included. A higher number 
indicated greater agreement with the statement. 
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Perceived susceptibility. The respondents tended to agree that social media 
messages say that their child is at risk to get HPV (M = 4.31, SD = 1.39), and slightly 
disagreed that social media messages say that it is unlikely that their child will ever 
get HPV (M = 2.78, SD = 1.55).  
Perceived severity. Respondents mostly agreed that social media says that 
HPV can cause genital warts (M = 4.54, SD = 1.35) and cancer (M = 4.87, SD = 
1.33), and mostly somewhat agree that it could kill their child (M = 4.02, SD = 1.75). 
Perceived benefits and barriers. When recalling how social media portrays 
the benefits and barriers of getting the HPV vaccine for their children, the Kansan 
parents and guardians leaned toward slightly agreeing that social media messages say 
that the HPV vaccine can prevent HPV (M = 4.31, SD = 1.46), genital warts (M = 
4.31, SD = 1.41), and cancer (M = 4.36, SD = 1.43). They also leaned toward slightly 
disagreeing that social media represent the HPV vaccine as inconvenient to get for 
their child (M = 2.79, SD = 1.53), and slightly agreed that vaccine is represented as 
affordable (M = 4.04, SD = 1.49). There was agreement that social media sends the 
message that the HPV vaccine will not make your children more sexually active (M = 
4.02, SD = 1.81). The respondents appeared to be more divided on whether or not 
social media say that society discourages them from getting their children vaccinated 
against HPV (M = 3.78, SD = 1.71), that the people closest to them would respect 
them for getting their children the HPV vaccine (M = 3.58, SD = 1.45), and that the 




Cues to action and self-efficacy. When asked if social media say that society 
encourages them to get their children vaccinated against HPV, the respondents were 
also quite divided (M = 3.70, SD = 1.68), but agreed that there was a message that 
they could protect their children from HPV (M = 4.70, SD = 1.27).  
 Perceived risk. The respondents appeared to also be divided about social 
media messages about representing the HPV vaccine as a risk. Opinions did not lean 
strongly in either direction when asked if social media say the HPV vaccine could 
cause their children harmful side effects (M = 3.61, SD = 1.69), could kill their 
children (M = 3.44, SD = 1.74), is risky for their children to receive (M = 3.67, SD = 
1.73), and whether or not the HPV vaccine was riskier than HPV infection (M = 3.33, 
SD = 1.76).    
 













   
 Your child is at risk to 
get HPV. 
48 [63] 4.31 [4.68] 1.39 [1.23] 
  
It is unlikely that your 
child will ever be 








   
 HPV can cause genital 
warts. 
39 [51] 4.54 [4.49] 1.35 [1.32] 
  







   4.02 [3.85] 1.75 [1.75] 
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 The HPV vaccine can 
prevent HPV. 
42 [47] 4.31 [4.40] 1.46 [1.42] 
  
The HPV vaccine can 
prevent genital warts. 
36 [40] 4.31 [4.33] 1.41 [1.42] 
  
The HPV vaccine can 
prevent cancer. 
42 [47] 4.36 [4.32] 1.43 [1.46] 
  
The HPV vaccine is 
not convenient to get 
for your child. 
38 [44] 2.79 [2.75] 1.53 [1.50]  
  









The HPV vaccine will 
not encourage your 
child to be more 
sexually active. 
46 [52] 4.02 [4.10] 1.81 [1.77] 
  
Society discourages 
you from getting your 
child vaccinated 
against HPV. 
46 [51] 3.78 [3.73] 1.71 [1.74] 
  
The people closest to 
you would respect you 
if you got my child the 
HPV vaccine. 
31 [37] 3.61 [3.68] 1.77 [1.51] 
  
The HPV vaccine has 
more consequences 
than benefits for you 
child. 
46 [52] 3.58 [3.54] 1.45 [1.80] 
Cues to action*     
 Society encourages 
you to get your child 
vaccinated against 





You can protect your 
child from HPV. 




   
 Your child will 
experience harmful 
side effects if they 
receive the HPV 
vaccine. 
46 [52] 3.61 [3.54] 1.69 [1.73] 
  
The HPV vaccine 
could kill your child. 
45 [51] 3.44 [3.35] 1.74 [1.73] 
  
It is risky for your 
child to receive the 
HPV vaccine. 
46 [52] 3.67 [3.63] 1.73 [1.74] 
  
There are more risks 
for your child getting 
the HPV vaccine than 
having HPV. 
46 [52] 3.33 [3.38] 1.76 [1.75] 
Note. The information presented in the table first shows the results from the responses of the 50 HPV 
and HPV vaccine aware adults who have seen information about the HPV vaccine on social media, and 
Facebook is their most used social media platform. The information followed by brackets ( [ ] ) where 
results from all survey responses are recorded. For perceived susceptibility, severity, and self-efficacy 
there were 50[66] respondents. Other variables had 95 [56] respondents. Missing cases resulted from 
respondents answering “I do not know” to the statements.  
 
 Risk amplification. Parents and guardians were also asked to report their 
perception of how social media’s representation of the HPV vaccine had influenced 
their perception of the vaccine as a risk hazard. The respondents were asked on a five-
point Likert scale how they perceived social media support for the HPV vaccine 
(recoded: 1 = “always against,” 2 = “mostly against,” 3 = “equally in favor and 
against,” 4 = “mostly in favor,” and 5 = “always in favor”). The parents and 
guardians were divided. When looking at the results from all 64 respondents who 
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answered the question, they leaned very slightly towards perceiving posts being 
mostly in favor of the vaccine (M = 3.05, SD = 1.20), but the 50 participants who 
completed the survey and primarily use Facebook leaned slightly towards perceiving 
the posts being mostly against the HPV vaccine (M = 2.94, SD = 1.20) (see Figure 
28). When asked if social media increases or decreases their fear about getting their 
children the HPV vaccine (recoded; -1= “decreases,” 0 = neither increases nor 
increases,” and 1 = increases), both the sample of all 56 respondents (M = 0.11, SD = 
0.49) and the 50 participants (M = 0.14, SD = 0.49; see  
Figure 29) leaned slightly towards perceiving that social media increases their fear. 
The respondents were also asked if social media influences their risk perception about 
their children being the harmed by HPV vaccine (recoded; -1 = “lesser,” 0 = neither 
greater, nor lesser,” and 1= “greater”). The group of 56 (all that answered) parents 
and guardians mostly that social media neither increased nor decreased their fear (M 
= 0.00, SD = 0.50), but the group of 50 leaned toward perceiving that their children 
were at greater risk of being harmed by the HPV vaccine (M = 0.04, SD = .49; see  




Figure 28: Perception of social media support of the HPV vaccine. The parents and guardians were asked if social 
media is in favor of the HPV vaccine. This graph is from the responses of parents and guardians who have seen 
information about the HPV vaccine on social media and primarily use Facebook (n = 50). 
 
 
Figure 29: Perception of social media influence on HPV vaccine fear. The parents and guardians were asked if 
social media has influenced how much fear they have about getting their children HPV vaccine. This graph is 
from the responses of parents and guardians who have seen information about the HPV vaccine on social media 
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Figure 30: Social media influence on risk perception of HPV vaccine and its potential to harm children. The 
parents and guardians were asked if social media has influenced risk for harm they felt their children would face in 
relation to the HPV vaccine. This graph is from the responses of parents and guardians who have seen information 
about the HPV vaccine on social media and primarily use Facebook (n = 50). 
 
Prevalent HPV Vaccine HBM and SARF Messages on Social Media 
The third research question of this study looked at the prevalent messages 
about the HPV vaccine on social media in the context of the health belief model 
(HBM) and social amplification of risk framework (SARF). A content analysis was 
performed on 6,537 Facebook posts. Of the 6,537 posts, 6,506 were from a search of 
all public Facebook posts (not containing CDC posts) and the remaining 31 were 
from Centers for Disease Control official pages (“CDC” and “CDC STD”). The 
researcher analyzed the sample of public Facebook frames and coded various content 
characteristics, and for prevalent HBM concepts (susceptibility, severity, benefits, 



















Social Media Influence,  
Level of Risk Perception of HPV Vaccine Harming Children 
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how to access the HPV vaccine]) and the social amplification of risk framework 
(amplification, ripple, impacts). 
Content characteristics. Posts (n = 6,506) were published between June 11, 
2006 and June 8, 2016. From the sample, the fewest number of posts were published 
in 2006 (n = 39) and the most in 2012 (n = 1,035) (see Table 8). More than half of 
the posts were published on individual profiles (n = 3,795, 58.3%; Facebook pages n 
= 2,711, 41.7%), and nearly seventy percent (n = 2,649; 69.8%) of profile posts 
published by individuals were authored by females (males: n = 1,002, 26.4%; unsure: 
n = 144, 3.8%). Concerning the audience, most posts were posted to the general 
public (n = 4,918, 75.6%), while fewer were directed to a page (n = 1,549, 23.8%) or 
profile (n = 30, 0.6%). Nearly sixty percent of the posts had an external hyperlink 
embedded in the post (n = 3,763, 57.8%), but fewer than ten percent had embedded 
picture or video content (n =579, 8.9%). 
 The posts had between zero and 11,000 reactions (M = 30.24, Mdn = 0, SD = 
305.19); however, more than half had none (n = 3,559, 51.6%). Concerning 
comments (M = 7.42, Mdn = 0, SD = 136.45), most posts also did not have any (n = 
4,043, 62.1%), but those that did ranged from having between one and 6,100. 
Regarding shares (M = 184.89, Mdn = 0, SD = 7086.64), the majority of posts were 
also unshared (n = 5,439, 83.6%), but those that were had between one and 329,000 
shares.  
Given the potential complications of the HPV vaccine, the researcher also 
analyzed the presence of the terms “warts” and “cancer.” Only a few posts (n = 208, 
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3.2%) mentioned warts, but approximately a quarter mentioned cancer (n = 1,646, 
25.3%).  
Additionally, the tone of the posts and the tone of toward the HPV vaccine 
were coded. Most of the posts had a negative tone (n = 3,501, 53.8%), followed by a 
neutral tone (n = 1,527, 23.5%), and then a positive tone (n = 1,478, 22.7%). 
Concerning the tone towards the HPV vaccine, slightly fewer than half had a negative 
tone (n = 2,928, 45.0%), followed by a positive tone (n = 1,932, 29.7%), and neutral 
tone (n = 1,646, 25.3%). 
 Health belief model content. In a large majority of posts, content that 
suggested HPV infection susceptibility was absent (n = 6,236, 95.8%) (see Figure 31 
for example), as was content suggesting that HPV infection would be severe (n = 
5,487, 84.3%). Barriers to getting the vaccine were mentioned in more posts (n = 
3,056, 47.0%) than benefits (n = 1,281, 19.7%). Concerning cues to action, most 
posts did not tell people either way to get or avoid the HPV vaccine; but a few did 
explicitly tell people to get vaccinated (n = 208, 3.2), and fewer told people explicitly 
to avoid the HPV vaccine (n = 119, 1.8%). Very few self-efficacy messages were 




Figure 31: This is an example of a Facebook post retrieved from the search using the term “Gardasil.” Because 
this was the first result populated, this screenshot also includes the results’ header “Public Posts” – which indicates 
that posts under this header are available to be searched to all Facebook users (with the exception of blocked 
users). This post was coded as a page (author), with a general audience. It has 36 reactions, 3 comments, and 14 
shares. “Cancer” is mentioned, but not “warts.” The post does not suggest susceptibility to HPV infection, or that 
HPV infection is severe. HPV vaccine benefits are unmentioned, as are self-efficacy messages. However, as 
Gardasil may be causing cancer (according to the post), the presence of a barrier is coded. Furthermore, it is coded 
as risk amplifying, but there are no indications for the presence of ripples or impacts. 
 
 Social amplification of risk framework content. More than half of posts (n 
= 3,752, 57.7%) neither amplified nor attenuated the perception of risk to one’s 
health that the HPV vaccine could cause. However, nearly forty percent of the posts 
amplified HPV vaccine risk (n = 2,568, 39.5%) and only a very few attenuated risks 
(n = 186, 2.9%). The vast majority of posts did not discuss ripples (n = 6,110, 93.9%) 
or impacts (n = 6,312, 97%) from the perceived risks of the HPV vaccine.  
HPV Vaccine Representation and the CDC’s Facebook posts: 2006-2006   
For the final research question of this study, the researcher compared the 
general representation and the CDC’s representation of the HPV vaccine on Facebook 
over the decade since the vaccine’s first FDA approval. A separate content analysis of 
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CDC page Facebook posts (n = 31) was performed, analyzing them in the context of 
HBM and SARF variables. 
CDC Facebook posts: Content characteristics, HBM and SARF content. 
Thirty-one posts were published from February 5, 2010 to April 28, 2016 (M = 4.43, 
SD = 2.76) (see Figure 32for example). The fewest posts were published in 2012 (n = 
1) and the most were published in 2013 (n = 8) (refer to Table 2). All of the posts 
were posted to the general audience. Nearly all of the posts had an embedded external 
hyperlink (n = 30, 96.8%), and approximately a quarter had embedded picture or 
video content (n =8, 25.8%). Reactions ranged from zero to 1,701 (M = 364.32, Mdn 
= 129, SD = 451.19), the range of comments was between zero and 132 (M = 39.77, 
Mdn = 33, SD = 33.94), and shares ranged between zero and one thousand (M = 
220.61, Mdn = 84, SD = 288.25).   
 The researcher also analyzed the CDC Facebook posts for presence of the 
terms “warts” and “cancer.” Only one post (3.2%) mentioned warts, but more than 
three-quarters mentioned cancer (n = 24, 77.4%). Additionally, the tone of the posts 
and the tone toward the HPV vaccine were coded. Most of the posts had a positive 
tone (n = 20, 64.5%), followed by a neutral tone (n = 10, 32.2%), and then a negative 
tone (n = 1, 3.2%). Concerning the tone towards the HPV vaccine, the tone was 
mostly positive (n = 30, 96.8%), and one post was neutral (3.3%). 
The posts were also coded for health belief model variables. One post made 
allusions to susceptibility to HPV infection (3.2%) and more than half discussed 
aspects of HPV infection’s severity (n = 20, 64.5%). Barriers to HPV vaccination 
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were unmentioned and most of the posts discussed benefits (n = 27, 87.1%). Self-
efficacy messages were present in about one-fifth of the posts (n = 19.3%) and cues 
to vaccinate were present in more than twenty percent of the posts (n = 7, 22.6%). 
None of the posts had cues to avoid the HPV vaccine. 
CDC posts were also coded for social amplification of risk framework 
variables. Posts neither amplified nor attenuated HPV vaccine-related risk 
perceptions. Ripples and subsequent impact messages were not in the sample.
 
Figure 32: A Facebook post retrieved from the search using the term “HPV vaccine” on the Centers for Disease 
Control and Prevention’s Facebook page. This is their first HPV-vaccine related post. This post was coded as a 
page (author), with a general audience. It has 26 reactions, 19 comments, and no shares. “Cancer” is mentioned, 
but not “warts.” The post does not suggest susceptibility to HPV infection, but it does suggest that HPV infection 
is severe, as it can cause cancer. HPV vaccine benefits are mentioned (preventing cancer), while barriers and self-
efficacy messages are not mentioned. This post does not contain messages that either amplify or attenuate risk 
perception, and there are no ripples or impacts mentioned. 
 Comparing over a decade. When looking at reactions, since their first post in 
2010, the CDC Facebook posts have had a higher average number of reactions (see 
Figure 33) and comments than Facebook posts (see Figure 34). Most years, with the 
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exception of 2014, CDC Facebook posts have had a higher average of shares than the 
sample of Facebook posts (see Figure 35). 
 
Figure 33: Average number of reactions to HPV-vaccine related Facebook posts. This graph shows the average 
number of reactions that HPV vaccine-related Facebook posts received each year. One trend line represents 
reactions to posts from across Facebook and the other from the CDC (CDC and CDC STD) Facebook pages. 
 
Figure 34: Average number of comments to HPV-vaccine related Facebook posts. This graph shows the average 
number of comments that HPV vaccine-related Facebook posts received each year. One trend represents 


































































Figure 35: Average number of shares HPV-vaccine related Facebook posts receive. This graph shows the average 
number of shares that Facebook posts about the HPV vaccine had each year, one trend represents shares of posts 
from across Facebook and the other of posts from CDC (CDC and CDC STD) Facebook pages. 
 
The CDC only mentioned “warts” in one instance in 2016 (M = 16.67), 
however warts have been mentioned in Facebook posts over the decade (see  
Figure 36). Concerning cancer mentions, the CDC has had a higher percentage 
of posts mentioning cancer than posts across Facebook (see Figure 37).   
 





























































Figure 37: Average percent of HPV vaccine-related posts that mention cancer. 
 
The tone of the posts was recoded (-1 = “negative,” 0 = “neutral,” 1 = 
“positive”) and averaged by year. Compared to the CDC pages, posts from the 
Facebook sample had a tone that had on average remained negative after 2006, 
moved towards neutral until 2014, and then became more increasingly negative 
thereafter. The tone of the CDC posts has remained neutral or positive on average 
(see Figure 38).  
The tone towards the HPV vaccine was also recoded (-1 = “negative,” 0 = 
“neutral,” 1 = “positive”) and averaged by year. Compared to the CDC pages, posts 
from the Facebook sample became increasingly negative over the decade, while the 
tone of the CDC posts towards the HPV vaccine has always been very positive on 













































Figure 38: Average tone of HPV vaccine-related posts. The “0” marker represents neutrality, “1” is “always 
positive,” and “-1” is “always negative.” 
 
 
Figure 39: Average tone of HPV vaccine-related posts toward the HPV vaccine. The “0” marker represents 
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Health belief model variables. This study compared the messages in HPV 
vaccine-related posts on Facebook in general to the messages in posts from CDC 
Facebook pages in the context of the health belief model (see Table 13 for summary). 
Concerning perceived susceptibility (see Figure 40), after 2006, there was a decline in 
the average number of messages in Facebook posts from 23% to 4% that would never 
rise again above 6% percent during the decade. Perceived susceptibility messages did 
not appear in CDC posts until 2016. Severity messages (see Figure 41) in Facebook 
posts had a greater average presence in 2006, but would later decline. Meanwhile the 
CDC posts varied, but would ultimately increase. The average presence of posts that 
mentioned benefits of the HPV vaccine (see Figure 42) also peaked in 2006, while the 
average presence in CDC posts was always above 70%, peaking in several years. 
Concerning barriers (see Figure 43), there was an overall increase in the average 
presence of Facebook posts over the decade mentioning barriers to HPV vaccination. 
Meanwhile, the CDC posts never mentioned barriers. Self-efficacy messages (see 
Figure 44) were consistently low in Facebook posts over the decade, never rising 
above ten percent. Among CDC posts, self-efficacy messages did not appear until 
2013 and peaked in 2015. The average presence of cues to vaccinate (see Figure 45) 
dropped by 20% over the decade in Facebook posts. Cues to vaccinate did not have a 
presence in CDC posts until 2013, and the average peaked in 2015. Cues to not 
vaccinate messages were low (see Figure 46), but experienced an increasing average 




Table 13: Yearly averages of Health Belief Model Variables  
 
 





Cues to Not 
Vaccinate 
 FB CDC FB CDC FB CDC FB CDC FB CDC FB CDC FB CDC 
2006 0.23 - 0.44 - 0.51 - 0.31 - 0.10 - 0.23 - 0.00 - 
2007 0.04 - 0.16 - 0.20 - 0.39 - 0.03 - 0.04 - 0.01 - 
2008 0.05 - 0.09 - 0.16 - 0.52 - 0.02 - 0.05 - 0.02 - 
2009 0.03 - 0.08 - 0.08 - 0.50 - 0.02 - 0.02 - 0.01 - 
2010 0.04 0.00 0.14 0.50 0.15 1.00 0.50 0.00 0.05 0.00 0.02 0.00 0.01 0.00 
2011 0.06 0.00 0.14 0.50 0.17 1.00 0.48 0.00 0.04 0.00 0.03 0.00 0.02 0.00 
2012 0.06 0.00 0.15 0.00 0.21 1.00 0.43 0.00 0.07 0.00 0.03 0.00 0.02 0.00 
2013 0.02 0.00 0.21 0.37 0.30 0.87 0.42 0.00 0.03 0.12 0.03 0.12 0.00 0.00 
2014 0.05 0.00 0.23 0.71 0.32 0.71 0.37 0.00 0.09 0.28 0.05 0.28 0.00 0.00 
2015 0.04 0.00 0.22 0.80 0.24 0.80 0.46 0.00 0.04 0.40 0.04 0.40 0.02 0.00 
2016 0.03 0.17 0.16 1.00 0.17 1.00 0.63 0.00 0.04 0.17 0.03 0.33 0.05 0.00 
Note. This table shows the average presence of health belief model variables in post on Facebook (FB) and posts 





Figure 40: Trends of posts with susceptibility to HPV infection messages from Facebook and CDC Facebook 


































































Figure 41: Average presence of posts with HPV infection severity messages from Facebook and CDC Facebook 
pages, by year. 
 
 
Figure 42: Average presence of posts that mention HPV vaccine benefits from Facebook and CDC Facebook 

















































































































Figure 43: Average presence of messages about barriers to HPV vaccination in posts from Facebook and CDC 
Facebook pages, by year. 
 
 
Figure 44: Average presence of HPV vaccine-related self-efficacy messages in posts from Facebook and CDC 


















































































































Figure 45: Average presence of cue to get the HPV vaccine messages in posts from Facebook and CDC Facebook 
pages, by year. 
 
Figure 46: Average presence of cue to not get the HPV vaccine messages in posts from Facebook and CDC 
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Social amplification of risk variables. This study also compared Facebook’s 
representation of the HPV vaccine with the CDC Facebook pages’ representation in 
the context of the social amplification of risk framework (see Table 14 for summary). 
Risk amplification was recoded on a scale (-1 = “attenuating risk,” 0 = “neither 
amplifies nor attenuates risk,” and 1 = “amplifies risk”) to measure the average level 
of risk amplification throughout the decade. While in 2006 Facebook there was a 
higher average of posts with risk attenuating messages, the presence of posts with risk 
amplification messages would increase over the decade (see Figure 47), as would the 
presence of ripples and impacts. CDC posts did not have posts with messages that 
amplified or attenuated HPV vaccine-related risks, that mentioned ripples, or 
mentioned impacts (see Figure 48). 
 
Table 14: Average Presence of Social Amplification of Risk Messages 
 Risk Level Ripples Impacts 
 FB CDC FB CDC FB CDC 
2006 -0.02 - 0.00 - 0.00 - 
2007 0.22 - 0.02 - 0.02 - 
2008 0.36 - 0.04 - 0.00 - 
2009 0.37 - 0.07 - 0.01 - 
2010 0.37 0.00 0.06 0.00 0.00 0.00 
2011 0.40 0.00 0.07 0.00 0.02 0.00 
2012 0.31 0.00 0.02 0.00 0.01 0.00 
2013 0.32 0.00 0.09 0.00 0.05 0.00 
2014 0.24 0.00 0.06 0.00 0.03 0.00 
2015 0.44 0.00 0.08 0.00 0.10 0.00 
2016 0.59 0.00 0.10 0.00 0.10 0.00 
 
Note. This table shows the average presence of social amplification of risk variables in post on 





Figure 47: Average presence of posts with risk amplifying messages. The “0” marker represents neutrality, “1” is 
amplifies, and “-1” is attenuation. 
 
Figure 48: Average presence of HPV vaccine risk-related ripple and impact messages in posts from Facebook and 
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Chapter 5: Discussion 
This dissertation had several aims. First, this study was designed to examine 
HPV vaccine-related perceptions held by Kansan parents and guardians in the context 
of the health belief model and social amplification of risk framework. Second, this 
study was designed to investigate how Kansan parents and guardians engage with 
HPV vaccine-related information on social media. Third, this research sought to study 
how the HPV vaccine is represented in social media messages through the lenses of 
the health belief model and social amplification of risk framework. Last, this study 
looked to analyze how the representation of the HPV vaccine has changed over ten 
years and compares with messages from the Centers from Disease Control and 
Prevention. The goal was that the findings from this study would provide insight into 
why HPV vaccination rates are low among Kansan children.  
Kansan parents and guardian of children ages 9-17 years were specifically 
targeted for study because while HPV vaccination in adults is also important and has 
been a subject of study  (e.g., Cohen & Head, 2013), HPV vaccination and 
subsequent immunization earlier in age puts Kansan children at a lower risk for 
exposure to HPV and infection. It reduces their risks of experiencing HPV-associated 
genital warts and cancer; it reduces their risk of death. Understanding HPV vaccine 
perceptions and social media representations provides insight into some of the factors 
influencing low HPV vaccination rates. The findings can inform strategies to improve 
vaccination rates in Kansas. By extension, future research may help improve HPV 
vaccination rates nationwide.  
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This study finds that low HPV vaccination rates are likely not due to a lack of 
awareness of the virus or the vaccine. The majority of interview participants and 
survey respondents had heard of both HPV and the HPV vaccine, yet their children 
had not received the HPV vaccine, consistent with state vaccination data (Centers for 
Disease Control and Prevention, 2016a). It is more likely that low vaccination rates 
are a matter of HPV vaccine-related perceptions held by Kansan parents and 
guardians. 
HPV Vaccine Perceptions (HBM and SARF) 
Most of the surveyed Kansan parents and guardians agreed that their children 
are susceptible to HPV infection, but some did not feel their children were 
susceptible. The finding that  some parents and guardians believe that their children 
are not susceptible supports the findings of Cohen and Head (2013) that low HPV 
infection susceptibility perceptions exist. Concerning HPV infection severity, the 
respondents to the dissertation survey also mostly agreed that HPV infection could 
cause genital warts and cancer. There was a lower level of agreement with the 
statement that HPV infection could kill their children. It is possible that while many 
agree that HPV infection is inevitable in their children and that infection has some 
associated health complications, that the threat of HPV infection does not generate 
enough motivation to get their children vaccinated.   
Survey respondents overall agreed that the HPV vaccine prevents HPV, 
genital warts, and cancer. These agreement levels were not as high as they were with 
susceptibility and severity statements. It is possible that the HPV vaccine may not be 
130 
 
perceived as beneficial enough to motivate parents and guardians to get their children 
vaccinated. Barriers to the vaccine may also aggravate the perception of the HPV 
vaccine’s benefits. 
The survey respondents overall did not feel that the HPV vaccine was 
inconvenient and slightly leaned towards perceiving the vaccine to be affordable. 
Also, they did not feel that HPV vaccination would encourage their children to 
become more sexually active, aligning with the findings in the Smith et al. (2014) 
study. The parents and guardians had mostly not been discouraged from getting their 
child vaccinated, and felt that they would be respected by people closest to them if 
they chose to do so. Furthermore, they slightly leaned toward disagreeing that the 
HPV vaccine has more consequences than benefits for their children. While the 
perception of HPV vaccine-related barriers may not be prevalent among the majority 
of parents and guardians, they may be prevalent enough to influence low vaccination 
rates. 
Concerning self-efficacy, respondents mostly agreed that they could protect 
their children from HPV. To a lesser extent, parents agreed that they had been 
encouraged to vaccinate their children. It is possible that more frequent, stronger 
recommendations would be useful to increase HPV vaccination rates, which was a 
recommendation, put forth by the CDC and ACIP (Centers for Disease Control and 
Prevention, 2015e, 2015g; Petrosky et al., 2015). 
The health belief model was a useful framework for analyzing Kansan parent 
and guardian perceptions of the HPV vaccine. HBM (Rosenstock, 1974) posits that 
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there are several factors that influence one’s decision to perform a preventive health 
behavior. This study suggests, in alignment with HBM, that just because the HPV 
vaccination is a health behavior that can prevent HPV infection and associated 
disease, does not mean that parents will accept it for their children. An ad hoc 
analysis reviewed one of the survey questions that asked if participants support the 
HPV vaccine. Of the eligible 124 respondents that answered, 26 disagreed on various 
levels and 6 did not know. Of the 95 eligible respondents that completed the survey, 
20 of the 95 disagreed on various levels, and 4 did not know. In both samples of all 
respondents and the respondents who completed the survey, a quarter of participants 
did not indicate support for the HPV vaccine. If this is mirrored in the population, this 
could suggest that this vaccine in particular does not have a lot of support. Still, that 
means that some support the vaccine, but even supporters may experience barriers.  
The barriers also may extend from the regional environment and social 
influences. Ad hoc research found that the Kansas vaccination rates for children 13-
17 years for the tetanus toxoid, reduced diphtheria toxoid (also known as Td); tetanus 
toxoid, reduced diphtheria toxoid, and acellular pertussis (also known as Tdap); and 
the meningococcal conjugate (also known as MenACWY) vaccine are all below U.S. 
national averages (Centers for Disease Control and Prevention, 2015a). Ultimately, 
low HPV vaccination rates may not just be solely a problem regarding the Kansan 
parent and guardian perceptions of the HPV vaccine, but may also have to do with 
socially shared perceptions about vaccines in general.   
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This study also examined if the HPV vaccine is perceived as a risk event, 
despite it being a preventive health measure. One could consider HPV vaccine-related 
risk perceptions as an extension of barriers. However, by looking at the HPV vaccine 
in the context of SARF, and not collapsing it into barriers, it is possible to develop 
research to see how this variable interacts with behavior intentions.  
The respondents overall did not feel that the HPV vaccine would cause 
harmful side effects or death in their children. They also did not feel that there are 
more risks related to the HPV vaccine than HPV infection. However, the level of 
disagreement with the HPV vaccine being risky for their children was not as high as it 
was with the other statements. All of the averages for these statements leaned towards 
“somewhat disagreeing.” This suggests that while most of the respondents likely 
believe that the HPV vaccine is not a risk, there are some respondents who do, which 
also may be an explanation for low HPV vaccination rates.  
The interviews provide some clues as to why the HPV vaccine may be 
perceived as risky. Two of the participants indicated that they believed that part of the 
virus is present in the vaccine, and exposure to the vaccine could compromise their 
children’s immune systems. This supports the findings of the Doherty et al. (2015) 
that there is a population of people who are concerned about vaccine ingredients, 
specifically that vaccination means exposure to the virus that the vaccine is designed 
to immunize against. It also supports in part the Gellin et al. (2000) study that found 
that parents believed that immunizations can weaken the immune system. Though the 
HPV vaccine does not contain the actual virus and likely would not weaken a 
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recipient’s immune system (U.S. Food and Drug Administration, 2009b, 2011, 
2014b), the perception exists. This also suggest that while there is awareness about of 
HPV and the HPV vaccine, that knowledge about the HPV vaccine may be lacking, 
and education efforts may need to be directed towards the vaccine, and not just the 
virus.  
Furthermore, while the findings from the interview and the survey show that 
many are aware of the HPV vaccine, it does not mean that everyone knows about it, 
as four people did not know there was a HPV vaccine. Two of the survey participants, 
when exposed to information about the HPV indicated that they either planned to talk 
to a healthcare provider, or get their children vaccinated. This suggests that there may 
be an opportunity to encourage HPV vaccination among those who are unaware of 
the vaccine if they are first exposed to accurate and factual information about the 
disease and the vaccine from certain sources (e.g., the CDC). 
In summary, while there is a general acceptance that children are susceptible 
to HPV infection, the perception of severity and HPV vaccine benefits may just not 
be strong enough to motivate higher rates of HPV vaccination. If there is awareness 
about HPV infection susceptibility and severity, then it is also likely that discussion 
of the virus itself is not motivating vaccination. The conversation may need to be 
focused more on the HPV vaccine. The HPV vaccine is perceived by survey 
respondents to have fewer barriers than benefits, but the influence that those barriers 
possess is unknown. It is possible that the barriers, and perhaps a larger social 
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phenomenon, may have an influence on HPV vaccination rates among Kansan 
children.  
Perceptions of Social Media HPV Vaccine-Related Messages (HBM and SARF) 
Given the pervasiveness of social media use, this study was also interested in 
what Kansan parents and guardians are seeing on public posts on social media about 
the HPV vaccine. While the main source for HPV vaccine information is still 
healthcare providers, a few participants did mention that social media was their main 
source. The ad hoc analysis even found that more than 15% of all eligible respondents 
who completed the survey had searched social media for information about the HPV 
vaccine. Also, the majority of survey respondents reported that they had seen 
information about the HPV vaccine online. These results are in alignment with the 
findings of Fox and Duggan (2013) and  with the Moorhead et al. (2013), that while 
social media is not the primary source of health information, it is still a prominent 
source, even if it’s just by passive exposure, and might be a stakeholder in influencing 
perceptions.  
When looking at how Kansan parents and guardians perceived HPV vaccine-
related social media messages in the context of HBM, some of their perceptions of 
social media messages reflect their own personal perceptions. The respondents 
reported that social media messages generally say that their children are susceptible to 
HPV infection. They also agreed, but to a lesser extent, that social media message 
suggest that HPV infection is severe (causing genital warts, cancer, and death). 
Concerning the benefits, the respondents agreed that social media messages state that 
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the HPV vaccine can prevent HPV, genital warts, and cancer. While the perception of 
benefit messages on social media was minimized when compared to their personal 
perceptions, barriers were mostly maximized. The findings suggest that respondents 
perceived that social media messages portray the HPV vaccine overall more 
negatively – more inconvenient, more likely to make their children more sexually 
active, and that the people closest to them would not be as likely to respect their 
decision to vaccinate their children, when compared to their personal perceptions (the 
exception being affordability). These findings suggest that social media is perceived 
to have a more negative, anti-HPV vaccine slant than their own personal perceptions. 
The perception of social media’s negative slant was also present in the 
analysis of SARF variables. The findings suggest that respondents perceive that social 
media messages relay that it is risky for their children to receive the HPV vaccine, 
that children will experience harmful side effects or death if vaccinated, and that there 
are more risks for their children being vaccinated than having HPV infection, at a 
higher level than their own personal perceptions. However, respondents appeared to 
be divided on whether social media messages are overall mostly in favor or against 
the HPV vaccine. These findings suggest that though perceptions of the HPV 
vaccine’s representation on social media may be more divided, there is the perception 
that HPV vaccine-related social media messages magnify the negative aspects of the 
HPV vaccine while minimizing benefits. It may also suggest that negative HPV 




Concerning the influence of HPV vaccine-related social media messages, 
most of the participants indicated that social media neither increased nor decreased 
their HPV vaccine risk perceptions. However, the results report that there were more 
respondents who reported that social media more often amplified than attenuated their 
HPV vaccine risk perceptions. These findings, in part, support the Nan and Madden 
(2012) and the Dunn et al. (2015) studies, which found that exposure to negative HPV 
vaccine messages have a greater influence on HPV vaccine perceptions than positive 
messages. This suggests the possibility that social media may in fact be negatively 
influencing Kansan parents to avoid getting their children the HPV vaccine. 
HPV Vaccine Representations on Facebook (HBM and SARF) 
This study looked at HPV vaccine representations on Facebook because it is 
the most used social media site in the United States among adults 18 years of age and 
older (Greenwood et al., 2016). Also, Facebook is a popular platform for discussions 
about sexual health (Moorhead et al., 2013). As the survey results show that most of 
the respondents had seen HPV vaccine-related information on social media, have 
Facebook accounts, and that most Facebook users reported that Facebook is their 
most used social media site, this study posits that Facebook content was the most 
relevant social media platform, thus the obvious choice on which to perform a content 
analysis.  
In the context of HBM, the vast majority of the HPV vaccine-related 
Facebook post over the decade since the first vaccine’s FDA approval did not contain 
messages about susceptibility to HPV infection or associated severity. Barriers to 
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getting the vaccine were present in more posts than benefits. Also, very few posts had 
HPV vaccine-related self-efficacy messages or cues directing people to get 
vaccinated. Overall, the tone of most of the posts was against the HPV vaccine. These 
findings are contrary to what Ache and Wallace (2008) found about the vaccine’s 
representation on YouTube, to the findings that Battles (2010) found about HPV 
vaccine representations on internet message boards,  and to the findings on Myspace 
presented by Keelan et al. (2010). However, the results of this study support the 
findings of what Briones et al. (2012)  found in their study of the representation of the 
HPV vaccine on YouTube, and aligns with the survey findings of this dissertation’s 
study. This study’s finding suggests that social media messages lean more towards 
discussion of barriers to HPV vaccination, and that are becoming increasingly 
negative over time. 
Concerning risks, most of the posts had neither HPV vaccine risk amplifying 
nor attenuating messages. However nearly 40% of posts had risk amplifying 
messages and only 2% had risk attenuating messages. An ad hoc analysis found that 
across Facebook, posts that had a negative tone towards the HPV vaccine received a 
higher average number of reactions, comments, and shares than posts with a positive 




Figure 49: HPV vaccine-related Facebook post, average interactions 
 
 Such findings suggest that risk amplifying messages may have a greater reach 
and generate more engagement across Facebook audiences. Provided that the findings 
of Nan and Madden (2012) and Dunn et al. (2015) can be generalized, it is possible 
that social media users, particularly Facebook users who have been exposed to HPV 
vaccine-related posts, are more often exposed to negative HPV vaccine-related 
messages. Additionally, these negative posts may have negatively influenced 
audience perceptions of the HPV vaccine, and made them more inclined to share the 
negative information, further magnifying risk perceptions. Exposure to the current 
Facebook environment may ultimately not be conducive to increasing HPV 
vaccination rates. That is not to say that internet use or using social media to find 




































Greiner, 2011), that users need training to understand how and where to search online 
for information about the HPV vaccine. 
A Decade of HPV Vaccine Representations on Facebook (HBM and SARF) 
The last research question of this study was interested in trends related to 
HPV vaccine representation in posts across Facebook, and how these trends 
compared with CDC Facebook posts over ten years since the first HPV vaccine 
received FDA approval. The CDC did not begin posting content about the HPV 
vaccine on Facebook until 2010. Furthermore, the sheer volume of posts was very 
different across Facebook and the CDC-specific Facebook pages. Before constructing 
the final sample of approximately 6,500 Facebook posts, searches found over 20,000 
non-CDC HPV vaccine-related Facebook posts, and were it not for technological 
limitations, more could have been collected. However, since 2010, only 31 HPV 
vaccine-related posts were published across two CDC Facebook pages. Ultimately, 
the CDC has not been a frequent contributor to the HPV vaccine conversation on 
Facebook. 
While the CDC is not a frequent contributor on the subject of the HPV 
vaccine on Facebook, it has prompted social media users’ engagement. On average, 
since 2010, the CDC posts have received more reactions, comments and shares than 
HPV vaccine-related posts across Facebook. The exception being for comments and 
shares in 2014, where one particular Facebook post would receive an exceedingly 
high amount of attention: more than 11,000 reactions, 6,100 comments, and 329,000 




Figure 50: The most engaging HPV vaccine-related Facebook post. This post appeared three different times in the 
sample: twice in 2014, and once in 2016. Of the posts in the sample analyzed, it received to most reactions, 




Because this post occurred three different times in the sample, the researcher 
felt that it was important to keep all three instances in the analysis, as it represents the 
trend of the tone of HPV vaccine and the spread of negative HPV vaccine-related 
messages. The attention that this negative post received is enormous. It is also a 
demonstration of the power that anti-HPV vaccine messages have in generation 
attention, which may also generate negative sentiment, and influence HPV 
vaccination rates to be lower.  
When looking at the tone, the CDC’s posts have been neutral or positive on 
average, while the tone across Facebook has been mostly negative. Toward the HPV 
vaccine, the CDC has published HPV vaccine positive messages, while there have 
been an increasing number of HPV vaccine-negative messages across Facebook, with 
the largest proportion occurring in 2016, according to our data. 
 Looking at HBM-related messages, the average presence of susceptibility to 
HPV infection messages have been low in both CDC Facebook posts and posts across 
Facebook. Severity messages are generally more present in CDC posts. Also, while 
CDC posts have a high average presence of HPV vaccine benefits, the presence of 
benefits in posts across Facebook has been decreasing. Barriers to HPV vaccination 
are absent in CDC posts, but are present and increasing across Facebook. Self-
efficacy messages for both the CDC posts and posts across Facebook are low, but are 
more present in CDC posts since 2013. Regarding cues to get the HPV vaccine, the 
CDC posts would not have these messages until 2013. For posts across Facebook, 
these messages would peak in 2006, but would be lower thereafter. Cues to not 
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vaccinate were absent from CDC posts, and low across Facebook, but were on the 
rise, peaking in 2016. The findings from the content analysis suggest that HPV 
vaccine-related posts on Facebook overall emphasize barriers to vaccination more 
than other HBM variables, and that this emphasis has only increased over the decade 
since the first HPV vaccine was approved by the FDA. This is contrary to CDC posts, 
where the average presence of benefits is much higher. In both sets of data, the 
presence of susceptibility messages was low. This may be likely due to susceptibility 
being common knowledge. However, the presence of severity messages across 
Facebook posts being generally lower than in CDC posts suggests that, based on the 
interpretations of the data, that the sets of posts may have different foci. That is, the 
CDC may be more focused on discussing the benefits of the HPV vaccine, orienting it 
as a preventive health behavior, whereas posts across Facebook may suggest more 
often that the HPV vaccine is a risk event.  
In the context of SARF, there was an absence of HPV vaccine-related risk 
amplifying messages in CDC Facebook posts. This was not the case across Facebook. 
In fact, the analysis found that on average, Facebook posts contain more risk 
amplifying messages, and that trend was on the rise. This finding suggests that, at 
least on Facebook, the HPV vaccine may be oriented, and thus perceived, more as a 
risk than a preventive health behavior. This would line up with the findings that 
barrier messages are also increasing on Facebook.  
Concerning ripples and impacts, most of the HPV vaccine-related posts across 
Facebook did not contain messages related to these variables, and the CDC did not 
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have any. This suggests that Facebook messages may not be as concerned with the 
consequences of HPV vaccination when it is oriented as a risk event. It also suggests 
that the majority of authors of public HPV vaccine-related posts across Facebook do 
not share the perspectives of the CDC about the HPV vaccine. Instead, the messages 
are focused on how the HPV vaccine is perceived: a tool to protect public health, a 
harmful formula, or something in between. The varied representation of the HPV 
vaccine on social media suggests varied opinions by society. Thus, it is not enough 
for the CDC to keep advocating the HPV vaccine as a preventive health behavior 
because not all of the public, and certainly not all of Kansan parents and guardians, 
are buying into the messages the CDC wants to sell. 
Implications and Recommendations 
Though this study targeted parents, both male and female, the majority of the 
survey respondents who completed the survey were female (n = 83, 87.4%). Also, the 
content analysis found that Facebook posts published by owners of individual profiles 
were mostly female (n = 2,649; 69.8%). These findings are not necessarily a surprise, 
given that research demonstrates that in the United States, women are more often the 
managers of their children’s health (Ranji & Salganifcoff, 2014). Research shows that 
females are vaccinated with the HPV vaccine at a greater rate than men (Reagan-
Steiner et al., 2016). Though HPV can infect males and females, these findings 
support that this is a female-centric issue. Though the HPV vaccine was not made 
available to males before 2009 (U.S. Food and Drug Administration, 2009a), years 
have passed and it is important to emphasize to include males – fathers and sons, in 
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the conversation about HPV vaccination so that they can protect themselves and their 
possible future intimate partners. 
Since many Kansan parents and guardians are aware of HPV and its 
associated diseases and are aware of the HPV vaccine and its benefits, a different 
approach to promote vaccination may be needed. This is because in spite of 
awareness about the infection, disease, and the vaccine, there are concerns about HPV 
vaccine-related risk and barriers. Healthcare professionals and health communication 
researchers might consider focusing the conversation on HPV vaccine-related 
concerns instead of focusing on HPV prevention. By minimizing the perception of 
barriers and attenuating the perception of risks, it is likely that there will be a positive 
effect on intent to get children the HPV vaccine. 
Facebook has a large and captive audience and many of the posts do not 
contain pro-HPV vaccine messages. While the survey participants mostly believe that 
what they see on social media does not influence their fears about getting their 
children the HPV vaccine, research supports otherwise. Thus, it is important for 
healthcare providers to remain aware and take into account that social media may 
influence patient perceptions of the HPV vaccine. Addressing these concerns, not just 
about HPV, but also the vaccine, may make the difference in convincing a parent, in 
Kansas or elsewhere, to comply with getting their child the HPV vaccine. 
As the CDC has the capability to be a stakeholder, they and other 
organizations might consider increasing their efforts to produce more pro-HPV 
vaccination messages. Though the majority of HPV vaccine-related Facebook posts 
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go without any reactions, comments, or shares, it does not mean that they have not 
been seen, they could have been witnessed. The over 21,000 initial Facebook posts 
are only a piece of what is out there about the HPV vaccine. That sheer volume 
compared to CDC’s only 31 posts over ten years demonstrates that they do not have a 
sizeable role in the conversation. Their ability to reach people is also likely 
diminished by another characteristic – that their posts are likely only seen if someone 
follows their pages, or actively searches for the information they contain. This means 
that promotion of the HPV vaccine by the CDC alone will likely not move HPV 
vaccination rates higher. It will take connecting with other stakeholders (the larger the 
network, the better) to influence and increase in HPV vaccination of children. It will 
take time and a lot of pro-HPV vaccine messages to change the trends, as the negative 
tone towards the HPV vaccine, the mentions of barriers, and HPV vaccine-risk related 
messages have continued to increase over the last few years. 
Concerning theory, it is recommended that health communication 
practitioners consider testing risk perceptions as a distinct variable in the health belief 
model. When Rosenstock et al. (1988)  updated the health belief model to include the 
component of self-efficacy, they did so with the belief that one must actually believe 
that she or he could actually perform the preventive health behavior. This study posits 
that one must also believe that desired preventive health behavior is not a risk event, 
or else the model is diminished from an epistemological standpoint. The performer 
must believe that behavior will be of use to preventing a disease, not believe it to 
possibly cause harm. 
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With a change in approach to promoting HPV vaccination and addressing 
barriers to HPV vaccination and HPV-vaccine risk perceptions, there may be some 
improvement in HPV vaccination rates among Kansan children. It is important to 
continue to research and disseminate information about HPV to the public, but also 
important as this study finds, is addressing concerns about the HPV vaccine itself. 
Limitations 
 This study is snapshot representing part of what is going on with Kansan 
parents and guardians perceptions about the HPV vaccine. Future research, with 
larger and more representative participant samples, could provide a more 
comprehensive understanding of the role of Kansan parent and guardian perceptions, 
and the influence of these perceptions on low HPV vaccination rates in Kansas. Still, 
this research contributes to addressing low HPV vaccination rates among Kansan 
children eligible for vaccination, and contributes to the understanding a regional 
phenomenon. Recruitment of such a specific population was a challenge, likely given 
the nature of the subject. This study would likely have had even fewer respondents 
were it not for the efforts of the state and several county health departments who 
agreed to post a link to the survey on web and social media pages they manage. In 
most cases, non-participation by county health departments was the result of 
unreturned calls and un-replied emails. Other times, it was because county health 
departments declined to participate. Additional research with more collaborators 
would likely result in higher rates of survey participation. 
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While more than 150 eligible respondents began the survey, almost 40% did 
not complete the survey. The survey, in an effort to measure HPV vaccine 
perceptions in the contexts of both HBM and SARF, perceptions of social media 
representation of the HPV vaccine, and collect information about their children’s 
vaccination status, ended up being extensive, and perhaps a bit lengthy. Though many 
surveys ended up being incomplete, the data for many of the variables was still useful 
and informed that even when samples were larger it did not change the interpretations 
of the findings. 
The survey respondents were mostly white and female which aligns with 
Kansas’ demographics (United States Census Bureau, 2017). However, the 
respondents in the survey were on average more educated and wealthier than Kansans 
overall. Based on research showing that minorities and those below the poverty line 
are out-vaccinating white and wealthier people (Reagan-Steiner et al., 2016), it is 
possible that the survey research found HPV vaccine perceptions that are more 
negative among the sample than would be for the population of Kansas. Future 
research of HPV vaccine perceptions held by Kansas across various demographics 
(e.g., racial, education level, and socioeconomic) could contribute to a greater 
understanding of factors contributing to low vaccination rates.  
With regard to the content analysis, there were a few technological 
limitations. First, the Facebook search feature does not allow users to organize results 
by date or engagement. This limits flexibility in data collection, however the search 
feature did allow for the collection of thousands of posts for analysis since the 
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vaccine debuted. Technology also limited the ability to archive Facebook posts. 
When loading the search results, one would have to scroll down to make the area 
printable. Scrolling down too far would cause internet browsers to crash; it would be 
near impossible at this point in time to archive the entire population of HPV vaccine-
related Facebook posts unless one possesses a computer with large memory 
capabilities.  
Also, this study only collected public Facebook content in an effort to only 
analyze content that would be available to any Facebook user, because access to 
private social media feeds is not possible without specific participant consent. It is 
likely that collection from personal profiles may be met with more difficulty in the 
future. An ad hoc analysis found that after since 2012, the number of posts collected 
from Facebook profiles was fewer than those from Facebook pages (see Figure 51).
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This suggests that Facebook users are increasingly limiting the access of the public to 
their posts, as the number of Facebook users has only increased since its debut in 
2004, and has over a billion active users as of 2016 (Facebook, 2017f). The use of 
non-public posts may have added more in terms of post quantity to the analysis, 
however as the researcher had fewer than 600 mutual connections at the time of the 
study, the ability to access non-public HPV vaccine-related posts was limited  
(Facebook, 2017a). 
Directions for Future Research 
This study serves a stepping stone to analyzing future research about low HPV 
vaccination rates among children in Kansas, and by extension, other places where 
HPV vaccination rates are low among children. This study has more data about white 
respondents more than any other racial group. Because nationwide statistic show that 
adolescents (13-17) belonging to other racial groups are receiving the HPV vaccine at 
higher rates (Reagan-Steiner et al., 2016) than whites, future studies should analyze if 
there is a similar phenonmenon taking place in Kansas, which may further explain 
low immunization rates through this demographic indicator. In the same vein, future 
studies should also analyze socioeconomic and sex identity in relation to vaccination 
rates in Kansas to see if they reflect the national trends, as this study found that there 
may be a difference. 
While the content analysis portion of this study focused on the presence of 
certain types of messages that were in Facebook posts, it did not analyze the 
qualitative content of those messages. The intersection of mass media and the cases of 
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arsenic-related illness and Plague in India, Susarla (2003) inferred that the 
characteristics of mass media blaming messages may matter as much as message 
volume. Similarly, there is certainly a gap that future research could address in 
analyzing the qualitative characteristics of HPV vaccine-related messages more in-
depth. Specifically, it would be of great use to understand what types of risks and 
barriers to HPV vaccination are mentioned in Facebook posts so that interventions are 
able to target these concerns. This information would allow researchers to conduct 
more experiments similar to the works of Nan and Madden (2012) and Dunn et al. 
(2015), and also test the effectiveness of interventions. Interventions could also test 
the efficacy of HPV-focused messages and compare these with the HPV vaccine-
focused messages to see if which messages influence a greater intent of parents to get 
their children vaccinate. Furthermore, it may also be useful to apply additional 
theoretical models expand on the representation of the HPV vaccine on social media. 
Additionally, as this study only analyzed HPV vaccine-related Facebook 
posts, there is an opportunity to research Facebook posts from a variety of collection 
and analytical methods. Looking at Facebook pages that have a great number of 
followers could provide information about how the HPV vaccine is represented in a 
variety of contexts. Also post comment analysis could provide more detailed 
information about how Facebook users engage with posts containing certain types of 
messages beyond the analysis of the number of reactions, comments and shares that a 
posts receives. In the future, it also may be worthwhile to investigate how Facebook 
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users react to HPV vaccine-related posts with, as reactions have become more 
dynamic, having more options since 2016 (Facebook, 2017f; Krug, 2016).  
In the interest to not make the survey any longer, the survey did not ask 
questions about the ripples and impacts that occurred as a result of the respondent’s 
perception of HPV vaccine-related risk. The content analysis found that the presence 
of ripple and impact messages was low. Future research should also consider 
investigating the secondary impacts, whether it is the recall of individuals or message 
presence in other media, so that the consequences of HPV vaccine-related risk 
perceptions can be traced and targeted to improve vaccination rates. 
Conclusions 
The health belief model has been applied to analysis of intentions to engage in 
preventive health behaviors and the analysis of communicated messages about 
preventive health behaviors. Application of this model to the analysis of how Kansan 
parents and guardians perceive the vaccination is useful, and focusing on a 
geographic region provides acknowledges the diversity of what may be happening in 
different geographic areas. As Kansas is underperforming in the context of the HPV 
vaccination rates, this research, while does not give a complete picture, is the start to 
a greater understanding of a regional phenomenon and the influence of health beliefs. 
 This study suggests that the HPV vaccine being communicated by various 
government organizations as a preventive health behavior is not enough to motivate 
vaccination alone. This study posits that there may be several factors discouraging 
Kansan parents and guardians from vaccinating their children, which may be 
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contributing to low vaccination rates. Specifically, the perceptions of barriers and 
risks may have a substantial influence. 
It may seem unconventional to research the HPV vaccine as a risk event, but 
even the HPV vaccine inserts indicate the possibility of side effects, which one may 
perceive as risks (U.S. Food and Drug Administration, 2009b, 2011, 2014b). HBM 
(Rosenstock, 1974; Rosenstock et al., 1988) holds the perspective that people want to 
avoid disease and engagement in preventive health behavior depends on how several 
variables interact. However, the model appears to assume that certain actions are 
universally perceived as preventive health behaviors in the first place. If an 
individual, perhaps a Kansan parent, does not perceive the HPV vaccine as a 
preventive health behavior, it can be argued that this is more than just a barrier to 
HPV vaccination. Again, the model in essence appears to collapse from an 
epistemological standpoint when applied to the perspectives of that individual. It is 
curious, then, if people should take the HPV vaccine for granted to be perceived as a 
preventive health behavior, when a population exists that appears to perceive the 
contrary. Thus, it may be useful and even necessary, to analyze the HPV vaccine, 
along with other such labeled preventive health behaviors, in multiple contexts to 
better understand non-compliance.  
There may be even more complex factors to consider if a particular Kansan 
perceives the HPV vaccine as a risk event. If such is the perception, SARF suggests 
that there is an opportunity, especially for media, to amplify or attenuate risk 
perceptions (Eldridge & Reilly, 2003; J. Kasperson et al., 2003; R. Kasperson et al., 
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1988; Susarla, 2003). Social media use is increasing. For now, Facebook is a 
dominant platform. So, for now, there is an opportunity to use this platform to 
communicate risk attenuating messages about the HPV vaccine. These messages, if 
tailored and effective, may minimize or even reverse the trend of the social media 
environment negatively portraying the HPV vaccine, as once upon a time, research 
found that the portrayal of the HPV vaccine was more positive than negative. In turn, 
there may be an effect, and among Facebook users, HPV vaccination perceptions may 
become more positive, and vaccination rates might increase.   
On the surface, HPV vaccination rates among Kansas children are 
comparatively lower when compared with national vaccination rates. Deeper, there 
are a variety of interacting variables that are influencing the perceptions that Kansan 
parents and guardians have toward the HPV vaccine, which likely have a role on the 
comparatively low vaccination rates among their children. These perceptions 
ultimately determine whether or not the HPV vaccine is perceived more as a 
preventive health behavior, as a risk event potentially harmful to their children, or 
something in between. Media representations also have a role in communicating and 
influencing HPV vaccine-related perceptions.  
Exploration and understanding of the dynamic confluence of these factors 
may be more complex than the process of developing a vaccine that can prevent 
cancer, but is necessary to addressing things such as anti-HPV vaccine messages 
shared between sisters. It is necessary for getting the vaccine out of a vial and into 
bodies of children who will one day, like a certain Uber driver, be adults. But, 
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hopefully unlike the Uber drive that a doctoral student (now graduate) met on a rainy 
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Appendix 1: Pre-Survey Interview Schedule 
Interview Schedule 
Topical Questions 
1) How many children do you have? 
2) How many of them are girls? Boys? 
3) How old are your children? 
4) When thinking about your children’s health, what are some of your greatest 
challenges? 
5) Where do you turn to for information about health issues related to your 
children? 
6) Have you heard of HPV, also known as the human papillomavirus? 
7) What do you know about HPV? 
8) Where did you learn about HPV? 
9) What have you seen about HPV on the internet? Social media? 
10) What have you seen about HPV on social media? 
11) How do you feel about vaccinations? 
12) Did you know there is a vaccine for HPV (also known as Cervarix® or 
Gardasil®)? 
13) What do you know about HPV vaccine? 
14) What have you seen about the HPV vaccine on the internet? Social media? 
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15) Has what you seen on social media influence how you feel about HPV and the 
HPV vaccine? 
16) Have your children gotten the HPV vaccine? 
17) Why did/didn’t get your children the HPV vaccine? (probe about risks, 
benefits, barriers, if they could be convinced if they did not) 
18) What advice would you give to someone considering whether or not to get 
their child the HPV vaccine? 
 
Demographic Questions 
19) What is your race? 
20) Are you Hispanic or Latino? 
21) How older are you? 
22) What county do you live in? 
23) I am going to read some income intervals. Can you please stop me when I 
read the one that is closer to your current family income? 
a. Less than $5,000 per year 
b. Between $5001 and $10,000 per year 
c. Between $10,001 and $20,000 per year 
d. Between $20,001 and $40,000 per year 
e. Between $40,001 and $60,000 per year 
f. Over $60,001 per year 
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24) I am going to read some education levels. Can you please stop me when I read 
the one that is closer to yours? 
a. Primary/Junior High 
b. High School Diploma/GED 
c. Some college 
d. Associate’s Degree 
e. Bachelor’s Degree 
f. Master’s Degree 
g. Doctoral Degree 
h. Professional Degree (e.g., JD, MD). 
25) I am going to read some education levels. Can you please stop me when I read 
the one that is closer to yours? 
a. Primary/Junior High 
b. High School Diploma/GED 
c. Some college 
d. Associate’s Degree 
e. Bachelor’s Degree 
f. Master’s Degree 
g. Doctoral Degree 





















5 Please indicate your guardian identity. 
 Mother 
 Father 
 Other (please explain) ____________________ 
 
6 How many children do you have that are 9-17 years of age? 
 




8 Which is your main source for learning about <strong>HPV </strong>(<i>human 
papillomavirus</i>)? 
 Printed materials (books, magazines, brochures, pamphlets, etc.) 
 Television (such as "The Doctor Oz Show") 
 Websites (such as WedMD.com) 
 Social media (such as Facebook, YouTube, etc.) 
 Radio 
 A healthcare provider (such as a doctor or nurse) 
 Family members 
 Friends 




9 Please indicate how much you either agree or disagree with the following 



































              

















              
My child is 
at risk to 
get HPV. 
              
 
 
10 <p><span style="font-variant-numeric: normal; font-stretch: normal; font-size: 7pt; 
line-height: normal; font-family: "Times New Roman";"> </span>Have you heard of 
the <b>HPV vaccine</b> or ANY of the following terms, that the HPV vaccine goes 
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by:<br><br></p><p>- Cervarix®, Bivalent HPV vaccine, HPV2, or 2vHPV?</p><p>- 
Gardasil®, Quadrivalent HPV vaccine, HPV4, or 4vHPV?<br>- Gardasil® 9,  9-valent 
HPV vaccine, or 9vHPV?<br></p><p>- genital warts vaccine?</p><p>- human 
papillomavirus (HPV) vaccine/immunization?</p><p>- human papillomavirus (HPV) 
shot?</p><p>- cervical cancer vaccine</p><p> 




11 Which is your main source for learning about the <b>HPV vaccine</b>? 
 Printed materials (books, magazines, brochures, pamphlets, etc.) 
 Television (such as "The Doctor Oz Show") 
 Websites (such as WedMD.com) 
 Social media (such as Facebook, YouTube, etc.) 
 Radio 
 A healthcare provider (such as a doctor or nurse) 
 Family members 
 Friends 




12 Please indicate how much you either agree or disagree with the following 
statements about the<b> HPV vaccine</b><font face="Times New Roman, 


































              







              








              
The HPV 
vaccine 
could kill my 
child 





              





























17 years of 
age. 





to those 18 
years of age 
and older. 
              
There 
should not 
be an HPV 
vaccine. 








              



















for my child. 
              
I have been 
encouraged 





              







              







              
It is risky for 















I am a good 
parent if I 
get my child 
the HPV 
vaccine. 
              
There are 
more risks 
































13 Which is your main source for learning about<b> health information</b> for your 
child? 
 Printed materials (books, magazines, brochures, pamphlets, etc.) 
 Television (such as "The Doctor Oz Show") 
 Websites (such as WedMD.com) 
 Social media (such as Facebook, YouTube, etc.) 
 Radio 
 A healthcare provider (such as a doctor or nurse) 
 Family members 
 Friends 
 Other (please explain): ____________________ 
 





















16 Please rank your <b>three</b> most used social media accounts, 1 being your 












______ Other, please identify: 
 






18 Have you ever seen information about <strong>HPV </strong>(<em>human 
papillomavirus</em>) on social media? This also includes if you've only seen the 




19 Have you ever searched for information about 





20 Have you ever posted or shared anything about 




21 <div><span style="font-size: 16px;">Think about 
<strong>HPV </strong></span>(<em>human papillomavirus</em>) on social 
media<span style="font-size: 16px;">. On which social media site do you recall 
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seeing </span><strong>the most </strong><span style="font-size: 












 Other, please identify: ____________________ 
 
22 Who posts or shares the information that you see about <strong>HPV 
</strong>(<em>human papillomavirus</em>) on <b>social media</b>? Please 
check all that apply.  
 Myself 
 Family member(s) - with whom I have a close relationship 
 Family member(s) - with whom I have a distant relationship 
 Friend(s) - with whom I have a close relationship 
 Friend(s) - with whom I have a distant relationship 
 Health organization(s) (government, such as the Centers for Disease Control and 
Prevention [CDC]) 
 Health organization(s) (non-government) 
 Health blogger(s) 
 Celebrity 
 News organization(s) 
 Advertisement(s) 




23 Now think about <strong>HPV </strong>(<i>human papillomavirus</i>) and social 
media. Please indicate if the messages on social media, in general, agree with the 
following statements about HPV. There are no right or wrong answers - we want to 




















































              
Your child 
is at risk to 
get HPV. 





24 Please complete the following sentence:<div>I believe that what I read on social 
media _________ my fear about HPV (also known as the <i>human 
papillomavirus</i>) for my children.<b> </b></div> 
 Increases 
 Decreases 
 Neither increases, nor decreases 
 
25 Please complete the following sentence:<div>I believe that what I read on social 
media<b> </b>makes me feel that my child is at a ____________ risk to get HPV 
(also known as the <i>human papillomavirus</i>).<b> </b></div> 
 Greater 
 Lesser 
 Neither greater, nor lesser 
 
26 Have you ever seen information about the<b> HPV vaccine </b>on social media? 
















29 <div><span style="font-size: 16px;">Think about the <b>HPV vaccine</b>. On 
which <b>social media </b>site do you recall seeing </span><strong>the 













 Other, please identify: ____________________ 
 
30 <span style="font-size: 16px;">In general, would you say that posts you have 
seen on <b>social media </b>about the <b>HPV vaccine</b> are:</span> 
 Always in favor of HPV vaccine 
 Mostly in favor of the HPV vaccine 
 Equally in favor and against the HPV vaccine 
 Mostly against the HPV vaccine 
 Always against the HPV vaccine 
 
31 Who posts or shares the information that you see about the <strong>HPV 
vaccine</strong> on <b>social media</b>? Please check all that apply. 
 Myself 
 Family member(s) - with whom I have a close relationship 
 Family member(s) - with whom I have a distant relationship 
 Friend(s) - with whom I have a close relationship 
 Friend(s) - with whom I have a distant relationship 
 Health organization(s) (government, such as the Centers for Disease Control and 
Prevention [CDC]) 
 Health organization(s) (non-government) 
 Health blogger(s) 
 Celebrity 
 News organization(s) 
 Advertisement(s) 




32 Now think about the <strong>HPV vaccine. </strong>Please indicate if the 
messages on <strong>social media</strong>, in general, agree with the following 
statements about HPV vaccine. Again, there are no right or wrong answers - we 











































              

























to get for 
your child. 






















17 years of 
age. 





to those 18 
years of age 
and older. 
              
There 
should not 
be an HPV 
vaccine. 





your child to 
be more 


























              
Society 
encourages 























              
It is risky for               
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              
You are a 
good parent 







































33 Please complete the following sentence:<div>I believe that what I read on social 
media<strong> </strong>_________ my fear about getting the HPV 
vaccine<b> </b>for my child.<strong> </strong></div> 
 Increases 
 Decreases 
 Neither increases, nor decreases 
 
34 Please complete the following sentence:<div>I believe that what I read on social 
media<b> </b>makes me feel that my child is at a ____________ risk to be harmed 
by the HPV vaccine.</div> 
 Greater 
 Lesser 
 Neither greater, nor lesser 
 




 Prefer not to answer 
 
36 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>What is their 










 prefer not to answer 
 
37 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>Has this child 
received the <b>HPV vaccine</b>? 
 Yes, how many shots? ____________________ 
 No 
 Unsure 




38 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>How long ago 
did this child receive their last HPV vaccine shot? 
 less than a month ago 
 1 month ago 
 2 months ago 
 3 months ago 
 4 months ago 
 5 months ago 
 6 months ago 
 more than 6 months ago 
 
39 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>Do you intend 
on getting this child the <b>HPV vaccine </b>before the child is 18 years of age?  
 Definitely yes 
 Probably yes 
 Might or might not 
 Probably not 
 Definitely not 
 Prefer not to answer 
 
40 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>Have you ever 




 Prefer not to answer 
 
41 For your ${lm://Field/1}${lm://Field/2} child, 9-17 years of age:<br>Has a doctor or 
any other health care provider talked to you about getting the <b>HPV vaccine</b> 




 Prefer not to answer 
 
42 <p><strong>About the human papillomavirus (HPV)<o:p></o:p></strong></p>  
<p>The human papillomavirus (HPV) is a group of 150 viruses HPV types, of which 
more than 40 can infect humans [1]. HPV is spread through skin-to-skin contact with 
someone who is infected  [2], most commonly the result of contact during vaginal 
and anal sexual activity, but also can be contracted during oral sex. Whether or not a 
person infected with HPV is symptomatic, it is still possible for that person to spread 
the infection. Many individuals with HPV infection do not show signs of infection, but 
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some people do experience symptoms.  <o:p></o:p></p>  <p>Symptoms and 
complications attributed to HPV infection include genital warts and cancer [3]. HPV-
associated cancers include cervical, vulvar, vaginal, penile, anal, and oropharyngeal 
(back of the throat). Each year in the United States of America, there is average of 
more than 38,000 of new cases of these forms of cancer [4], and each year these 
forms of cancer are responsible for nearly 16,000 deaths [5-8].<o:p></o:p></p> 
 
43 <p><strong>About the human papillomavirus (HPV) 
vaccine<o:p></o:p></strong></p>  <p>The human papillomavirus (HPV) vaccine is a 
series of injections that immunize recipients against many HPV types, and 
consequently prevents HPV-associated disease [9]. It has been approved for use in 
females since 2006 [10] and for males since 2009 [11].<o:p></o:p></p>  <p>The 
vaccine is also known by several other brands and names, including 
[12]:<o:p></o:p></p>  <p>-<span style="font-variant-numeric: normal; font-stretch: 
normal; font-size: 7pt; line-height: normal; font-family: "Times New 
Roman";">          </span>Cervarix®, Bivalent HPV vaccine, HPV2, 
2vHPV<o:p></o:p></p>  <p>-<span style="font-variant-numeric: normal; font-stretch: 
normal; font-size: 7pt; line-height: normal; font-family: "Times New 
Roman";">          </span>Gardasil®, Quadrivalent HPV vaccine, HPV4, or 
4vHPV<o:p></o:p></p>  <p>-<span style="font-variant-numeric: normal; font-stretch: 
normal; font-size: 7pt; line-height: normal; font-family: "Times New 
Roman";">          </span>Gardasil® 9,  9-valent HPV vaccine, or 
9vHPV<o:p></o:p></p>  <p>-<span style="font-variant-numeric: normal; font-stretch: 
normal; font-size: 7pt; line-height: normal; font-family: "Times New 
Roman";">          </span>the genital warts vaccine<o:p></o:p></p>  <p>-<span 
style="font-variant-numeric: normal; font-stretch: normal; font-size: 7pt; line-height: 
normal; font-family: "Times New Roman";">          </span>the human papillomavirus 
(HPV) vaccine/immunization , human papillomavirus (HPV) shot<o:p></o:p></p>  
<p>The Advisory Committee on Immunization Practice (ACIP), “a group of medical 
and public health experts that develop recommendations on the use of vaccines in 
the civilian population of the United States” [13], recommends HPV vaccination for 
females ages 11 or 12 years, with catch-up vaccines for females age 13-26 years. 
For males, the ACIP recommends vaccination at ages 11 or 12 years, with catch-up 
vaccines at ages 13-21 years, or if immunocompromised, through age 26 years. It is 
also recommended that men who engage in sexual relationships with other men 
(MSM) also receive catch-up vaccinations through age 26 years. Children can begin 
vaccination as early as age 9 years [14], and recommendation of HPV vaccination 
prior to adolescence has been done with the goal of getting children vaccinated and 
immunized against HPV prior to potential exposure to infection [15].<o:p></o:p></p> 
 
44 <p><em>If you would like more information about HPV or the HPV vaccine, 
please speak to a healthcare provider. Also, you may refer to the sources 
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below.<br><br><o:p></o:p></em></p>  <p><b>Sources</b><o:p></o:p></p>  
<p>1.         Centers for Disease Control and Prevention. <em>Human papillomavirus 
(HPV)</em>. 2015  [cited 2015 September 30]; Available from: 
http://www.cdc.gov/hpv/parents/whatishpv.html.<o:p></o:p></p>  <p>2.         Centers 
for Disease Control and Prevention. <em>Human papillomavirus (HPV): Genital HPV 
infection - fact sheet</em>. 2016  [cited 2015 September 30]; Available from: 
http://www.cdc.gov/std/HPV/STDFact-HPV.htm.<o:p></o:p></p>  
<p>3.         Centers for Disease Control and Prevention. <em>Human papillomavirus 
(HPV): HPV and cancer</em>. 2015  [cited 2015 September 30]; Available from: 
http://www.cdc.gov/hpv/cancer.html.<o:p></o:p></p>  <p>4.         Centers for 
Disease Control and Prevention. <em>HPV and cancer</em>. 2016  [cited 2016 July 
12]; Available from: 
http://www.cdc.gov/cancer/hpv/statistics/cases.htm.<o:p></o:p></p>  
<p>5.         Centers for Disease Control and Prevention. <em>Gynecological 
cancers</em>. 2016  [cited 2016 July 12]; Available from: 
http://www.cdc.gov/cancer/cervical/statistics/index.htm.<o:p></o:p></p>  
<p>6.         Centers for Disease Control and Prevention. <em>Gynecological 
cancers: Vaginal and vulvar cancers statistics</em>. 2016  [cited 2016 July 12]; 
Available from: 
http://www.cdc.gov/cancer/vagvulv/statistics/index.htm.<o:p></o:p></p>  
<p>7.         American Cancer Society. <em>Penile cancer: What ae the key statistics 
about penile cancer?</em> 2016  [cited 2016 July 12]; Available from: 
http://www.cancer.org/cancer/penilecancer/detailedguide/penile-cancer-key-
statistics.<o:p></o:p></p>  <p>8.         National Institutes of Health and National 
Cancer Institute. <em>SEER stat fact sheets: Anal cancer</em>. 2016  [cited 2016 
July 12]; Available from: 
http://seer.cancer.gov/statfacts/html/anus.html.<o:p></o:p></p>  <p>9.         Centers 
for Disease Control and Prevention. <em>For parents: Vaccines for your children: 
HPV vaccine for preteens and teens</em>. 2015  [cited 2016 July 13]; Available 
from: http://www.cdc.gov/vaccines/parents/diseases/teen/hpv.html.<o:p></o:p></p>  
<p>10.       U.S. Food and Drug Administration, <em>June 8, 2006 approval letter - 
human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant</em>. 
2006, Departement of Health and Human Services: Rockville, MD.<o:p></o:p></p>  
<p>11.       U.S. Food and Drug Administration. <em>FDA approves new indication 
for Gardasil to prevent genital warts in men and boys</em>. 2009  [cited 2016 June 
19]; Available from: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187003.htm.<
o:p></o:p></p>  <p>12.       Centers for Disease Control and Prevention. 
<em>Vaccines and immunizations</em>. 2016  [cited 2016 December 15]; Available 
from: https://www.cdc.gov/vaccines/terms/vacc-abbrev.html.<o:p></o:p></p>  
<p>13.       Centers for Disease Control and Prevention. <em>Advisory Committee 
on Immunization Practices (ACIP)</em>. 2016  [cited 2016 December 4]; Available 
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from: https://www.cdc.gov/vaccines/acip/.<o:p></o:p></p>  <p>14.       Petrosky, E., 
et al., <em>Use of 9-Valent human papillomavirus (HPV) vaccine: Updated HPV 
vaccination recommendations of the advisory committee on immunization 
practices.</em> MMWR: Morbidity & Mortality Weekly Report, 2015. 
<strong>64</strong>(11): p. 300-304.<o:p></o:p></p>  <p>15.       Schuchat, A., 
<em>HPV "coverage".</em> The New England Journal of Medicine, 2015. 
<strong>372</strong>(8): p. 775-776.<o:p></o:p></p> 
 
45 Based on the information that you have just read about HPV and the HPV 
vaccine, would you consider (please check all that apply): 
 Getting the HPV vaccine for your child? 
 Talking to a doctor or health care provider about HPV? 
 Talk to a doctor or health care provider about the HPV vaccine? 
 Talking to a family member about HPV? 
 Talking to a family member about the HPV vaccine? 
 Talking to a friend about HPV? 
 Talking to a friend about the HPV vaccine? 
 Doing more research about HPV? 
 Doing more research about the HPV vaccine? 
 None of the above. 
 
46 What is your sex? 
 Male 
 Female 
 Prefer not to answer 
 
47 What is your race? Check all that apply. 
 White 
 Black or African American 
 American Indian or Alaska Native 
 Asian 
 Native Hawaiian or Pacific Islander 
 Other 




48 Are you Hispanic or Latino? 
 Yes 
 No 
 Prefer not to answer 
  
49 What is your birth year? (Enter "0" if you prefer not to answer. Enter "1234" if you 
do not know) 
 














































































































 Prefer not to answer 
 
51 What is your highest level of education? 
 Less than high school 
 High school graduate or GED equivalent 
 Some college 
 2 year degree or Associate's degree 
 4 year degree or Bachelor's degree 
 Master's degree 
 Doctorate or terminal degree (e.g. Ph.D., M.D., J.D.) 




52 What is your current yearly household income?  
 Less than $10,000 
 $10,000 - $19,999 
 $20,000 - $29,999 
 $30,000 - $39,999 
 $40,000 - $49,999 
 $50,000 - $59,999 
 $60,000 - $69,999 
 $70,000 - $79,999 
 $80,000 - $89,999 
 $90,000 - $99,999 
 $100,000 or more 



















Appendix 3: Content Analysis Codebook 
CODEBOOK 
Parameters:  
- Posted between June 8, 2006 – June 8, 2016 (dates inclusive) 
- Search terms: “Cervarix,” “Gardasil,” “HPV vaccine,” and “human 
papillomavirus vaccine” 
Exclusion Criteria 
- Non-public post 
- Non-English  




Coding Instructions Notes 
Content Characteristics 
What year was the 
Facebook post published? 
Year Code the year that 
the post was 
published 
 
What day was the 
Facebook post published? 
Date List the month and 
day 
 
Who authored this post? Author 1 – Facebook 
profile 
 
2 – Facebook 
page or group 
You generally 
have the ability 
to add a profile 
as a friend, 
whereas a page, 
you can only 
like and follow. 
If you aren’t 
sure, hover over 
the name to see 
options 
What is the gender of the 
author? 
Gender 0 – author is the a 
page 
1 – Female 
2 – Male  
3 – Unsure 
4 – CDC 
If the author is a 
Facebook 
profile, then 
attempt to code 
the gender 
Who is the audience for 
this post? 
Audience 0 – general 
1 – to a Facebook 
page 
2 – to Facebook 
profile 
 
If a post is a 
general post, it 
will just have 
the author. If 
there’s an 
expressed 
audience, it will 
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have the author, 
then a space 
followed by the 
name of the 
audience 
Does the post have 
hyperlinks? 
Link 0 – absent 











Does the post have picture 
or videos embedded? 
Picvid 0 – absent 
1 – present 
Pictures may be 
in the original 
post or in the 
link, they 
however should 
not be attached 
to the 
embedment. 
Pictures take up 
the post 
window. 




the word “Like” 
How many comments does 
this post have? 
Comments Record the 
number 
Located on 
lower right of 
post, if any 
How many shares does this 
post have? 
Shares Record the 
number 
Located on 
lower right of 
post, if any 
What is the tone of this 
post? 
PostTone 0 – neutral 
1 – positive 
2 – negative 
 
What is the tone of this 
post toward the HPV 
vaccine? 
PostTone 0 – neutral 
1 – positive 
2 – negative 
 
HPV-Associated Disease 
Does the post mention Warts 0 – absent  
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genital warts? 1 – present 
Does this post mention 
cancer? 
Cancer 0 – absent 
1 – present 
 
Health Belief Model Content 
Does this post suggest that 
people are susceptible HPV 
infection? 
Sus 0 – absent 
1 – present 
 
Does this post suggest that 
HPV has severe side 
effects? 
Sev 0 – absent 
1 – present 
 
Are benefits of the HPV 
vaccine mentioned in the 
post? 
Benefit 0 – absent 
1 – present 
 
Are barriers of the HPV 
vaccine mentioned in the 
post? 
Barriers 0 – absent 
1 – present 
 
Does this post mention 
self-efficacious messages 
related to getting the HPV 
vaccine? 
Selfef 0 – absent  
1 – present 
 
Does the post tell the 
audience to get the HPV 
vaccine? 
CueYes 0 – absent 
1 – present  
 
Does the post tell the 
audience to avoid HPV 
vaccine? 
CueNo 0 – absent  
1 – present 
 
Social Amplification of Risk Framework Content 
Does this post amplify or 
attenuate the perception of 
the risk of the HPV vaccine 
being dangerous? 
RiskAmp 0 – absent 
1 – amplifies 
2 - attenuates 
 
Does this post indicate that 
at least one individual has 
changed his or her behavior 
as a result of the risk of the 
HPV vaccine? 
Ripple 0 – absent 
1 – present 
 
Does this post indicate that 
there are results from the 
change in behavior that 
occurred because of the 
threat of the HPV vaccine? 
Impact 0 – absent 












What year was the Facebook post published? Year 1.00 
What day was the Facebook post published? Date 1.00 
Who authored this post? Author 0.96 
What is the gender of the author? Gender 0.93 
Who is the audience for this post? Audience 0.91 
Does the post have hyperlinks? Link 0.90 
Does the post have picture or videos embedded? Picvid 0.81 
How many reactions Reactions 0.96 
How many comments does this post have? Comments 0.96 
How many shares does this post have? Shares 0.95 
What is the tone of this post? PostTone 0.81 




Does the post mention genital warts? Warts 0.96 
Does this post mention cancer? Cancer 0.88 
Health Belief Model Content 
Does this post suggest that people are susceptible to 
HPV infection? 
Sus 0.71 
Does this post suggest HPV has severe side effects? Sev 0.81 
Benefits of the HPV vaccine mentioned in the post? Benefit 0.85 
Barriers to the HPV vaccine mentioned in the post? Barriers 0.84 
Does this post mention self-efficacious messages 
related to getting the HPV vaccine? 
Selfef 0.88 
Does the post tell the audience to get the HPV 
vaccine? 
CueYes 0.89 
Does the post tell the audience to avoid the HPV 
vaccine? 
CueNo 0.90 
Social Amplification of Risk Framework Content 
Does this post amplify or attenuate the perception of 
the risk of the HPV vaccine being dangerous? 
RiskAmp 0.85 
Does this post indicate that at least one individual has 
changed his or her behavior as a result of the risk of 
the HPV vaccine? 
Ripple 0.77 
Does this post indicate that there are results from the 
change in behavior that occurred because of the threat 
of the HPV vaccine? 
Impact 0.67 
 
